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ABSTRACT 
 
Amyotrophic lateral sclerosis (ALS) is a progressive and degenerative disease of the motor 
system clinically defined by the presence of upper and lower motor neuron (UMN/LMN) 
signs.  With the currently utilised diagnostic criteria the revised El Escorial and the Awaji 
criteria, there is a diagnostic delay of up to 14 months, whereby patients may miss the 
optimum ‘therapeutic window’.   To improve upon the diagnostic criteria in ALS we initially 
undertook a meta-analysis to evaluate the currently utilized criteria, the revised El Escorial 
(rEEC) and the Awaji criteria.  The included primary studies in the meta-analysis were single 
centre by design, the majority being retrospective in nature and lacking in specificity data.  
Having identified a modest improvement in the Awaji criteria we designed the first 
multicenter prospective study looking at both these diagnostic criteria. Whilst the Awaji 
criteria yet again proved to me more sensitive than the rEEC criteria, the lack of an objective 
UMN biomarker resulted in a delay in some patients being diagnosed with ALS. This was 
explored with the addition of a novel threshold tracking transcranial magnetic stimulation 
(TMS) technique to measure cortical hyperexcitability, as a biomarker of UMN dysfunction, 
in a cross-sectional study.  Adding cortical hyperexcitability as a biomarker of UMN 
dysfunction, resulted in a greater proportion of ALS patients reaching a definitive diagnosis.  
Subsequent to this finding, we then designed a multicenter prospective study, undertaken 
according to the STARD criteria (Standards for Reporting Diagnostic accuracy studies).  
These studies highlighted that threshold tracking TMS objectively identified abnormalities in 
ALS at an early stage of the disease process.  Given that cortical hyperexcitability appeared 
to be an early and specific biomarker of UMN dysfunction, we then utilized the threshold 
tracking TMS technique to gather insights into the most common cause of familial ALS, the 
c9orf72 repeat expansion.  Cortical abnormalities were evident in the familial ALS cohort 
4 
  
and were identical to the sporadic ALS cohort. But interestingly, asymptomatic carriers of the 
c9orf72 gene expansion did not have any signs of cortical dysfunction, thereby suggesting 
that patients may not be born with an abnormal motor cortex dysfunction, but rather may be 
predisposed to developing ALS secondary to the underlying genetic abnormality, potentially 
triggered by environmental factors. We also explored peripheral changes in c9orf72 familial 
ALS, highlighting that peripheral dysfunction, as measured by axonal excitability was similar 
to the sporadic ALS cohort.  Having established that cortical hyperexcitability was a robust 
biomarker of UMN dysfunction, we then studied atypical ALS phenotypes such as the 
clinically UMN predominant variant, primary lateral sclerosis (PLS), reliably differentiating 
PLS from mimic disorders such as hereditary spastic paraparesis (HSP).  In the lower motor 
neuron variant of ALS, termed flail leg syndrome, cortical hyperexcitability was only evident 
in patients with upper motor neuron signs.  Taken together, these findings suggest that 
cortical hyperexcitability is a potentially robust diagnostic and pathophysiological biomarker 
in sporadic, familial and some atypical ALS variants. 
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Introduction 
Amyotrophic lateral sclerosis (ALS), commonly referred to as Motor Neuron Disease (MND) 
is a rapidly progressive and invariably fatal neurodegenerative disorder of motor neurons in 
the spinal cord, brainstem, and motor cortex.  To this day, there exists no cure for this 
progressive disorder.  The condition was first described in the mid-19th century by the 
French neurologist Jean Martin Charcot (1).  The incidence of ALS has been estimated at two 
per hundred thousand (2), with a median survival of 3-5 years (3, 4).  In Australia an 
estimated two people die from ALS every day (5).  The diagnosis of amyotrophic lateral 
sclerosis (ALS) relies on the identification of a combination of upper (UMN) and lower 
motor neuron (LMN) signs.  The Awaji criteria are the currently utilized diagnostic criteria to 
aid in the diagnosis of ALS (6).  ALS results in the rapid development of physical disability, 
which can subsequently impact on the quality of life, placing tremendous strain on carers, 
families and the health care system. 
  
Demographics 
The mean age of disease onset is estimated at 65 years in population-based studies (7). ALS 
can affect people of all ages but the age-adjusted incidence rate varies greatly in different age 
groups. The incidence is very low in the first four decades (1.5/100,000/year) and then 
increases abruptly around age 40, reaching its peak between ages 60 and 79 (10–
15/100,000/year), thereafter decreasing (7). The presence of a peak in the age-specific 
incidence curve suggests that the disease may result from a time dependent exposure to 
genetic and environmental risk factors.  
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Clinical features and neurophysiological features 
The majority of ALS patients (65-75%) present with asymmetrical weakness and wasting of 
the limb muscles, typically spreading along the neuraxis to affect contiguous motor neurons 
(8-10).  Preferential wasting and weakness of thenar muscles, termed the ‘split-hand 
phenomenon’ is a specific clinical feature of ALS (11-13).  Furthermore there appears to be 
selective involvement of the abductor pollicis brevis, sparing the flexor pollicis longus, 
although both muscles have an identical nerve (median) and myotomal innervation, termed 
the ‘split-hand plus sign’ (14).   
 
Bulbar-onset disease can occur in 20% of ALS cases and presents with progressive dysphagia 
and dysarthria (15).  Late in the course of the disease, respiratory symptoms develop in the 
vast majority of ALS patients, ultimately being the most common cause of their demise (10, 
16, 17), but only rarely is respiratory dysfunction the presenting feature (18, 19).  In addition 
to motor symptoms, mild frontal lobe-type cognitive abnormalities are evident in 30-50% 
(20-23) and frank dementia in 3.5% of ALS patients (20).  Extraocular and sphincter muscles, 
innervated by motor neurons not receiving direct projections from the motor cortex, are 
characteristically spared in ALS (24, 25). 
 
Neurophysiological studies, in the form of routine nerve conduction studies (NCS), disclose a 
marked reduction of compound muscle action potential (CMAP) amplitudes, although this is 
typically evident in advanced stages of ALS and reflects axonal loss (26).  In addition, a mild 
reduction in motor conduction velocity (not less than 70% of the lower limit of normal), 
along with a mild prolongation of distal motor and F-wave latencies (<30% of upper limit of 
normal) may also be evident in ALS and is secondary to degeneration of large diameter, fast-
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conducting fibres (26-28).  Sensory NCSs are typically normal in ALS and when evident may 
suggest an alternative diagnosis (28, 29).   
 
Needle electromyography (EMG) forms an essential part of the diagnostic algorithm and is 
essential in identifying LMN loss (28).  The most frequently recognized abnormalities on 
EMG are fasciculations and spontaneous “denervation” discharges (fibrillation potentials and 
positive sharp waves (PSWs), indicative of ongoing motor neuron loss [Figure 1A, B] (28, 
29).  However, fibrillation potentials and PSWs are not universally identified in all weak 
muscles and may not develop until one third of the motor neurons have deteriorated (28).  
Collateral sprouting of surviving motor axons results in large-amplitude, long-duration motor 
unit potentials (MUPs), also referred to as chronic neurogenic changes [Figure 1C] (28, 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Ongoing degeneration of 
motor neurons accompanied by 
collateral sprouting of surviving 
motor neurons results in the 
classical electromyography findings 
including (B) ongoing denervation 
(fibrillation potentials and positive 
sharp waves) accompanied by (C) 
chronic neurogenic changes (large 
amplitude, long-duration, 
polyphasic motor unit action 
potentials with reduced voluntary 
recruitment). From Vucic S, 
Rothstein, J. D. Kiernan, M. C. 
Advances in treating amyotrophic 
lateral sclerosis: insights from 
pathophysiological studies. Trends 
Neurosci. 2014. 
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Surviving motor units may fire spontaneously, as fasciculations.  Fasciculations are a 
classical feature of ALS and usually become widespread as the disease progresses, however it 
is rarely the initial presenting symptom (15).   Fasciculations are often seen commonly in 
muscles with normal strength, and their incorporation into the Awaji criteria has improved 
the diagnostic sensitivity (6, 30).  Bilateral tongue fasciculations in the presence of 
progressive weakness are pathognomonic for ALS and are highly specific (31).  Insights from 
axonal excitability studies have revealed changes in axonal membrane conductances, in 
particular increased persistent sodium (Na+) and reduced potassium (K+) conductances, which 
may then contribute to the generation of fasciculations (32-35).  Fasciculations are generated 
at the nerve terminals, though some arise at more proximal regions including at the level of 
the motor neuron (36, 37).  As ALS progresses, fasciculations develop a complex 
morphology with increased duration, amplitude and degree of polyphasia (28).   
 
One of the challenges in diagnosing ALS is objectively identifying upper motor neuron 
dysfunction (38).  Clinical evidence of UMN dysfunction may be elusive in ALS and 
obscured by motor neuron loss (38).  Transcranial magnetic stimulation (TMS) techniques 
may provide a useful clinical tool in identifying UMN dysfunction in a clinical setting (39).  
The TMS parameters routinely measured in ALS patients include; motor threshold, Motor 
evoked potential (MEP) amplitude, central motor conduction time (CMCT) and cortical silent 
period (CSP) duration (see TMS section).  Abnormalities of the TMS parameters may aid in 
the identification of UMN dysfunction, thereby permitting an earlier diagnosis of ALS (29, 
40-46) 
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Diagnosis of ALS 
The diagnosis of ALS relies on the identification of a combination of upper and lower motor 
neuron signs in multiple body regions, along with evidence of ongoing disease progression.  
Importantly, ALS mimic disorders may need to be excluded prior to establishing a definitive 
diagnosis of ALS (47, 48).  Routine nerve conduction studies are utilised in a clinical setting 
to exclude mimic ALS disorders, such as autoimmune demyelinating neuropathies, diseases 
of the neuromuscular junction or muscle disorders (49).  
 
Diagnostic criteria:  In order to facilitate the diagnosis of ALS, specific diagnostic criteria 
were developed. The first of the diagnostic criteria was the El Escorial criteria (EEC), 
proposed at a World Federation of Neurology meeting in El Escorial, Spain [Table 1] (50).  
The EEC had two stipulations to aid in the diagnosis of ALS; (i) That all other mimic 
disorders needed to be excluded after relevant clinical, laboratory, neuroimaging and 
neurophysiological evaluation and (ii) Presence of both, LMN and UMN signs with a 
progressive spread of symptoms/signs over time, thereby confirming that the disease 
universally progresses in all individuals.  The EEC divided the body into four regions; 
‘brainstem’, ‘cervical’, ‘thoracic’ and ‘lumbosacral’. For a given region to be graded as 
abnormal, concomitant upper and lower motor neuron signs had to be present.  Lower motor 
neuron (LMN) clinical features include fasciculations, muscle wasting/atrophy and weakness, 
whilst upper motor neuron (UMN) clinical features include hyper-reflexia, 
spasticity/increased tone, and the presence of pathological reflexes (extensor plantar 
responses, and Hoffman’s sign).  To fulfill the diagnosis of ALS by the EEC, patients needed 
to exhibit dysfunction in at least two of these regions (Table 1).   
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El Escorial Criteria 
Clinically definite ALS 
 Evidence of UMN plus LMN signs in the bulbar region and in at least two spinal 
regions, or 
 The presence of UMN plus LMN signs in three spinal regions 
Clinically probable ALS 
 Evidence of UMN plus LMN signs in at least two regions with some UMN signs 
rostral to LMN signs 
Possible ALS 
 UMN plus LMN signs in only one region, or 
 UMN signs alone in two or more regions, or 
 LMN signs found rostral to UMN 
Regions: Bulbar, Cervical, Thoracic, and Lumbosacral 
 
While the El Escorial criteria were highly specific, the main limitation pertained to reduced 
sensitivity, leading to a reconsideration of the criteria in 1998, termed the Airlie House or 
revised El Escorial criteria (49).  The revised El Escorial criteria introduced a “clinically 
probable-laboratory supported” diagnostic category (Table 2), enabling the assessment of 
LMN dysfunction by utilising objective neurophysiological biomarkers. 
 
 
 
 
 
 
Table 1. The classification of ALS under the El Escorial criteria (50). A minimum criteria 
of El Escorial ‘Probable’ classification was necessary for diagnostic confirmation and 
entry into clinical trials. LMN – Lower motor neuron, UMN - Upper motor neuron. 
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 Revised El Escorial Criteria 
Clinically definite ALS 
 Evidence of UMN plus LMN signs in the bulbar region and in at least two spinal 
regions, or 
 The presence of UMN signs in two spinal regions and LMN signs in three spinal 
regions 
Clinically probable ALS 
 Evidence of UMN plus LMN signs in at least two regions with some UMN signs 
rostral to LMN signs 
Probable laboratory supported ALS 
 Clinical evidence of UMN and LMN signs in only one region, or 
 UMN sings alone in one region and LMN signs defined by EMG criteria in at least 
two muscles of different root and nerve origin, in two limbs 
Possible ALS 
 UMN plus LMN in only one region, or 
 UMN signs alone in two or more regions, or 
 LMN signs found rostral to UMN 
Regions: Bulbar, Cervical, Thoracic, and Lumbosacral 
 
 
 
Although the revised El Escorial criteria (rEEC) resulted in an increased sensitivity, 
significant diagnostic delays remained, which approximated 14 months (51).  Consequently, a 
neurophysiologically based diagnostic criteria, termed the Awaji criteria were proposed in 
2006 (6).  The Awaji criteria proposed that neurophysiological features of LMN dysfunction, 
including chronic and ongoing neurogenic changes (fibrillation potentials/positive sharp 
waves) were equivalent to clinical LMN signs. In addition, fasciculations were deemed to be 
a biomarker of LMN dysfunction when combined with chronic neurogenic changes. In order 
for a region to be classified as being abnormal, the neurophysiological abnormalities had to 
Table 2. The classification of ALS under the revised El Escorial criteria (49). With this 
criteria there was the addition of the ‘Probable laboratory supported’ criteria permitting 
utilisation of electrophysiology to identify subclinical lower motor neuron (LMN) 
abnormalities. UMN - Upper motor neuron  
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be identified in two muscles innervated by a different nerve and nerve root for the spinal 
region (upper or lower limbs) or one muscle for the bulbar and thoracic region.  The 
assessment of UMN function remained clinically based. 
Awaji Criteria 
The diagnosis of ALS requires the presence of 
(1) evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiological or 
neuropathological examination 
(2) evidence of upper motor neuron (UMN) degeneration by clinical examination; and 
(3) progressive spread of symptoms or signs within a region or to other regions, as 
determined by history, physical examination, or electrophysiological tests 
The diagnosis of ALS requires the absence of 
(1) electrophysiological or pathological evidence of other disease processes that might 
explain the signs of LMN and/or UMN degeneration, and 
(2) neuroimaging evidence of other disease processes that might explain the observed clinical 
and electrophysiological signs 
Diagnostic categories 
Clinically definite ALS is defined by clinical or electrophysiological evidence by the 
presence of LMN as well as UMN signs in the bulbar region and at least two spinal regions or 
the presence of LMN and UMN signs in three spinal regions 
Clinically probable ALS is defined on clinical or electrophysiological evidence by LMN and 
UMN signs in at least two regions with some UMN signs necessarily rostral to (above) the 
LMN signs 
Clinically possible ALS is defined when clinical or electrophysiological signs of UMN and 
LMN dysfunction are found in only one region; or UMN signs are found alone in two or 
more regions; or LMN signs are found rostral to UMN signs. 
Neuroimaging and clinical laboratory studies will have been performed and other diagnoses 
must have been excluded. 
Regions: Bulbar, Cervical, Thoracic, and Lumbosacral 
 
Table 3. The classification of ALS under the Awaji criteria (6).  These changes allowed 
the combining of clinical and electrophysiological findings within a given region, and 
accepted ‘fasciculations’ as a marker of ongoing nerve injury.   
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The diagnostic utility of the Awaji criteria was assessed in retrospective and prospective 
studies, most of which established an increased sensitivity when compared to rEEC (30, 52-
59), although one study reported a lower sensitivity (60). This unexpected finding was 
attributed to the omission of a “probable-laboratory supported” diagnostic category.  Two 
study-level meta-analyses reported an improved diagnostic performance of the Awaji criteria, 
with higher sensitivity and diagnostic odds ratios (30, 61).  The diagnostic benefits, however, 
appeared to be most prominent in ALS patients with bulbar-onset disease.  Interestingly, one 
study reported that 20% of patients classified as “probable laboratory-supported” on the rEEC 
were downgraded to Awaji “possible” (61), although this latter study was criticised for 
utilising incomplete data sets (62).  A potential limitation of both previous meta-analyses was 
the lack of specificity data.   
 
The most recent emendation to the diagnostic criteria was proposed in 2015 by the World 
Federation of Neurology MND/ALS sub group committee (63). The 2015 criteria proposed 
that the ‘possible’ category be deemed diagnostic of ALS, once mimic disorders were 
excluded after extensive clinical, neurophysiological and neuroimaging assessment.    
 
Variant forms of ALS 
Adding to the complexity of diagnosis ALS and understanding the underlying 
pathophysiology, is the existence of atypical phenotypes.  These atypical phenotypes vary 
from the clinically pure upper motor neuron primary lateral sclerosis (PLS) phenotype, to 
the predominant LMN phenotypes encompassing the flail-arm and flail leg syndrome 
variants of ALS.   
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Primary lateral sclerosis is a pure upper motor neuron presentation of ALS.  The term PLS 
was first coined by Erb in 1875 (64), with earlier pathological findings described by Charcot 
in 1865 (65).  The incidence of PLS is estimated at 1-4% of ALS cases (66-69). The first 
diagnostic criteria were proposed by Pringle and colleagues, who proposed that UMN 
dysfunction be present for at least 3 years prior to development of LMN signs (70) [Table 4].   
Clinical Insidious onset of spastic paresis, usually beginning in the lower 
extremities, but occasionally involving bulbar or upper extremities 
 Adult onset, usually in the fifth decade or later, with an absence of a family 
history 
 Gradually progressive course (no step-wide deterioration) 
 Duration of approximately 3 years 
 Clinical findings limited to those associated with corticospinal dysfunction 
 Symmetrical distribution, ultimately developing severe spastic spinobulbar 
paresis 
Laboratory  (to aid in  
exclusion of other 
diagnoses) 
Normal routine blood tests, including normal serum chemistry including 
normal vitamin B12 levels, negative serologic tests for syphilis, negative 
Lyme and HTLV-1 serology 
 Normal CSF parameters, including the absence of oligoclonal bands 
 Absent denervation potentials on Needle EMG or at most, occasional 
fibrillation and increased insertional activity in a few muscles (late and 
minor) 
 Absence of compressive lesions of cervical spine or foramen magnum 
(spinal MRI scanning) 
 Absence of high signal lesions on MRI similar to those seen in MS 
Additionally features 
suggestive of PLS 
Preserved bladder function 
 Absent or very prolonged latency on cortical motor evoked responses in the 
presence of normal peripheral stimulus-evoked maximum compound 
muscle action potentials 
 Focal atrophy of the precentral gyrus on MRI 
 Decreased glucose consumption in the pericentral region on PET scan 
 
 
Table 4. The diagnostic criteria in PLS, proposed by Pringle and colleagues in 1992 (70).  
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The original PLS criteria exhibited a poor specificity, with up to a third of ALS patients being 
misdiagnosed with PLS, resulting in prognostication and management issues (66).  
Consequently, Gordon and colleagues proposed a modification of the criteria in 2006 (66) 
[Table 5].  The main modification was the requirement that UMN dysfunction be present in 
isolation for at least 4 years from symptom onset.  In addition, subtypes of PLS were 
proposed to highlight the heterogeneity of the disease process and to aid in diagnosis.  The 
salient features are outlined in Table 5.   
 
Autopsy proven PLS Clinically diagnosed PLS with degeneration in motor cortex and 
corticospinal tracts, no loss of motor neurons, no gliosis in anterior 
horn cells, and no Bunina or Ubiquinated inclusions. 
Clinically pure PLS Evident upper motor neuron signs, no focal muscle atrophy or visible 
fasciculation, and no denervation in EMG 4 years from symptom 
onset. Age at onset after 40. Secondary and mimicking conditions 
excluded by laboratory and neuroimaging. 
UMN-dominant ALS Symptoms less than 4 years, or disability due predominantly to UMN 
signs but with minor EMG denervation or LMN signs on 
examination, not sufficient to meet diagnostic criteria for ALS. 
PLS plus Those with predominant UMN signs who also have clinical, 
laboratory, or pathologic evidence of dementia, parkinsonism, or 
sensory tract abnormalities. Note: If cerebellar signs, urinary 
incontinence, or orthostatic hypotension are evident, multiple system 
atrophy could be considered. 
Symptomatic lateral 
sclerosis 
Clinically diagnosed PLS with evident possible cause (HIV, 
paraneoplastic syndrome). 
 
 
 
Table 5. The diagnostic criteria in upper motor neuron predominant ALS, proposed by 
Gordon and colleagues in 2006 (66). 
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Primary lateral sclerosis exhibits a more favorable prognosis with regards to survival, 
although disability remains a critical feature (66, 67).  The mean age of onset is in the early 
50’s, with males and females equally affected (66).  Lower limb onset is typically evident 
with subsequent spread of symptoms to upper limb and bulbar regions, although there is a 
rare hemiplegic variant termed the Mills syndrome (71).  Bulbar dysfunction, along with 
preserved bladder and sensory function may distinguish PLS from mimic disorders. 
Development of lower motor neuron dysfunction or bulbar palsy, may herald an adverse 
prognosis (66, 72).  Importantly, the development of cognitive impairment and aphasia may 
be also be associated with an adverse prognosis in PLS (73).   
 
Neuroimaging studies have reported marked cortical atrophy within the precentral and 
parietal region in PLS patients (70, 74-76), signifying significant cortical neuronal loss. In 
addition, abnormalities of the corticospinal tract have also been identified in PLS signifying 
degeneration of the UMN (77). Underscoring the marked UMN dysfunction, are findings of 
motor cortex inexcitability and markedly prolonged central motor conduction time on TMS 
testing (70, 78). 
 
Neuropathological studies have reported widespread degeneration of Betz cells and 
corticospinal tracts, potentially forming the basis of the clinical, radiological and 
physiological findings (69, 79-81).  Ubiquinated inclusions with and without Bunina bodies 
along with skein like lesions have also been reported within the precentral, frontal and 
temporal cortices (67, 79, 80, 82, 83).  Importantly, the anterior horn cell  population remains 
preserved, although ubiquitin-positive inclusions have been reported (69).    
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Progressive muscular atrophy (PMA) is thought to comprise approximately 10% of patients 
with motor neuron disease (84).   Primary muscular atrophy presents with predominantly 
LMN dysfunction, although at least one-third of cases can develop UMN dysfunction (85, 
86).  The flail leg (FL) syndrome, also termed leg amyotrophic diplegia and 
pseudopolyneuritic variant of ALS, is an unusual PMA phenotype first described in the early 
20th century (87). Clinically, the FL syndrome is characterized by a predominantly lower 
motor neuron phenotype, with weakness and wasting confined to the distal lower limbs for at 
least 12 months (88)[Table 6]. Upper motor neuron (UMN) signs are typically absent, or if 
evident are subtle (84, 87, 88).  Although the prognosis for FL syndrome is favorable with a 
median survival of 90 months (84, 88), there appears to be a heterogeneity, with patients 
exhibiting a greater degree of UMN dysfunction having a shorter survival that mirrors the 
classical ALS phenotype (89).   
Inclusion criteria Lower motor neuron disorder of the lower limbs 
 Characterized by progressive distal onset weakness and wasting 
 Flail leg pattern of weakness with evidence of pathological deep 
tendon reflexes (without hypertonia or clonus) 
Exclusion criteria Functionally significant weakness or wasting in upper limbs, bulbar 
and respiratory musculature within 12 months after onset of lower 
limb symptoms 
 Hypertonia or clonus in lower limbs 
 Wasting or weakness beginning proximally in legs without distal 
involvement at presentation 
 
 
 
 
 
Table 6:  The inclusions and exclusion criteria for the flail leg syndrome as proposed 
by Wijesekera and colleagues (88). 
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Pathophysiology of ALS 
Although the mechanisms underlying ALS pathogenesis remains to be fully elucidated, 
emerging evidence suggests the importance of genetic factors and dysfunction of vital 
molecular pathways and processes (Figure 2). A genetic etiology has been identified in up to 
20% of sporadic and 70% of familial ALS cases, with at least 20 genes and genetic loci 
implicated in ALS pathogenesis (90-96).  Importantly, these genetic breakthroughs have shed 
significant insights into the mechanisms underlying the development of ALS with clear 
diagnostic and therapeutic implications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  The pathophysiological mechanisms underlying neurodegeneration in amyotrophic lateral 
sclerosis (ALS) is complex and multifactorial.  Evidence exists for complex interplay between 
molecular and genetic pathways.  Dysfunction of the astrocytic excitatory amino acid transporter 2 
(EAAT2) results in reduced uptake of glutamate from the synaptic cleft potentially leading to 
glutamate excitotoxicity.  Glutamate-induced excitotoxicity results in increased influx of Na+ and Ca2+ 
ions and ultimately neurodegeneration through activation of Ca2+-dependent enzymatic pathways.  In 
addition, glutamate excitotoxicity results in generation of free radicals which in turn contributes to 
neurodegeneration.  Mutations in the c9orf72, TDP-43 and FUS result in deregulated RNA 
metabolism that ultimately leads to formation of intracellular aggregates which are harmful to 
neurons.  Of further relevance, mutant SOD-1 enzyme increases oxidative stress, induces 
mitochondrial dysfunction, forms intracellular aggregates and adversely affect neurofilament and 
axonal transport processes.  Activation of microglia results in secretion of proinflammatory cytokines, 
producing further toxicity.  Figure from Vucic S, Rothstein, J. D. Kiernan, M. C. Advances in treating 
amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014. 
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C9orf72 hexanucleotide expansion:  A major advance in the understanding of ALS 
pathogenesis occurred with the discovery of the dominantly inherited c9orf72 gene [increased 
hexanucleotide repeat expansion (GGGGCC)] in the non-coding region of chromosome 
9p21, which underlies over 40% of familial ALS cases (97, 98).  Importantly, the frequency 
of the c9orf72 hexanucleotide expansion exhibits significant geographic variations, 
accounting for nearly 50% of Finnish familial ALS cases with lower frequencies reported in 
Italian and German populations (97). In keeping with other repeat expansion genetic diseases, 
apparent anticipation has also been reported in c9orf72 expansions, with the disease onset 
being 7-10 years earlier in the offspring of affected parents (99).  The pathogenic expansion 
was reportedly non-penetrant in carriers under the age of 35 years, 50% penetrant at age 28 
years and almost fully penetrant by 80 years of age (100).  In addition to being causative in 
familial ALS, the c9orf72 hexanucleotide expansion has been reported in 4.1-8.3% of 
apparently “sporadic” ALS cases (100).   
 
This monumental discovery has radically altered the understanding of ALS pathogenesis, 
implying that ALS is a multisystem neurodegenerative disorder, rather than a pure 
neuromuscular disease.  Underscoring this notion are findings that the c9orf72 
hexanucleotide expansions are also causative for frontotemporal dementia (97, 98, 100).  
Accumulation of TDP-43 along with p62 positive TDP-43 negative inclusions in the 
hippocampus and cerebellar neurons, as well neurons located within the cortex, appears to be 
a pathological hallmark of c9orf72 associated ALS and FTD (101), suggesting the existence 
of a common pathophysiological pathway. 
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Clinical presentation:  Although the pathognomonic clinical features in c9orf72 familial 
ALS are dominated by a combination of upper and lower motor neuron signs, with rapid 
disease progression, phenotypic differences have been observed in c9orf72 associated ALS 
patients.  Specifically, ALS patients exhibiting the c9orf72 expansion are more likely be 
female, exhibit bulbar-onset disease and report a family history of ALS (99, 100, 102).  In 
addition, patients with the pathogenic expansion exhibit an earlier age of onset and shorter 
survival (102, 103), with size of the c9orf72 expansion correlating with the age of onset 
(104).  Atypical phenotypes have also been reported in the c9orf72 hexanucleotide expansion 
including monomelic amyotrophy, progressive muscular atrophy, mixed flaccid/spastic 
dysarthria and primary lateral sclerosis (102).  
 
Cognitive impairment and frontotemporal dementia are significantly more common in 
c9orf72 ALS patients (99).  Clinically, the frontotemporal dementia is characterized by 
executive and language dysfunction, irrational behavioral, personality changes, apathy, poor 
insight, loss of apathy, irritability and disinhibition (105, 106).   Deficits in social cognition, 
emotional processing and theory of the mind have recently been identified in ALS (107).   
 
Importantly, frontotemporal dementia may precede the onset of ALS by up to 4 years, 
although the converse has also been reported with ALS preceding the onset of FTD (99, 102).  
Interestingly, c9orf72 FTD is invariably characterized by behavioral symptoms, with 
semantic dementia and progressive non-fluent aphasia FTD phenotypes infrequently reported 
(102).  In addition, psychotic symptoms such as delusions and hallucinations are more 
frequent in patients carrying the c9orf72 repeat expansion (99, 108, 109).   
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Neuroimaging studies disclose symmetrical and bilateral frontotemporal cortical atrophy, 
with subcortical white matter changes, a finding in keeping with the clinical findings (102, 
110).  Importantly, the pattern of cortical atrophy evident in the c9orf72 expansion cohorts, 
was distinct to that evident with progranulin and tau gene mutations (110). Of relevance, 
hypermetabolism and hypoperfusion of the frontal cortical regions accompanied the cortical 
atrophy, with the deficits most evident in the anterior and middle cingulate gyrus (102).  
 
Pathophysiological mechanisms underlying c9orf72 gene expansion:  The mechanisms by 
which c9orf72 hexanucleotide expansion causes neurodegeneration in ALS remains to be 
fully elucidated (97, 98), although three potential pathogenic mechanisms have been 
proposed, including (i) haploinsufficiency, (ii) repeat RNA-mediated toxicity and (iii) 
dipeptide protein toxicity related to repeat associated non-ATG (RAN) translation of the 
expanded c9orf72 gene (111).  Evidence for haploinsufficiency is suggested by studies 
reporting a reduction in the c9orf72 short and long isoforms in ALS patients (97, 98), 
although a reduction in the corresponding c9orf72 protein is yet to be established.  In 
addition, reduced expression of the c9orf72 transcript in the zebrafish model of ALS resulted 
in motor axonal degeneration with locomotion deficit, providing additional support for 
haploinsufficiency as a factor in ALS pathogenesis (112).    
 
Of further relevance, RNA-mediated toxicity has also been proposed as a potential 
mechanism. Such a process was inferred from observations of intranuclear RNA foci 
containing c9orf72 hexanucleotide repeats (98), and supported by findings that specific RNA-
binding proteins associate with the c9orf72 expansion resulting in formation of intranuclear 
and cytoplasmic inclusions (113).  More recently, studies utilizing induced pluripotent stem-
cell differentiated neurons from C9orf72 patients provided additional support for RNA 
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toxicity and importantly established that the pathological changes were mitigated by 
antisense oligonucleotide therapeutic approaches (114).  
 
In addition, non-ATG related translation of the c9orf72 expansion (RAN translation) has also 
been proposed as a potential pathogenic mechanism (115).  Specifically, RAN translation 
results in generation of insoluble di-peptides (anti-C9RANT), which form intraneuronal 
(nuclear and cytoplasmic) inclusions and appear to be specific for c9orf72 associated 
ALS/FTD (115).  Given that neuronal degeneration and dysfunction may result from 
accumulation of insoluble proteins, and that C9RANT-positive pathology appears specific for 
c9orf72 related ALS/FTD, novel therapeutic strategies aimed at modulating such a process 
may prove useful. 
 
Importantly, the c9orf72 hexanucleotide expansion is associated with characteristic 
neuropathological features dominated by neuronal cytoplasmic inclusions containing 
hyperphophylated-TDP43 as well as ubiquitin and p62 [sequestosome 1] (101). These 
inclusions are evident in the interneurons of the neocortex as well as neurons in the 
cerebellum and hippocampus, and are similar to neuropathological changes evident in FTD 
(101, 116, 117).  The TDP-43 pathology can be variable in c9orf72 ALS, but the vast 
majority of cases were classified as type A in one large series (118). The type A (Mackenzie 
type 1) is characterized by many cortical neuronal cytoplasmic inclusions and dystrophic 
neuritis, often with intranuclear inclusions and widespread involvement of subcortical areas. 
The type B (Mackenzie type 3) classification meanwhile have many neuronal cytoplasmic 
inclusions, but few dystrophic neurites and more limited subcortical pathology (119).  
Importantly, excessive protein accumulation, secondary to c9orf72 expansions, could 
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potentially underlie neuronal degeneration by activation of ubiquitin-proteasome system 
(UPS) or by autophagosome–lysosome pathways (101).  
 
Other genetic mutations 
Mutations in other DNA/RNA-processing genes, namely the transactive-region DNA-binding 
protein gene (TARDBP) (120) and fused in sarcoma (FUS) genes (121) were described prior 
to the c9orf72 hexanucleotide expansions and represent 4-6% of familial and up to 2% of 
sporadic ALS (90, 122).  To date, approximately 50 mutations have been identified in each 
gene, and most mutations are dominantly inherited (120, 123).  The TARDBP mutations are 
localized in the highly conserved C-terminal glycine-rich domain (120), while FUS mutations 
are located in the nuclear localization signal domain that translocates the FUS protein into the 
nucleus (123).  The mutant proteins are redistributed from the nucleus to the cytoplasm, 
resulting in toxicity.  
 
Multiple pathophysiological mechanisms appear to underlie neuronal degeneration in 
TARDBP/FUS gene mutations, including gain of toxicity, loss of nuclear function, or 
formation of large stress granules (111).  Transgenic mouse models have provided evidence 
for a toxic gain of function, whereby increased expression of the mutated TDP-43 proteins 
leads to neurodegeneration (124-131).  The severity of cortical and spinal motor neuron 
degeneration appears proportional to the TDP-43 protein levels (125), suggesting a potential 
role for TDP-43 in regulating disease severity.  In addition, cytoplasmic accumulation of 
TDP-43 aggregates has been well established in ALS patients (132), implying a potential role 
for a TDP-43 loss of nuclear function mechanism in ALS pathogenesis, and recent  
transgenic mouse models provide support for such a theory (133, 134).   
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Of further relevance, cytoplasmic accumulation of FUS positive inclusions in ALS patients 
(121, 123) implies a loss of nuclear function of FUS as a potential mechanism in ALS 
pathogenesis, being similar to TARDBP mutations.  Support for such a notion was provided 
by studies demonstrating that expression of a FUS variant in transgenic mice, at lower levels 
than endogenous FUS, leads to selective motor neuron degeneration (135).  Conversely, a 
toxic-gain of function of mutated FUS has also been inferred from studies demonstrating that 
expression of mutated FUS leads to progressive motor dysfunction, which was rescued by 
over expression of wild-type FUS (136).   
 
Pathological TDP-43 and FUS mutants appear to exhibit a greater propensity to associate and 
alter the dynamics of cytoplasmic stress granules (121, 137-140).  Importantly, wild-type 
TDP-43 and FUS proteins associate with cytoplasmic stress granules under physiological 
conditions in order to temporarily suppress translation of mRNA and stored pre-RNA 
complexes during periods of cellular stress, thereby safe-guarding the coded RNA 
information from deleterious chemicals (137, 141, 142).  Consequently, alteration of stress 
granule dynamics induces neuronal degeneration in ALS by sequestration of RNA-binding 
proteins and repression of RNA translation along with formation of pathological inclusions 
(137, 143-145).  
 
Mutations in the superoxide dismuates-1 (SOD-1) gene (see oxidative stress below), as well 
as genes responsible for regulating protein ubiquitination [ubiquilin-2, UNC13A] (146, 147), 
trafficking of endosomes [vesicle-associated membrane protein/synatobrevin-associated 
protein, charged multivesicular body protein ] (148-150), and protein homeostasis [valosin-
containing protein, optineurin, p62/SQSTM1] (151-153), have all been associated with ALS.  
These genetic mutations are dominantly inherited and appear to exert a pathogenic effect by 
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disrupting the function of vital cellular processes ultimately leading to neurodegeneration 
(111).   
 
Molecular processes and ALS pathogenesis 
In addition to genetic mutations, a host of potentially interdependent molecular processes 
have been implicated in ALS pathogenesis (Figure 2).  Critically, these molecular processes 
may be linked with underlying genetic mutations and may occur in a complex sequential 
multi-step process prior to the onset of neurodegeneration (154).   In addition, the 
predisposition to develop ALS may occur at conception, with a prolonged pre-clinical period 
emerging during which the deleterious molecular processes are activated (155). 
 
Glutamate-mediated excitoxicity:  Glutamate-mediated excitoxicity is a critical mechanism 
in ALS pathogenesis (47, 48, 156-158).  Glutamate is the major excitatory neurotransmitter in 
the central nervous system (159, 160).  During axonal depolarization, glutamate is released 
from presynaptic neurons, the major pool for glutamate, and activates postsynaptic receptors.  
The excitatory signal is terminated by removal of glutamate from the synaptic cleft by 
specific glutamate re-uptake transporters located on neurons and astrocytes (161, 162).  
Within astrocytes, glutamate is converted into glutamine by the enzyme glutamine 
synthetase, and then returned to the neuron for resynthesis of glutamate (163).   
 
Excessive activation of the postsynaptic glutamate receptors, broadly classified into 
ionotropic and metabotropic, leads to glutamate-mediated excitoxicity (160).  The ionotropic 
receptors are implicated in the pathogenesis in ALS, by resulting in excessive influx of  Na+ 
and Ca2+ ions (164).  Based on pharmacological studies, glutamate ionotropic receptors are 
further classified as: (i) N-methyl-D-aspartate (NMDA), (ii) α-amino-3-hydroxy-5-methyl-4-
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isoxazoleproprionic acid (AMPA), and (iii) kainite receptors.  This pharmacological 
classification is supported by cloning studies that have identified six different families of 
glutamate ionotropic receptors that conform to the original agonist studies (164).  N-methyl-
D-aspartate receptors are permeable to influx of Na+ and Ca2+ and efflux of K+ (164).   An 
essential feature of NMDA receptors is their voltage-dependent blockade by Mg2+ binding 
within the channel pore, which can be alleviated by depolarization (165).  NMDA receptors 
are involved in excitatory neurotransmission, which is characterized by a slow rise time and 
decay.   
 
The NMDA receptor complex is composed of different subunits derived from 6 genes; 
NMDAR1 (eight splice variants described), NMDAR2 (A-D) and NMDAR3 (A, B) (160, 
164).  While the NMDAR1 subunit forms the basic structure of the receptor (160), the 
NMDAR2 subunit determines ion channel properties and forms ligand-binding sites (166-
168).  Functional and pharmacological properties of NMDA receptors are determined through 
specific combination of NMDAR1 and NMDAR2 subunits (166, 169).  In addition, there are 
regional variations in the expression of NMDA receptor subtypes (166, 169-175), with the 
NMDAR3B subunit heavily expressed in somatic motor neurons (176, 177).   
 
AMPA receptors mediate a rapid influx of monovalent ions (Na+, K+ and chloride), but are 
impermeable to Ca2+ (160).  Four AMPA receptor subtypes have been cloned (GluR1-4) and 
are composed of three transmembrane domains (M1, M3, M4) with a fourth cytoplasmic 
hairpin loop (M2), contributing to a pore-lining region (164, 178).  The AMPA receptor 
exists as a pentameric structure in vivo, which is formed by the arrangement of subunits to 
create receptor diversity (160).  The GluR2 subunit influences Ca2+ permeability of AMPA 
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receptors, whereby editing defects within the GluR2 subunit render the APMA receptors 
more permeable to Ca2+ ions (160, 164).   
 
Kainate receptors are located in both presynaptic and postsynaptic neuronal membranes, 
existing as heteromeric pentamer complexes (179). The kainite receptors are thought to 
modulate slow synaptic responses and are unlikely to contribute to excitoxicity. Kainate 
receptors are involved in short-term synaptic plasticity, particularly at the mossy fiber 
synapses and also seem to be involved in long-term plastic phenomena. However, their signal 
transduction pathways, which are probably dual, need to be clarified and despite their wide 
distribution their exact role in excitability needs to be elucidated (180). 
 
Glutamate excitotoxicity has been postulated to underlie neuronal degeneration via a trans-
synaptic anterograde process mediated by corticomotoneurons, termed the dying forward 
hypothesis (24).  Transcranial magnetic stimulation studies (TMS) have provided support for 
this mechanism by identifying cortical hyperexcitability, a biomarker of glutamate 
excitotoxicity, as an early feature in sporadic and familial (SOD-1) ALS, linked to motor 
neuron degeneration (41, 42, 96, 181-186) and preceding the clinical onset of ALS (185, 
187).  In addition, disinhibition of the motor cortex, secondary to degeneration of γ-amino 
butyric acid (GABA) secreting inhibitory interneurons has been documented in ALS, thereby 
further contributing to development of cortical hyperexcitability (188, 189).    
 
At a molecular level, significant reduction in the expression and function of the astrocytic 
glutamate transporter (EAAT2), which mediates glutamate reuptake at synapses, has been 
reported in superoxide dismutase-1 (SOD-1) mouse model and the motor cortex and spinal 
cord of ALS patients (156, 190-193).  Of further relevance, dysfunction of the EAAT2 
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transporter appears to be a pre-clinical phenomenon (194, 195), and an increase in expression 
and activity of EAAT2 increases the lifespan of mutant SOD-1 mice (196).  In addition, 
activation of caspase-1, which normally inhibits the EAAT2 transporter, has been reported in 
the transgenic SOD-1 mouse model prior to onset of neuronal degeneration (194, 195).   
 
At a postsynaptic level, increased expression of the Ca2+ permeable AMPA receptors 
exhibiting an unedited GluR2 subunit, has been reported in motor neurons in ALS (197-201), 
potentially explaining the increased sensitivity of motor neurons to excitotoxicity (160, 202).  
In addition, vulnerable motor neurons lack the intracellular expression of Ca 2+ buffering 
proteins parvalbumin and calbindin D28k (203).  Increased expression and aberrant activity 
of the inositol 1,4,5-triphosphate receptor 2 (ITPR2) gene has been reported in ALS (204), 
which leads to excessive accumulation of Ca 2+ upon glutamate stimulation (204, 205).  Of 
further relevance, motor neurons in ALS, at least in animal models, appear to be larger, with 
an increase in distal dendritic branching (206).  Consequently, input conductance of motor 
neurons is increased rendering them more vulnerable to electrical and metabolic stresses, in 
particular those imparted by glutamate excitotoxicity (207).  
 
Although details of the molecular mechanisms by which glutamate exerts toxicity remain to 
be clarified, several pathways have been defined.  Initially, an influx of Na+ and Cl- ions, 
along with water molecules, leads to acute neuronal swelling that is potentially reversible 
(208-210). Subsequently, an influx of Ca2+ ions occurs via activation of ionotropic receptors 
such as the NMDA and Ca2+-permeable AMPA receptors, as well voltage-gated Ca2+ 
channels (208, 211).  Ultimately, increased intracellular Ca2+ concentration ensues with 
activation of Ca2+-dependent enzymatic pathways leading to neuronal death (202, 209, 212, 
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213).  In addition, glutamate excitotoxicity results in production of free radicals that can 
further damage intracellular organelles thereby causing cell death (214-216). 
 
The clinical benefit of the anti-glutaminergic agent riluzole in ALS (217-221), provides 
additional support for the importance of glutamate excitoxicity as a pathogenic mechanism in 
ALS. In addition, the neuroprotective benefits afforded by retigabine, a K+ channel activator 
which antagonizes neuronal hyperexcitability (222), lends further credence to the importance 
of glutamate excitoxicity in ALS pathogenesis. Although some have argued the glutamate 
excitoxicity was neuroprotective (223), the finding that riluzole normalizes cortical 
hyperexcitability argues against a neuroprotective role in ALS patients (224).       
 
Site of disease onset in ALS:  The notion that glutamate excitoxicity is an important, and 
possibly primary, pathogenic mechanism in ALS is of significance when considering the site 
of disease onset.  Three schools of thought have emerged pertaining to the site of disease 
onset, and include:  (i) “the dying forward” hypothesis; (ii) “the dying back” hypothesis and 
(iii) “the independent degeneration” hypothesis (Figure 3). 
 
The dying forward hypothesis proposed that ALS was primarily a disorder of the 
corticomotoneurons, which connect monosynaptically with spinal motor and bulbar neurons 
(24).  Corticomotoneuronal hyperexcitability was postulated to induce anterior horn cell 
degeneration trans-synaptically via an anterograde glutamate-mediated excitotoxic process 
(24, 96).  This dying forward hypothesis was based on a number of clinical observations 
including: (i) relative preservation of extraocular and sphincter muscles in ALS, postulated to 
be due to a paucity of corticomotoneuronal projections onto the motor nuclei innervating 
these muscles; (ii) absence of an animal model of ALS, ascribed to a lack of direct 
36 
  
corticomotoneuronal-anterior horn cell connections (225, 226); (iii) rarity of pure lower 
motor neuron forms of ALS, with subclinical upper motor neuron dysfunction invariably 
detected with TMS studies (227); and (iv) the specificity of the split hand phenomenon in 
ALS remains best explained by a dying forward mechanism (11, 12, 14, 228-232).    
 
 
 
As discussed above, threshold tracking TMS studies have identified cortical hyperexcitability 
as an early feature in sporadic and familial ALS, linked to the process of motor neuron 
degeneration (41, 42, 96, 181-185), preceding the development of lower motor neuron 
dysfunction (185, 187) and following the pattern of dissociated muscle atrophy (14, 187, 
232).  In keeping with a cortical origin of ALS are findings of concordance between 
Figure 3:  Controversy: Where does ALS 
begin? Despite Jean Martin Charcot’s initial 
observation of concomitant upper and lower 
motor neuron pathology in ALS, the issue of 
where ALS begins has not been resolved.  
Resolution of this question will enhance the 
understanding of ALS pathophysiology and 
be of therapeutic significance. 
 Dying forward hypothesis proposes that 
ALS is primarily a disorder of 
corticomotoneurons, which connect 
monosynaptically with anterior horn 
cell, mediating anterograde degeneration 
of motor neurons via glutamate 
excitotoxicity. This view was held by 
Charcot. 
 
 Dying back hypothesis proposes that 
ALS begins within the muscle cells or at 
the neuromuscular junction.   
 
 Independent degeneration hypothesis 
proposes that upper and lower motor 
neuron degeneration occurs 
independently. 
Figure from Vucic S, et al. JNNP, 2013 
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handedness and site of disease onset (233), the notion that upper motor neurons potentially 
mediate the site of disease onset and patterns of spread in ALS (234), as well the now 
accepted view that ALS and frontotemporal dementia (FTD) represent an overlapping 
continuum of the same disorder (235, 236), an observation underscored by recent genetic 
discoveries that increased hexanucleotide repeat expansions in the first intron of C9ORF72 
gene (9p21) [see above] was associated with both ALS and FTD (97, 98).    
 
The notion that cortical hyperexcitability is a compensatory mechanism in response to motor 
neuron degeneration has also been proposed (45). Given however, that cortical 
hyperexcitability was not evident ALS mimic disorders patients despite a comparable 
peripheral disease burden (187, 237-239), argues against a compensatory mechanism.  Of 
further relevance is the identification of cortical hyperexcitability in atypical ALS 
phenotypes, dominated by a paucity of upper motor neuron signs (240), further underscoring 
the importance of a dying forward mechanism in ALS pathogenesis.   
 
The dying back hypothesis proposed that ALS was primarily a disorder of lower motor 
neurons, with pathogens retrogradely transported from the neuromuscular junction to the cell 
body where they exert their deleterious effects (241).  Support for a dying back process has 
been largely provided by transgenic mouse model and pathological studies (241-245), 
although no pathogens have been identified.  In addition, the presence of widespread 
dysfunction within the frontal cortex, including the primary, supplementary and pre-frontal 
motor cortices in ALS remains difficult to reconcile with any dying back process (246-248).  
Finally, the absence of central pathology in other lower motor neuron mimic disorders such 
as Kennedy’s disease or poliomyelitis provides a further argument against a dying back 
process (238, 249).   
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The independent degeneration hypothesis suggested that upper and lower motor neurons 
degenerate independently and concurrently (250).  Neuropathological studies documenting an 
absence of significant correlation between corticomotorneuron and anterior horn cell 
densities formed the basis of the independent degeneration hypothesis (251, 252), a view held 
by Charcot’s contemporary, WR Gowers (253).  These correlative morphological techniques, 
however, were significantly confounded by the anatomical and functional complexity of the 
corticomotoneuronal system (254).  In particular, there remains considerable variability in the 
corticomotoneuronal to anterior horn cell ratio, due to synaptic changes, and as such, attempts 
to correlate upper and lower motor neurons on autopsy studies may not reflect an accurate 
model in vivo (249).   More recently, clinical studies documenting the pattern of disease 
spread documented an absence of correlation between upper and lower motor neuron signs 
(255), thereby invoking an independent degeneration mechanism.  These clinical 
observations were accompanied by neurophysiological assessments, and consequently 
subclinical upper or lower motor neuron dysfunction may have gone undetected.         
 
Other molecular processes and ALS pathogenesis 
Mitochondrial dysfunction:  In conjunction with glutamate excitotoxicity, mitochondrial 
dysfunction has also been implicated in ALS pathogenesis (92, 256-262).  Mitochondria are 
intracellular organelles whose main function is to generate energy for the cell in the form of 
ATP.  Glutamate excitotoxicity leads to production of free radicals by mitochondria, 
secondary to excessive Ca2+ accumulation (263), and thereby injury of critical neuronal 
cellular proteins and DNA.  In addition, mitochondria remain sensitive to free radical damage 
at both the protein and DNA level, resulting in further mitochondrial dysfunction (264). Of 
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relevance, mitochondrial damage may enhance glutamate excitotoxicity by disrupting the 
normal voltage-dependent Mg2+ mediated block of NMDA receptor channels (160, 209).    
 
Mitochondrial degeneration and dysfunction has been reported in ALS patients and in the 
transgenic SOD-1 mouse model (258, 261, 265).  Specifically, structural abnormalities of 
muscle mitochondria have been reported in ALS (257, 260, 266).  In addition, dysfunction of 
mitochondrial enzymes involved in energy generation, such as Cytochrome C Oxidase and 
respiratory chain complexes I and IV, as well as down-regulation of nuclear genes encoding 
mitochondrial components within the motor cortex have been reported in ALS (259, 260, 
266-268).  Reduction in protein import, impairment of Ca2+ sequestration and an exaggerated 
depolarizing response of the inner mitochondrial membrane has been reported in the pre-
symptomatic stages of ALS (269-273).  Ultimately, severe damage to the mitochondrial 
membrane potential, respiration, and electron transfer chain ensues, resulting in reduced ATP 
synthesis and neurodegeneration (207).   
 
The neuronal transportation of mitochondria appears to be impaired in ALS (207).  
Specifically, movement of mitochondria is regulated through Ca2+ signaling and synaptic 
activity (274), and increases in intracellular Ca2+ concentration, as may be induced by 
glutamate excitotoxicity, interrupts mitochondrial movement within the cell (275).  
Abnormalities of mitochondrial distribution and transport have been reported in ALS, with 
evidence of reduced distribution in the axons and more frequent pauses in mitochondrial 
movements (276).  Ultimately, this interruption in mitochondrial mobility may result in 
depletion of energy supply in critical neuronal segments, essential for the maintenance of the 
resting membrane potential and generation of action potentials, with resultant neuronal 
degeneration.    
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From a therapeutic perspective, a recent phase II trial of dexpramipexole, a pharmacological 
agent that enhances mitochondrial function (277), was shown to be effective in slowing ALS 
disease progression and reducing mortality over a 24 week period potentially offering hope in 
ALS (278).  Unfortunately, a phase III, multicenter international trial, undertaken to assess 
the clinical efficacy of dexpramipexole as add on therapy to riluzole in ALS, was shown to be 
ineffective (279), although a recent post-hoc analysis suggested benefits in a subgroup of 
riluzole-treated, short-symptom duration, rEEC definite ALS patients (280).   
 
Oxidative stress and the SOD-1 gene:  In concert with glutamate excitotoxicity and 
mitochondrial dysfunction, oxidative stress has also been implicated in the pathogenic 
process of ALS, although the importance of this mechanism seems limited (262).   Mutations 
in the SOD-1 gene, the first ALS gene reported and mapped to the long arm of chromosome 
21 [21 q22.1] implied a role for oxidative stress in ALS pathogenesis (281).  To date, over 
166 SOD-1 mutations have been reported, underlying 14-23% of familial and 1-7 % of 
sporadic ALS cases (90).  Intra- and interfamilial variation in penetrance, age and site of 
disease onset, rate of disease progression and survival has been reported for most SOD-1 
mutations, with  approximately 50% of patients expressing the disease by age 43 and more 
than 90% by 70 years (282).    
 
The pathophysiological mechanisms by which SOD-1 gene mutations mediates 
neurodegeneration in ALS remains to be fully elucidated (92). A toxic gain of function, as 
indicated by aberrant biochemical activity of the SOD-1 enzyme has been implicated as a 
potential pathogenic mechanism (283).  Specifically, SOD-1 mutations may lead to increased 
production of hydroxyl and free radicals (284), as well as nitration of tyrosine residues on 
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proteins (285-287).  The findings of normal SOD-1 enzyme activity in mutants (288), along 
with an absence of correlation between dismutase activity and disease severity (289), and 
lack of beneficial effects of antioxidant therapy in ALS patients (290), potentially argues 
against a significant role for oxidative stress in SOD-1 related ALS pathogenesis. 
 
In addition, aggregation of mutated SOD-1 peptides which may lead to toxicity and neuronal 
degeneration has also been proposed as a potential pathogenic mechanism (47).  Importantly, 
disease severity in SOD-1 mutants appear to correlate with instability of the SOD-1 mutant 
(291).  The mechanisms by which confirmation changes in the SOD-1 protein leads to 
neurodegeneration remains to be determined, although co-aggregation of essential cellular 
components or induction of aberrant catalysis by misfolded SOD-1 mutants have been 
proposed as potential processes (292). 
 
Impairment of axonal transport systems (241, 293, 294), endosomal trafficking (148, 149, 
241, 295), neuroinflammation (296-298), induction of an excessive endoplasmic reticulum 
stress response (299, 300), and expression of human endogenous retrovirus-K (301) have all 
been implicated in ALS pathogenesis, although their role remains to be fully clarified (47, 
157). 
 
Non-cell autonomous processes: An emerging concept in ALS pathogenesis pertains to non-
cell autonomous processes, whereby neighboring glial cells mediate motor neuron cell death 
(94, 156, 302).  Studies in transgenic mouse models reported that modulation of mutant SOD-
1 expressed in microglia, slowed disease progression (302), while astrocytes expressing the 
mutant SOD-1 gene exerted toxic effects in cultured primary motor neurons (303, 304).  
Importantly, silencing of astrocytic mutant SOD-1 genes significantly slowed disease 
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progression (305).  Non-neuronal cells appear to be important in regulating disease 
progression rather than initiating motor neuron disease (296, 302), and an interaction between 
motor neurons and non-neuronal cells seems to be critical for pathogenesis (306-308).    
 
The pathogenic mechanisms by which non-neuronal cells exert toxicity remain to be 
elucidated, although multiple mechanisms appear to be responsible (157).  Specifically, 
impairment of passive properties of astrocytes, such as uptake or recycling of 
neurotransmitters and regulation of extracellular ion homeostasis, along with activation of 
microglia cells with increased secretion of neurotoxic agents, such as glutamate and pro-
inflammatory cytokines, appear to be important mechanisms (94).   In addition, non-cell 
autonomous toxicity may also be mediated by a process termed to as necroptosis, a form of 
programmed cell death mediated by interaction of vital protein [receptor-interacting protein 1 
and the mixed lineage kinase domain-like protein] (309).  Importantly, non-cell autonomous 
processes may serve as important therapeutic targets in ALS. 
 
Assessment of cortical excitability  
To further explore and assess the function of the central nervous system in ALS and thereby 
gaining a better understanding of ALS pathophysiology, we utilised transcranial magnetic 
stimulation.  TMS is a relatively painless neurophysiological technique which can be 
performed non-invasively by stimulating the human motor cortex, being first described by 
Barker and colleagues (310).   
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Principles of magnetic stimulation 
Magnetic stimulators consist of a capacitor, thereby acting as a device which can store a 
charge, when discharged there is a flow of current through a coil which then subsequently 
generates a magnetic field.  This magnetic field in turn, induces an electric field in a nearby 
conductor (which in respect to our study are the cortical neurons), thereby resulting in current 
flow and subsequent neural stimulation (311, 312).  The position at which the cortical motor 
neuron is excited by the magnetic stimulation depends on the voltage gradient parallel to the 
nerve fibre.  Neural anatomy in the brain is very complex, the point of neural excitation 
occurs at bends, branch points or at the transition from cell body to axon (313).  Hence, it can 
be appreciated that the orientation of neurons, relative to the induced magnetic field, is 
critical in determining which neurons are activated. 
 
In addition to the positioning of the magnetic coil, the physical properties of the coil can also 
influence neural excitation, such that circular coils induce maximum current at the coil 
circumference.  Hence, when these magnetic circular coils are placed at the vertex, with the 
coil edge overlying the hand area, there will be preferential stimulation of the primary motor 
area.  If a more focal “figure-of-eight coil” which is formed by two smaller adjacent circular 
coils is utilised, more focal magnetic fields are generated and hence specific positioning and 
orientation of the coil over the motor cortex is required to ensure adequate cortical motor 
neuron activation (311, 312, 314).  The direction of current flow that is induced by the 
magnetic stimulation will dictate which cerebral hemisphere is stimulated, current flowing 
from a posterior-anterior direction (i.e. inion to nasion) is most effective at stimulating the 
motor cortex.  For a circular coil positioned at the vertex, clockwise current in the coil 
(viewed from above) preferentially stimulates the right hemisphere (311, 312, 314).   
 
44 
  
From animal experiments it has been demonstrated that cortical stimulation can result in 
generation of complex corticomotoneuronal volleys composed of direct  [D]-waves (due to 
direct stimulation of the corticospinal axon) and multiple indirect  [I]-waves arising from 
trans-synaptic excitation of pyramidal cells via excitatory cortical interneurons (315).  The D 
wave is produced by direct activation of corticospinal axons, whereas the I-waves are 
produced through secondary activation of neural elements presynaptic to the corticospinal 
cells (316). 
 
In humans, TMS activates the motor cortex at a depth of approximately 1.5 to 2.1 cm (317) 
and cervical epidural recordings have confirmed the presence of D and I-waves, at intervals 
of 1.5-2.5 ms (318, 319).  The I-waves are numerically labeled according to the time interval,  
such that the first I-wave is called I1, the second I2, the third I3 and so on (319).  I-waves are 
best elicited by cortical currents directed in a posterior-anterior direction, whereas D-waves 
are produced preferentially if the current runs in a lateral to medial direction (320-324).  The 
production of I-waves may not be sequential, such that I3 waves may be recruited prior to 
other I-waves, if the stimulating conditions are optimal (325).  Although numerous models 
have been proposed to attempt to explain how I-waves are produced within the motor cortex, 
the mechanisms continue to remain elusive (326). 
 
In a clinical setting, the assessment of cortical excitability and the integrity of corticospinal 
pathways are best evaluated by measuring the following neurophysiological parameters: (i) 
motor threshold; (ii) motor evoked potential (MEP) amplitude; (iii) central conduction time; 
(iv) cortical silent period; and (v) short interval intracortical inhibition and facilitation. 
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(i) Motor threshold 
Motor threshold (MT) reflects the ease with which corticomotoneurons are excited, the 
International Federation of Clinical Neurophysiology proposed its assessment to be the 
minimum stimulus intensity required to elicit a small (usually >50 μV) motor evoked 
potential (MEP) in the target muscle in 50% of trials (327).  Recently employed threshold 
tracking techniques, can measure MT as the stimulus intensity required to elicit and maintain 
a target MEP response of 0.2 mV (328-330).  Motor threshold is thought to reflect the density 
of corticomotoneuronal projections onto spinal motor neurons, whereby the intrinsic hand 
muscles exhibit the lowest MTs due to the highest density of projections (331-333), and 
whereby the MTs are lower in the dominant hand (333), and as such correlate with the ability 
to perform fine fractionated finger movements (334).  Further to reflecting the density of 
corticomotoneuronal projections, MTs may also be act as a biomarker of cortical neuronal 
membrane excitability (317, 335, 336).   Studies have shown that MTs can be influenced by 
the glutamatergic neurotransmitter system, through AMPA receptors, and excessive 
glutamate activity may reduce MTs (337). Inhibition of voltage-dependent Na+ channels with 
agents such as carbamazepine increases MT (338-340).  Of further relevance, MTs are 
influenced by the state of wakefulness and by the extent of target muscle activation (311, 
341). 
 
Motor threshold findings in ALS have been varied and inconsistent.  Some TMS studies have 
reported an increased MT or even an inexcitable motor cortex (40, 342-348), whereas other 
studies have shown either normal or reduced MT (41, 45, 183, 185, 349, 350).  Interestingly, 
in longitudinal studies, there is a reduction of MTs early in the disease course, thereafter, the 
MT increases to the point of cortical inexcitability, correlating with disease progression 
(350).   Early reductions in MTs appear to be most prominent in ALS patients with profuse 
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fasciculations, preserved muscle bulk and hyper-reflexia (249).  The findings of 
fasciculations preceding other clinical features of ALS by several months, when interpreted 
with reduced MTs, may suggest a cortical origin of fasciculations (351).  Excess glutamergic 
activity and thereby glutamate excitotoxity, along with reduced GABAergic inhibition may 
underlie the development of reduced motor thresholds in ALS.  The findings of reduced MTs 
early in the disease process may support an anterograde trans-synaptic process, where cortical 
hyperexcitability potentially underlies the development of progressive neurodegeneration.  
 
(ii)  Motor evoked potential (MEP Amplitude)  
The MEP amplitude reflects the summation of complex corticospinal volleys consisting of D 
and I waves onto the spinal motor neuron (335, 352).   At the motor threshold, TMS elicits I-
waves at intervals of 1.5 ms, which increase in amplitude with increasing stimulus intensity 
(352).  As the MEP amplitude increases with increasing stimulus intensity, it may then be 
possible to generate a stimulus-response curve which follows a sigmoid function (353).  The 
MEP amplitude is thought to reflect the density of corticomotoneuronal projections onto 
spinal and bulbar motor neurons (354), it may partly assesses the function of cortical neurons 
that are positioned further away from the center of the TMS field, or assess cortical neurons 
that are less excitable (312).  To accurately to account for LMN dysfunction, the MEP 
amplitude should be expressed as a percentage of the maximum peripheral CMAP response 
(327).  The sensitivity and thereby the diagnostic utility of the MEP/CMAP ratio in detecting 
UMN dysfunction, is limited by a large inter-subject variability (312, 355).  
 
The MEP responses may also be modulated other neurotransmitter systems within the central 
nervous system (354, 356).  Specifically, GABAergic neurotransmission via GABAA 
receptors suppresses, while glutamatergic and noradrenergic neurotransmission enhances the 
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MEP amplitude (340).  The changes in MEP amplitude may occur independently of MT 
changes, thereby suggesting that the physiological mechanisms underlying the generation of 
MEP amplitude and MTs are varied. 
 
Abnormalities of MEPs have been extensively documented in ALS patients (39, 312).  
Specifically, the MEP amplitude is increased in all forms of ALS, including both sporadic 
and familial forms of ALS, it appears to be most prominent in early stages of the disease 
process (183, 185, 240).  The MEP amplitude also correlates with surrogate biomarkers of 
axonal degeneration, thereby suggesting an association between cortical hyperexcitability and 
motor neuron degeneration (183, 184).  This increase in MEP amplitude appears to be 
specific for ALS, with no similar findings in mimic disorders, despite a comparable degree of 
LMN dysfunction, arguing against adaptive secondary changes as a result of simple cortical 
plasticity (237-239, 357).   
 
(iii) Central motor conduction time (CMCT)  
The central motor conduction time reflects the time from stimulation of the motor cortex to 
the arrival of corticospinal volley at the spinal motor neuron (327).  A number of factors have 
been attributed to the contribution of the CMCT including, time to activate the corticospinal 
cells, conduction time of the descending volley down the corticospinal tract, synaptic 
transmission and activation of spinal motor neurons (358).  The calculation of the CMCT 
may be done by two methods, the F-wave method (see Methodology) or cervical (or lumbar) 
nerve root stimulation methods (359, 360).  Given that both methods estimate the CMCT 
(311, 358), and a number of technical, physiological and pathological factors influence 
CMCT (358), a range of normative CMCT data exists.  
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The central motor conduction time has been shown to be prolonged in approximately 20% of 
ALS cases (40, 350, 361), it likely reflects degeneration of the fastest conducting 
corticomotoneuronal axons, with the possibility of concomitant increased desynchronization 
of corticomotoneuronal volleys secondary to the axonal loss (46, 349, 362).  Some have 
advocated for utilising the CMCT when clinical features of UMN signs are equivocal (40, 
350).  The sensitivity of detecting a prolonged CMCT in ALS may be improved by recording 
from both, the upper and lower limb muscles, or from the cranial muscles with bulbar-onset 
disease (39, 314, 348).  
 
(iv) Cortical silent period (CSP)  
The cortical silent period (CSP) refers to a neurophysiological parameter that results from 
interruption of voluntary electromyography (EMG) activity in a target muscle, when 
magnetic stimulation is applied over the contralateral motor cortex (363).  The measurement 
of the CSP duration is from the onset of the MEP response to the resumption of voluntary 
EMG activity (354, 363).  With increases in magnetic stimulus intensity, there is a 
prolongation of the CSP duration (363-365).   
 
The underlying mechanism of the CSP appears to be complex and multifactorial in nature.  It 
has been shown that the early segment of the CSP is mediated by spinal processes (364, 366), 
whilst the later segment is mediated by long-lasting inhibitory post-synaptic potentials 
(IPSP), generated via gamma-aminobutyric acid type B (GABAB) receptors (312, 364, 366, 
367), this is supported by pharmacological studies utilising GABAergic compounds (368, 
369).  The GABAB receptors are metabotropic receptors that are coupled to Ca
2+ and K+ 
channels via G proteins and second messenger systems, located at the pre-and postsynaptic 
nerve terminals (370).  It is postulated that post-synaptic GABAB receptors mediate CSP by 
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activating a specific G-protein, inducing an increase in K+ efflux, which then results in 
hyperpolarization of the postsynaptic membrane (370).  Conversely, the presynaptic GABAB 
receptors mediate inhibition through voltage-gated Ca2+ channels, resulting in inhibition of 
neurotransmitter release (371-373).  Furthermore, in addition to the GABAB receptor 
modulation, the CSP is also influenced by the density of the corticomotoneuronal projections 
onto motor neurons, motor attention, the extent of voluntary drive and other 
neuromodulators, such as dopamine (312, 338, 374, 375). 
 
The CSP abnormalities are well described in ALS (354), specifically a reduced or unchanged 
CSP duration has been reported in ALS, with the reduction is CSP duration being most 
prominent early in the disease process (43, 45, 182, 183, 185, 238, 239, 361, 376, 377).  
Amongst neuromuscular disorders the reduction of CSP duration appears specific for ALS, 
with a normal CSP reported in Kennedy’s disease, acquired neuromyotonia and distal 
hereditary motor neuronopathy with pyramidal features (237-239, 357).  Although the 
underlying mechanisms of the reduced CSP duration in ALS remain to be fully established, 
reduced GABAergic inhibition and decreased motor drive, due to a combination of inhibitory 
interneuronal degeneration or dysfunction of GABAB receptors, may underlie the reduced 
CSP duration in ALS.   
 
(v)  Paired-pulse techniques 
Transcranial magnetic stimulation may also be performed by a paired-pulse technique to 
assess cortical excitability, in this paradigm a conditioning stimulus modulates and precedes 
the effects of a second test stimulus.  To date there have been several different paired-pulse 
paradigms developed (39, 312, 354).  Neurophysiologically the two parameters that have 
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been utilised most commonly are the short interval intracortical inhibition (SICI) and 
intracortical facilitation (ICF), frequently utilised in ALS clinical research as methods to 
determine cortical excitability.  Hence, in this thesis the two parameters discussed and 
utilised are the SICI and ICF. 
 
When a subthreshold conditioning stimulus (set to 70 of RMT) is delivered by a paired-pulse 
paradigm at pre-determined time intervals before a suprathreshold test stimulus, it is possible 
to measure the short interval intracortical inhibition (SICI) (329, 378-380).  When the 
technique was first developed, the conditioning and test stimuli remained constant and the 
effects of the conditioning stimulus were measured by recording changes in the MEP 
amplitude.  When the pulses are delivered between the interstimulus interval (ISI) of 1-5 ms, 
the test response was inhibited (SICI).  With increasing interstimulus intervals of 7 and 30 
ms, there is a facilitation of the test response (ICF) (312). 
 
Both, SICI and ICF are generated at the level of the motor cortex (352, 380).  Epidural 
recordings have established that SICI is associated with reduction in number and amplitude 
of late I-waves, mediated by inhibitory cortical interneurons via GABAA receptors (379, 
381).  Conversely ICF was associated with an increase in the I-wave amplitude, being 
reduced by GABAA receptor agonists (338).  GABAA receptors are ionotropic in that they 
directly gate Cl− selective ion channels and possess modulatory binding sites for 
benzodiazepines, barbiturates, neurosteroids and ethanol (382, 383).  The GABAA receptors 
consist of five protein subunits arranged around a central pore, each subunit consists of an 
extracellular N-terminal domain, followed by three membrane spanning domains (M 1-3), of 
which the M2 domain forms the pore channel, an intracellular loop and a fourth membrane 
spanning domain (M4) (384).  Sixteen different subunits could potentially comprise the 
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GABAA receptor, including α1–6, β1–3, γ1–3, δ, ɛ, π and θ, with the α1β2/3γ2, α2β3γ2, and 
α3β3γ2 subunit combinations being the most frequent (384-386). 
 
SICI appears to be mediated by GABAA receptors comprised of the alpha 1 subtype (387).  
Furthermore both SICI and ICF are also modulated by other cortical neurotransmitter systems 
including  glutamate (39, 224, 388, 389), dopamine (338, 390) and norepinephrine (338), and 
selective serotonin re-uptake inhibitors (391).  Importantly, SICI and ICF appear to be 
physiologically distinct processes as evident by lower thresholds for activation of SICI and 
that SICI remains independent of the direction of subthreshold conditioning current flow 
within the motor cortex, while ICF appears to be preferentially generated by current flowing 
in a posterior-anterior direction (392). 
 
One of the limiting factors with the original “constant stimulus” technique was marked 
variability in the MEP amplitude with consecutive stimuli (379, 393).  The variability of the 
MEP responses in part was related to spontaneous fluctuations in the resting threshold of 
cortical neurons.  To overcome this variability, a threshold tracking technique was 
developed, whereby a constant target MEP response (0.2 mV) was tracked by a test stimulus 
(328, 329).  By utilizing threshold tracking, two distinct phases of SICI were identified (328, 
329, 394, 395), a smaller phase at ISI ≤1 ms and a larger phase at ISI 3 ms.  The second 
phase of the SICI it thought to be related to synaptic neurotransmission through the GABAA 
receptors (381, 396-398), however, the precise mechanisms underlying the first phase of SICI 
remains unresolved.  One suggestion was that the first phase of SICI reflected local 
excitability properties, particularly relative refractoriness of cortical axons, with resultant 
resynchronization of cortico-cortical and corticomotoneuronal volleys (328, 399). 
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Synaptic processes therefore, could best explain the development of the initial phase of the 
SICI, driven by activation of cortical inhibitory circuits that were distinct from the circuits 
mediating the later SICI phase (394, 395, 400).  Hyperexcitability therefore, is defined as a 
reduction or absence of SICI, with increase in ICF also supporting this notion.  These 
findings of reduced SICI and increased ICF have been well documented in sporadic and 
familial ALS patients (45, 183, 185, 238, 357, 388, 401-405).   Cortical hyperexcitability 
appears to be an early pathophysiological process in ALS, correlating with measures of 
peripheral neurodegeneration and preceding the clinical development of familial ALS (183, 
185).   
 
The reduction or absence of SICI in ALS have been attributed to degeneration of inhibitory 
cortical interneurons (406) along with glutamate-mediated excitotoxicity (224, 388).  
Underscoring this notion is the findings of SICI abnormalities in ALS at low (40% of resting 
motor threshold (RMT), medium (70% of RMT) and high (90% of RMT) conditioning 
stimulus intensities (407).  One potential therapeutic option in ALS is attempting to preserve 
the integrity of intracortical inhibitory circuits, and counteracting excitatory cortical circuits.   
 
Axonal Excitability Testing 
Threshold tracking techniques can also be utilized to assess peripheral nerve function (408, 
409).  In the context of axonal function, the term threshold refers to the stimulus current 
required to produce a specific potential.  Utilising threshold tracking, changes in the test 
stimulus current intensity required to generate a preset amplitude can be adjusted on-line to 
keep the target amplitude constant (see Methodology).  The utility of axonal excitability to 
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probe axonal ion channel function, may provide unique insights into the generation of the 
peripheral findings that underlie the generation of symptoms in ALS, such as fasciculations 
and cramps, as well as probe processes responsible for motor neuron degeneration in ALS 
(35, 410-413).  In this thesis, we utilized the threshold tracking protocol, measuring the 
following parameters of axonal excitability: threshold; strength-duration time constant; 
rheobase; threshold electrotonus; current/threshold relationship; and recovery cycle. 
 
(i)  Threshold  
In axonal excitability studies, the term threshold refers to the amount of stimulus current 
required to activate an axon and thereby produce a compound muscle action potential of a 
specific amplitude (408, 409).  The threshold may be utilised as a surrogate biomarker of 
membrane potential, whereby membrane hyperpolarization increases and depolarization 
decreases the membrane threshold.  The threshold can be influenced by such instances of 
hyperventilation or nerve ischemia, and in that instance it may not accurately reflect 
membrane potential.  Therefore, in those circumstances the ambiguity may be resolved by 
measuring other indices of axonal excitability (414-418).   
 
(ii)  Strength duration time constant and rheobase  
The strength-duration time constant (SD), which is also known as chronaxie, measures the rate 
at which the threshold current for a target potential declines as the stimulus duration is 
increased (419-421).  The SD in human peripheral nerves can be calculated by using the ratio 
between stimulus-response curves for two different stimulus durations according to the 
Weiss' formula (422).  Rheobase is the threshold current (mA) for stimulus of infinitely long 
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duration (409).  The SD and rheobase are properties of the nodal membrane, being dependent 
on passive membrane properties and persistent Na+ channel conductances [INaP] (423).  
 
The persistent Na+ currents, constitute approximately 1-2% of the total Na+ current  (423-
425) and are conducted through voltage-gated Na+ channels composed of one alpha (α) and 
four beta (β1-4) subunits (426, 427).  The channels are structured, such that the α subunits are 
organized in four homologous domains (I-IV), each consisting of six transmembrane α 
helices (S1-S6) and a pore loop located between the S5 and S6 segments that acts as a 
selectivity filter.  The S4 segments of each domain functions as a voltage sensor.  The 
inactivation of Na+ channels is mediated by a short intracellular loop connecting homologous 
domains III and IV, which fold into the channel structure and blocks the pore from the inside 
during sustained membrane depolarization.  When there is inactivation of the INaP , it occurs 
very slowly or incompletely (428).  At least ten distinct Na+ channel isoforms have been 
identified to date, Nav 1.1 to Nav 1.9 and Nax (426, 427, 429), with INaP conducted by the 
Nav1.6 isoform which is expressed at the nodes of Ranvier  (426, 427, 429, 430).   
 
A full understanding of the INaP channel is yet to be determined, however it has been proposed 
that a uniform population of Na+ channels may generate both transient and persistent Na+ 
currents by switching between different gating modes (431).  Amino-acid residue 
phosphorylation within the alpha subunit of voltage-gated Na+ channels may underlie these 
gating changes (432, 433).   
 
Changes in the strength duration-time constant and rheobase may be influenced by the resting 
membrane potential, such that depolarization reduces rheobase and prolongs SD, whilst 
hyperpolarization exerts the opposite effects.  Furthermore, changes in nerve geometry, such 
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as axonal loss or demyelination, may also influence the SD, as may discrete changes in nodal 
Na+ conductances (434-437).  In ALS, the finding of prolonged SD may lead to excessive 
ectopic axonal activity, underlying the generation of fasciculations and cramping, as well as 
neurodegeneration (34, 183, 184, 413, 437-439).  Furthermore, upregulation of INaP may 
underlie neurodegeneration by increasing the intracellular concentration of Ca2+ (210, 440, 
441). 
 
 (iii)  Threshold Electrotonus  
Threshold electrotonus (TE) describes the changes in threshold produced by long-lasting 
subthreshold currents and provides insight into into both nodal and internodal membrane 
conductances (408).  This technique measures changes in threshold current produced by a 
long-duration polarizing current (408, 442)  The conditioning currents are subthreshold and 
in themselves do not trigger an action potential, but rather result in local changes in the 
membrane potential (408, 409).  The TE is usually measured by long duration 1 ms current 
pulses, which is long compared to the time constant of the nodes of Ranvier, but short 
compared with the time constants of the internodal membrane and slowly activating ion 
channels (443).  The changes in the threshold current can be measured at varying 
conditioning-time intervals in response to subthreshold conditioning currents (444, 445).   By 
conventional TE is plotted in a way that, an increase in excitability (threshold reduction) 
produces an upwards deflection and a decrease in excitability, a downward deflection.  The 
reason this convention was adopted was so changes in threshold electrotonus would resemble 
the underlying changes in membrane potential. The ‘threshold tracking’ protocol of axonal 
excitability testing utilizes test stimuli of 1-ms duration to produce the target CMAP response 
(40% of maximal) and changes in threshold induced by subthreshold polarizing currents of 
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100 ms in duration, set to + 40% (depolarizing) and − 40% (hyperpolarizing) of the control 
threshold current (444).   
 
The initial fast response (“F” phase, Figure 4) reflects rapid changes in threshold at the node 
of Ranvier, resulting from the application of either a depolarizing or hyperpolarizing 
subthreshold current.  This is followed by slower changes in threshold over tens of 
milliseconds in both depolarizing and hyperpolarizing directions, called the “S1” phase, and 
reflects the spread of current to the internodal membrane (Figure 4). During the 
depolarization phase, the S1 phase peaks at 20 ms after the onset of the current pulse, after 
which threshold begins to return to baseline, the S2 phase.  This S2 phase occurs due to 
activation of nodal and internodal slow K+ channels (408, 442).   
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Figure 4.  Threshold changes to polarising currents of 100 ms duration set to ± 40% of resting 
threshold.  Changes are plotted with threshold reductions, with depolarisation represented as an 
upward deflection and hyperpolarization in a downward direction.  Reproduced with permission 
S.Vucic 2007. 
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During the hyperpolarization phase, the S1 phase peaks at 100-150 ms after the onset of the 
subthreshold conditioning current and then proceeds to return to baseline thereafter, termed 
the S3 phase (Figure 4).  This accommodative phase, the S3 phase, is due to activation of the 
hyperpolarizing-activated inward rectifying currents (IH) (408, 409, 446, 447).  On 
termination of the subthreshold conditioning currents, there is an overshoot of threshold with 
both depolarization and hyperpolarization.  With depolarization, slow K+ channels mediate 
the overshoot, whilst in hyperpolarization the overshoot is mediate by IH. 
 
The voltage-gated K+ channels are members of the voltage-gated ion channel protein 
superfamily (448), and are composed of four alpha pore-forming subunits and accessory β 
subunits (449).   In human myelinated axons voltage-gated K+ currents are activated by 
depolarization, and three types of currents have been identified, including two fast (IKf1 and 
IKf2) and one slow current (IKs).  The slow (S) channels underlie the S2 phase of TE, exhibit 
slower deactivating kinetics and are located at both the node and internode (446, 450-454).  
The internodal S channels play an important role in the maintenance of the internodal resting 
membrane potential, thereby contributing to the nodal resting potential and increasing the 
safety factor of impulse conduction (450, 455). 
 
Alterations in membrane potential result in changes in threshold electrotonus.  Specifically, 
with membrane depolarization there is a reduction in the resistance of the internodal 
membrane, due to activation of paranodal and internodal K+ channels, resulting in reduction 
of the S1 phase in both depolarizing and hyperpolarizing directions, thereby causing a 
“fanning in” appearance of TE (408, 409, 456).  Conversely, hyperpolarization closes the 
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paranodal and internodal K+ channels, thereby increasing the S1 and S2 phases producing a 
fanning out appearance (408, 409, 456). 
 
The alterations in TE were first described in ALS, whereby two distinct responses were 
described; (i) TE recordings with greater threshold reductions during depolarization (Type 1 
response) and (ii) TE recordings with an unexpectedly rapid increase in threshold during 
depolarisation (Type 2 response) (32, 413).  The mechanism underlying this was felt to be a 
reduction in internodal slow K+ channel conduction.  Abnormalities of TE have now been 
reported in several conditions including autoimmune neuropathies, such as multifocal motor 
neuropathy (457), as well as in metabolic and chemotherapy related neuropathies (33, 446, 
458-463). 
 
(iv) Current threshold relationship (I/V)  
Changes in threshold can also be plotted in response to long duration subthreshold currents 
(200ms duration) applied in a ramp like fashion, referred to as the current-threshold 
relationship (I/V plot), with currents applied from +50% (depolarizing) to −100% 
(hyperpolarizing) of the control threshold in 10% steps (444, 445).  Conventionally, threshold 
increases (hyperpolarization) are plotted to the left and threshold decreases (depolarization) 
to the right (Figure 5).  The I/V relationship estimates rectifying properties of both nodal and 
internodal axonal segments (408).  The I/V gradient induced by depolarizing sub-threshold 
currents reflects conduction through outward rectifying K+ channels, while the I/V gradient 
during hyperpolarizing sub-threshold currents reflects inwardly rectifying conductances [IH] 
(408).    
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Two basic types of current underlie inward rectification (464).  The first type, which is the 
classic inward rectifier, is related to a pure K+ conducting channel, which is activated at 
membrane potentials negative to the K+ equilibrium potential (465, 466).  The second type of 
inward rectification is mediated by a channel that exhibits conductance for both Na+ and K+ 
(467, 468).  This current begins to activate at between -45 mV and -60 mV and peaks at -
110mV (465, 469).  The second IH current activates and deactivates slowly, and the 
magnitude of the IH current is also dependent on extracellular K
+ concentration (468).   
 
A major function of internodal IH is to limit electrogenic hyperpolarization and the 
consequent reduction of axonal excitability in response to high-frequency activity (467).  
Given that high-frequency activity can induce failure of impulse conduction in axons with a 
reduced safety factor of transmission, the IH current may be critical in preventing such 
conduction failure (470).  In primary demyelinating neuropathies, motor nerves may have a 
Figure 5.  Current-threshold relationship: normalised threshold changes at the end of 200 ms 
duration currents are plotted, with depolarization represented to the right and hyperpolarization 
to the left.  The conditioning current is varied from +50 % to –100 % of control threshold. 
Reproduced with permission S.Vucic 2007. 
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predilection to develop activity-dependent conduction failure (471, 472) in contrast to 
sensory nerves, due to the reduced expression of IH in motor nerves (473, 474).  
 
(v) The recovery cycle of axonal excitability  
Once there is conduction of an action potential, the axons undergo a series of stereotyped 
excitability changes known as the recovery cycle (Figure 6).  Initially, there is a period of 
total axonal inexcitability, lasting for 0.5-1 ms during which the axon cannot generate an 
action potential, termed the absolute refractory period.  Following this period, the axon 
enters a relative refractory period (RRP), during this period an action potential may be 
generated by stronger than normal stimulus currents.  This period lasts for up to 4ms and may 
be measured as an increase in current required to generate a potential (termed refractoriness), 
or as the duration of the RRP, the point where the recovery cycle curve crosses the x-axis 
(Figure 6).  
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Figure 6.  Recovery cycle of excitability is assessed by tracking the changes in threshold that 
occur following a supramaximal conditioning stimulus of 1-ms duration.  RRP refers to the 
‘relative refractory period’. Reproduced with permission S.Vucic 2007. 
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The absolute refractory period is secondary to inactivation of nodal voltage-gated transient 
Na+ channels, while the RRP results from gradual recovery of these channels from 
inactivation (475).  Similar to the persistent Na+ channels these transient Na+ channels are of 
the Nav1.6 isoform, and consist of alpha and beta (β) subunits (427), and exhibit “fast” 
activation and inactivation kinetics, namely the channels open rapidly with depolarization and 
inactivate rapidly (427, 476).  Transient Na+ currents are first detected at membrane 
potentials of -55 mV, peaking at ~ -30 mV and underlie the rapid phase of depolarization of 
the action potential (409).   
 
The changes in membrane potential can influence Na+ channel kinetics, and subsequently 
affect refractoriness (409).  At normal resting membrane potential, approximately 30% of 
Na+ channels are inactivated, with hyperpolarization there is a shift to reduce the degree of 
“inactivated” Na+ channels, this then leads to a decrease in refractoriness. Conversely, 
depolarization increases the extent of Na+ channel inactivation, subsequently increasing 
refractoriness (409).   Refractoriness is also sensitive to temperature changes, with 
refractoriness being increased by reductions in limb temperature (477, 478). 
 
Following refractoriness there is a period of increased axonal excitability, termed 
superexcitability, lasting for approximately 15 ms.  This period is mediated by re-excitation 
of the nodal membrane by the discharge of current stored on the internodal membrane 
following an action potential, also known as the depolarizing long-lasting afterdepolarization 
(DAP) (409, 479).  The amplitude and time course of DAP is limited by activation of 
paranodal and juxtaparanodal K+ channels, which serve to reduce the degree of DAP, and 
thereby superexcitability, by shunting the internodal current (480).  Paranodal K+ channels 
are kinetically classified into fast (F) channels and intermediate (I) channels (452, 453, 481).  
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F channels are activated at potentials between -40 and +40 mV, then deactivating very 
rapidly at potentials between -120 mV and -65 mV (454, 482, 483).  In contrast, I channels 
are first activated by depolarization to around -70 mV, becoming fully activated at around -40 
mV and then deactivating slowly (483).   
 
Superexcitability can be influenced by changes in membrane potential, membrane 
depolarization reduces superexcitability by limiting Na+ influx and increasing K+ efflux 
through paranodal and juxtaparanodal fast K+ channels (484).  Conversely, membrane 
hyperpolarization increases DAP and therefore superexcitability.  Subsequently, 
superexcitability may be used as an indicator of membrane potential (444).   
 
The final phase of the recovery cycle is referred to as late sub excitability.  This period 
denotes a reduction in axonal excitability and lasts for approximately 100ms.  This period is 
defined by activation of nodal slow K+ channels (467) and is influenced by both the 
membrane potential and the K+ equilibrium potential.  As such, current induced membrane 
depolarization, which changes the electrochemical gradient for K+, increases late 
subexcitability.  Conversely, membrane depolarization secondary to increases in extracellular 
K+ concentration, as occurs with ischemia or renal failure, results in reduction of late 
subexcitability (456, 458, 460, 485). 
 
In this thesis both cortical excitability and axonal excitability studies will be utilised in 
sporadic and familial ALS patients, in order to determine the diagnostic utility of cortical and 
pathophysiological processes underlying neurodegeneration in ALS.   
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METHODOLOGY 
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Subjects 
 
The healthy subjects utilized in this study as the ‘control’ population had no clinical evidence 
of a peripheral nerve disorder or any history of medical conditions known to affect peripheral 
nerve function.  Before testing was undertaken it was ensured that patients were not on other 
medications which could influence the parameters of cortical excitability testing (338, 486-
488).  ALS patients who had a history of other illnesses like diabetes mellitus or other 
conditions which are known to cause neuropathy were excluded from all axonal excitability 
studies. All patients were diagnosed and catergorised using the Awaji criteria as ‘possible’, 
‘probable’, ‘probable lab-supported’ or ‘definite ALS’ (6).  Where patients were utilized in 
diagnostic studies, they were followed up over a three year period to confirm disease 
progression and thereby confirm the diagnosis of ALS. All patients and subjects gave written 
informed consent to the procedures, which had been approved by the Sydney West Area 
Health Service Human Research Ethics Committees and the University of Sydney Human 
Research Ethics committee. 
 
Equipment 
The list of equipment which was utilized to perform the studies in this thesis are listed:  
 
Hardware requirements:  
1) Personal computer fitted with a 16-bit data acquisition card (National Instruments PCI-
MIO-16E-4) that sampled signals at 10 kHz. 
2) Isolated linear bipolar constant stimulator (maximal output ± 50 mA) (DS5, Digitimer,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Welwyn Garden City, UK) 
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3) Conventional non-polarisable 5-mm Ag-AgCl surface EMG electrodes (3M Healthcare, 
MN, USA) for stimulation and recording. 
4) Preamplifier and filter (3 Hz-3 kHz) for recording sensory and motor potentials Nicolet-
Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys Healthcare 
Neurocare Group, Madison, USA).  
5) Electronic noise was further filtered by using a Hum Bug (Hum Bug 50/60 Hz Noise 
Eliminator, Quest Scientific Instruments, North Vancouver, Canada) 
6) Two high-power magnetic stimulators which were connected via a BiStim device 
(Magstim Co., Whitland, South West Wales, UK). 
7) Circular stimulation coil for transcranial magnetic stimulation (Magstim Company: High 
Power 90mm Coil -P/N9784-00)    
8) Purpose built thermometer for measuring skin temperature. 
9) Synergy EMG machine, Neurocare Group, Madison, USA. 
10) 26 G concentric EMG needle (Dantec DCN™ Disposable Concentric Needle Electrodes) 
 
Software requirements:  
1) Data acquisition and stimulation delivery (both electrical and magnetic) were controlled by 
a computerised threshold tracking programme, QTRACS software version 16/02/2009 (© 
Professor Hugh Bostock, Institute of Neurology, Queen Square, London, UK). 
 
Stimulating and Recording Paradigms 
The peripheral nerve studies which were described in Chapters 3-8 were undertaken over the 
median nerve (Figure 7) using conventional non-polarisable 5-mm Ag-AgCl surface EMG 
electrodes (3M Healthcare, MN, USA).  Median nerve stimulation was performed electrically 
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at the wrist, the cathode was placed at the wrist crease and the anode was placed at the mid-
forearm.  The compound muscle action potentials (CMAPs) were recorded via surface 
electrodes with the active recording electrode positioned over the motor point of the abductor 
pollicis brevis (APB), the reference electrode was placed 4 cm distally  over the proximal 
phalanx of the thumb (444) (Figure 7).  
 
Recording electrodes
(APB)
Stimulating electrode
(median nerve)
Temperature 
Ground
                                                                                                                                                                                                                          
               
 
 
 
 
 
 
 
Figure 7.  The configuration of the stimulating and recording electrodes for peripheral nerve 
stimulation.  The median motor is stimulated at the wrist with recording over the abductor 
pollicis brevis muscle (APB).  The motor evoked potentials are recorded over APB muscle using 
the same recording electrode configuration. 
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Threshold tracking and excitability protocols 
Cortical excitability studies 
Cortical excitability studies which are described in Chapters 3-5, 7-8 were performed by 
transcranial magnetic stimulation (TMS), with the motor cortex stimulated utilising a 90 mm 
circular coil.  The coil was oriented to induce a current flow in a posterior-anterior direction 
in order to preferentially activate the motor cortex.  The coil, initially centered over the 
vertex, was moved in the antero-posterior and medial-lateral directions in order to ascertain 
the optimal position for evoking responses of maximal amplitude from the target muscle 
(abductor pollicis brevis (APB)).  The magnetic currents were generated by utilising two 
high-power magnetic stimulators connected via a BiStim device (Magstim Co., Whitland, 
South West Wales, UK).  By utilising two stimulators the conditioning and test stimuli could 
be independently set and delivered through one coil.  The magnetic evoked potentials (MEPs) 
were recorded using surface electrodes and the peak-to-peak amplitude and onset latency 
were determined for MEPs. 
 
TMS threshold tracking (Figure 8): A paired pulse cortical stimulation technique was 
performed using the threshold tracking TMS protocol (329).  With this protocol, the output 
(MEP response) was fixed (at 0.2mV) and changes in the test stimulus intensity required to 
generate a target response, when preceded by either sub- or suprathreshold conditioning 
stimuli, were measured.   
 
It has been previously established by Fisher and colleagues in 2002 that the relationship 
between the logarithm of the MEP amplitude and the stimulus was close to linear over a 
hundred-fold range of responses, from about 0.02 to 2 mV (489).  Based on these findings, a 
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small target response of 0.2 mV (±20%), which lies in the middle of this linear range, was 
selected for the present study and subsequently tracked.  The resting motor threshold (RMT) 
was defined as the stimulus intensity required to produce and maintain the target MEP 
response (0.2 mV peak-to-peak) (329). 
 
Initially, the stimulus response (SR) curve for cortical stimulation was determined by 
increasing the intensity of the magnetic stimulus to the following levels: 60, 80, 90, 100, 110, 
120, 130, 140 and 150% of RMT.  Three stimuli were delivered at each level of stimulus 
intensity.  The maximum MEP amplitude (mV) and MEP onset latency (ms) were recorded.  
Central motor conduction time (CMCT, ms) was calculated according to the F-wave method 
(490, 491). 
 
 
 
Figure 8. Threshold tracking transcranial magnetic stimulation: equipment and recording 
configuration. 
QTRAC-S Software 
EMG trace display 
Recording electrode 
BiStim 
Circular coil 
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The cortical silent period (CSP), which was induced by single-pulse TMS was recorded 
whilst performing a weak voluntary contraction, estimated to be around 10-30 % of 
maximum voluntary contraction.  To aid in assessing the level of muscle contraction, audio 
feedback was provided to the subject, to help them sustain the contraction at the required 
force.  Similar to the generation of the SR curve, the magnetic stimulus intensity was varied 
at preset levels.  The duration of the silent period was measured from the beginning of the 
MEP response to the return of EMG activity (492). 
 
A paired-pulse paradigm was developed (329) whereby a subthreshold conditioning stimulus 
preceded a suprathreshold test stimulus at increasing interstimulus intervals (ISIs) as follows: 
1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 7, 10, 15, 20, and 30 ms.  The chosen subthreshold conditioning 
stimulus was set at 70% RMT, which did not evoke a response.  Stimuli were delivered 
sequentially as a series of three channels (Figure 9): channel 1 tracked the stimulus intensity 
required to produce the unconditioned test response (Figure 10A and B); channel 2 monitored 
the subthreshold conditioning stimulus so as to ensure that a MEP response was not produced 
and to ensure the subject remained relaxed; and channel 3 tracked the stimulus required to 
produce the target MEP when conditioned by a subthreshold stimulus equal in intensity to 
that on channel 2.  Tracking was deemed acceptable when the test stimulus produced two 
consecutive MEP responses that were within 20% of the target response (0.2 mV) or 
consistently oscillated about the target.  The three channels were applied sequentially.  The 
stimulus deliveries were limited by the charging capacity for the BiStim system and were 
delivered every 5-10 seconds.  The computer advanced to the next ISI only when tracking 
met the target criteria.  The precision of the tracking method was limited by the fact that the 
intensity of the magnetic stimulus was restricted to integral values from 1% to 100% of 
maximum stimulator output. 
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Figure 9.  Experimental paradigm and configuration of stimulus patterns used in Chapters 3-
5, 7 and 8.  Cortical excitability was assessed by measuring changes in stimulus intensity 
required to generate a target magnetic evoked potential response of 0.2 mV, when recording 
over the abductor pollicis brevis.  Channel 1 = unconditioned test stimulus, measuring 
resting motor threshold (RMT); Channel 2 = conditioning stimulus, which was set to 
subthreshold (70% RMT) when assessing short interval intracortical inhibition; Channel 3 = 
conditioned test stimulus at different interstimulus intervals (ISIs).  SICI was measured by 
increasing ISI from 1-30 ms. Reproduced with permission S.Vucic 2007  
 
Conditioned test stimulus
Unconditioned test stimulus
Conditioning stimulus 
(70% RMT)
ISI
Ch 3
Ch 1
Ch 2
 
Figure 10.  (A) Illustration of threshold tracking.  The dashed horizontal line represents the 
target output of 0.2 mV which was “tracked”.  The circles (clear and filled) represent the 
magnitude of the motor evoked potential (MEP) amplitude with each stimulus.  (B)  Illustration 
of three MEP responses of different amplitude.  The MEP response is initially larger (a), then 
smaller (b), and again larger (c) then the target output of 0.2 mV in three consecutive stimuli.  
These are depicted as filled circles in Figure A.  The dashed horizontal lines represent the 
tracking windows, which were set to 0.2 mV (peak-to-peak). Reproduced with permission 
S.Vucic 2007 
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Intracortical inhibition induced by a conditioning stimulus was measured as the increase in 
the test stimulus intensity required to evoke the target MEP.  Inhibition was calculated off-
line by using the following formula (489):  
 
 
 
 
Each of the data points were weighted (QTRACS software version 16/02/2009) such that any 
measures recorded outside the threshold target window (0.2mV, peak-to-peak) contributed 
least to the data analysis.  A student t-test was used for assessing differences between the two 
groups.  Analysis of variance (ANOVA) was used for multiple comparisons to assess the 
difference between the conditioned test and unconditioned test stimuli at different ISIs.  A 
probability (P) value of < 0.05 was considered statistically significant. 
 
Axonal excitability  
Axonal excitability can be investigated using a threshold tracking technique, where 
‘threshold’ refers to the stimulus current required to produce a target potential (408, 409).  
Utilising the threshold tracking technique, the resting threshold is measured and nerve 
excitability is altered by changing the nerve environment, which can be undertaken by 
applying a conditioning polarizing current (409).  This technique subsequently provides 
information about membrane potential and axonal ion channel function. 
 
In this thesis the threshold tracking software that was used was an automated tracking system, 
whereby the test stimulus intensity was automatically increased or decreased in percentage 
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
evoke the target MEP. 
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steps after each response, depending on the difference between the recorded and target 
responses (Figure 11).  For measurement of multiple excitability parameters, an automated 
multiple excitability protocol, TRONDF version 16/02/2009 (© Professor Hugh Bostock, 
Institute of Neurology, Queen Square, London, UK) was used.  This protocol contained a 
proportional tracking system, in which the change in test stimulus current intensity was 
proportional to the difference (or error) between the recorded response and target response.  
Proportional tracking can be more efficient, especially when excitability changes abruptly. 
 
 
 
 
 
 
 
 
 
 
 
Multiple excitability measures:  sequence of recordings 
The first step of the protocol is to generate a stimulus-response (SR) curve, using test current 
impulses of 0.2- and 1-ms (Figure 12A, B).  The target response (40% of supramaximal 
CMAP response) was generated by measuring the peak amplitude (from baseline to negative 
peak) from utilizing 1ms current intensities.  Stimuli were increased in 4% steps, with two 
responses averaged at each step until three averages were considered maximal. The ratio 
between the SR curves for two different stimulus durations that produced the same CMAP 
Figure 11.  With the threshold tracking technique, the target response is set to 40% of the 
supramaximal compound muscle action potential (CMAP) amplitude.  When the CMAP 
amplitude is smaller than the target response (dashed black line), the subsequent test stimulus 
current intensity is increased.  When the CMAP amplitude is larger than the target response 
(grey line), the subsequent test stimulus current intensity is reduced.  If the CMAP amplitude is 
equal to the target response, the subsequent test stimulus intensity remains unchanged.  
Reproduced with permission S.Vucic 2007. 
 
 
Target response
(40% maximum)
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response were used to calculate the rheobase, defined as the threshold current for a target 
response when the stimulus is of infinitely long duration (408, 409), and strength-duration 
time constant (τSD; Figure 12D) of motor axons of different thresholds using Weiss’ formula 
(408, 409, 420).   
 
Threshold electrotonus which refers to the threshold changes that occur in response to 
subthreshold depolarizing and hyperpolarizing pulses, was measured by altering nerve 
excitability using prolonged sub-threshold polarizing currents of 100 ms duration, set to + 
40% (depolarizing) and - 40% (hyperpolarising) of controlled threshold current (408, 409).  
There were a total of three stimulus combinations that were tested sequentially: test stimulus 
alone (measured control threshold current); test stimulus + depolarizing current; test stimulus 
+ hyperpolarizing current.  Threshold was tested at 26 time points before, during and after the 
100 ms polarizing pulse.  The stimulus combinations were repeated until three valid estimates 
were recorded within 15% of target response (444).   
 
A current-threshold relationship (I/V) was obtained by tracking the changes in threshold of 
1ms test pulses that occurred following sub-threshold polarizing currents of 200-ms duration 
which were altered in ramp fashion from +50% (depolarizing) to  -100% (hyperpolarizing) of 
controlled threshold in 10% steps.  Stimuli with conditioning currents were alternated with 
test stimuli until three valid threshold estimates were recorded.  The I/V relationship 
estimates rectifying properties of both nodal and internodal segments of the axon (467, 493).  
The I/V gradient during depolarizing sub-threshold currents reflects conduction through 
outward rectifying K+ channels, while the I/V gradient during hyperpolarizing sub-threshold 
currents reflects inwardly rectifying conductances activated by hyperpolarization (444, 465).   
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Finally, the recovery of axonal membrane excitability, referred to as the recovery cycle, was 
assessed by tracking the changes in threshold that occurred following a supramaximal 
conditioning stimulus of 1 ms duration.   Eighteen conditioning-test stimulus intervals were 
studied, decreasing from 200 to 2 ms.  Three stimulus combinations were recorded: (i) 
unconditioned test stimulus (1 ms duration); (ii) supramaximal conditioning stimulus alone; 
(iii) conditioning and test stimuli in combination.  The response in (ii) was subtracted on-line 
from response in (iii) so as to eliminate contamination of the measured CMAP response by 
the supramaximal conditioning response at short interstimulus intervals.  Each stimulus 
combination was repeated until 4 valid estimates were obtained (444).   
 
Following the completion of the recovery cycle, a profile of nerve excitability was generated 
using a customized plotting program (QTRACP version 16/02/2009), consisting of six 
different plots (Figure 12A-F). The 95% confidence limits were calculated as mean ± t 0.05 SD 
(where t 0.05 is the value of Student’s t-test which the probability of a larger value is 0.05) such 
that 95% of individual observations would fall within the limits if the variables were 
distributed normally.  For data plotted on logarithmic axes (Figure 12A, F), the logarithm of 
the variable was assumed to be normally distributed, and the mean plotted is the geometric 
mean.  Differences in excitability parameters were analysed using Student’s t-test.  A 
probability (P) value of < 0.05 was considered statistically significant. All results are 
expressed as mean ± standard error of the mean. 
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Data analysis 
Values for the multiple excitability parameters were automatically generated upon 
completion of the axonal excitability protocol.  Stimulus intensity (mA) was measured as the 
current required to elicit a target response set to 40% of maximal CMAP for a stimulus of 1 
ms duration.  Strength-duration time constant (ms), which reflects nodal persistent Na+ 
Figures 12.  To highlight the axonal excitability parameters, six plots that were recorded from 
the abductor pollicis brevis muscle in single subject are displayed.  (A) Absolute stimulus-
response relationship.  (B) Normalised stimulus-response relationship.  (C) Current-threshold 
relationship.  (D) Strength-duration time constant.  (E) Threshold electrotonus.  The 
conditioning-test interval corresponding to hyperpolarising threshold electrotonus at 90-100 ms 
(The 90-100 ms) and depolarising threshold electrotonus at the same time interval (Ted 90-100 
ms) are depicted.  (F) Recovery cycle, demonstrating the time point at which the relative 
refractory period (RRP) is measured, as well as superexcitability and late subexcitability. 
Reproduced with permission S.Vucic 2007. 
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conductances (494), was calculated for nine motor axonal populations, starting from axons 
contributing to CMAP responses between 5-15% up to the maximum of 85-95%, increasing 
in 10% batches (444).  Rheobase (mA), which is defined as the threshold current for a target 
response when the stimulus is of infinitely long duration, was also calculated.  Stimulus-
response slope was calculated from the normalized SR curves by subtracting the stimulus that 
evoked a 25% maximal CMAP response from that which evoked a 75% response and 
dividing the result by the stimulus evoking a 50% response.  
 
Threshold electrotonus parameters were calculated from data in Figure 12E.  TEd (peak) 
refers to the peak threshold reduction produced by a subthreshold depolarizing current.  The 
reduction in threshold was measured at three time points relative to onset of the subthreshold 
depolarizing current, i.e. at 10-20 ms, TEd (10-20 ms), 40-60 ms TEd (40-60 ms), and at 90-
100 ms TEd (90-100 ms).  Threshold changes were also measures at similar latencies 
following a subthreshold hyperpolarizing current and are referred to as TEh (10-20 ms) and 
TEh (90-100 ms).  S2 accommodation was calculated as the difference between the peak 
threshold reduction in the depolarizing direction and the plateau value, i.e. TEd (peak) – TEd 
(90-100 ms).  The peak threshold increase at the end of depolarizing current and peak 
threshold reduction at the end of hyperpolarizing current were averaged over 20 ms, being 
referred to as TEd (undershoot) and TEh (overshoot).   
 
From the I/V graph, the following parameters were recorded; (i) resting I/V slope, calculated 
from polarizing currents between +10% to -10%, minimal I/V slope, calculated by fitting a 
straight line to each three adjacent points in turn, and (iii) hyperpolarizing I/V slope, 
calculated from polarizing current between 0-100%. 
 
77 
  
For the recovery cycle of axonal excitability the following parameters were measured; (i) 
relative refractory period (RRP, ms), defined as the first intercept at which the recovery curve 
crosses the x-axis; (ii) superexcitability, expressed as a percentage reduction in threshold 
current, was calculated as the minimum mean of three adjacent point at conditioning-test 
intervals of 5-15 ms and (iii) late subexcitability (%), as the maximum mean of three adjacent 
points at interstimulus intervals > 15 ms. 
 
For the axonal excitability parameters, there already exist normative values for the median 
nerve motor axons (413, 444). 
 
Clinical Scores in Amyotrophic Lateral Sclerosis 
A neurological history and physical examination were undertaken in all ALS patients.  All 
ALS patients were clinically staged using the amyotrophic lateral sclerosis functional rating 
scale-revised (ALSFRS-R) (495) .  The ALSFRS-R is a questionnaire-based, 12-item 
functional rating scale administered to the patient or, if the patient cannot communicate 
effectively to an informant, such as the carer.  The ALSFRS-R incorporates assessment of 
bulbar function, fine motor function, gross motor function and respiratory function.  
Functional scores in each domain are graded from 0 (complete dependence for that function) 
to 4 (normal function), resulting in a total ALSFRS-R score ranging from 0 to 48 (normal).  
 
Muscle strength in all patients was assessed using the Medical Research Council (MRC) 
rating scale (496) with the following group of muscles tested bilaterally yielding a total MRC 
score of 90:  shoulder abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger 
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abduction; thumb abduction; hip flexion; knee extension; ankle dorsiflexion. The MRC scale 
is a five point scale ranging from 0 (no movement) to 5 (normal strength).    
 
The degree of upper motor neuron (UMN) dysfunction was assessed by an UMN score 
incorporating the following parameters: jaw jerk, facial reflex, upper and lower limb deep 
tendon reflexes and plantar responses with the score ranging from 0 [no UMN dysfunction] to 
16 [severe UMN dysfunction] (497). 
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Chapter 1 
 
AWAJI CRITERIA IMPROVES 
DIAGNOSTIC SENSITIVITY IN 
AMYOTROPHIC LATERAL SCLEROSIS 
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Summary   
One of the limitations of the current diagnostic criteria in amyotrophic lateral sclerosis (ALS) 
is the delay in diagnosis.  To determine the utility of the currently employed diagnostic 
criteria in diagnosing ALS and to propose a novel modification so as to enhance sensitivity, 
we utilised an individual patient data (IPD) analysis.  Our literature review identified 13 
studies that compared the diagnostic accuracy of the Awaji and revised El Escorial (rEEC) 
criteria. Individual patient data was available from 8 studies, which was included in the 
analysis. Predefined subgroup analysis was undertaken in bulbar and limb onset disease. The 
sensitivity of a novel updated Awaji criteria, incorporating a ‘probable-laboratory supported” 
category, was also undertaken.  Individual patient data was available from 1086 patients, 
consisting of 881 ALS and 205 mimic disorder patients.  Summary sensitivities based on 
random effects logistic regression modelling disclosed a higher sensitivity of the Awaji 
criteria (0.70, 95% Confidence Interval [CI] 0.51-0.83) and updated Awaji criteria (0.73, 95% 
CI 0.56-0.85) when compared to rEEC (0.58, 95% CI 0.48-0.68). Paired analysis revealed 
higher sensitivities of the Awaji criteria in 4 studies and updated Awaji criteria in 7 studies 
when compared to rEEC. A generalized estimating equation model confirmed a higher 
sensitivity of the Awaji and updated Awaji criteria (P<0.0001).  Using individual patient data 
analysis, the present study established a higher sensitivity of the Awaji criteria when 
compared to rEEC.  The updated Awaji criteria enhanced the diagnostic sensitivity in ALS, 
particularly in limb-onset disease, and should be taken into account as diagnostic criteria in 
clinical practice and future therapeutic trials.   
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Introduction 
There is no diagnostic test for Amyotrophic lateral sclerosis (ALS), a rapidly progressive and 
fatal neurodegenerative disorder of the motor neurons(48).  Rather, diagnosis of ALS relies 
on identification of a combination of upper (UMN) and lower motor neuron (LMN) signs 
across specific body regions (6, 48, 498).  Clinically based diagnostic criteria were designed 
to be highly specific for ALS, although their sensitivity is limited, particularly in early stages 
of ALS (51, 247, 499). Consequently, significant diagnostic delays are inevitable, leading to 
delay in the institution of neuroprotective therapies and recruitment into therapeutic trials, 
perhaps beyond the therapeutic window period. 
 
The neurophysiologically based Awaji criteria were developed (6) for use in conjunction with 
the clinical criteria as set out in the revised El-Escorial Criteria (rEEC) in an attempt to 
reduce diagnostic delays.  The Awaji criteria proposed that neurophysiological features of 
LMN dysfunction, including chronic and ongoing neurogenic changes (fibrillation 
potentials/positive sharp waves) were equivalent to clinical LMN signs. In addition, 
fasciculations were deemed to be a biomarker of LMN dysfunction when combined with 
chronic neurogenic changes. Subsequently, the diagnostic utility of the Awaji criteria was 
assessed in retrospective and prospective studies, most of which established an increased 
sensitivity when compared to rEEC (30, 52-59), although one study reported a lower 
sensitivity, a finding attributed to the omission of a “probable-laboratory supported” 
diagnostic category (60).   
 
The diagnostic accuracy of the Awaji criteria was also assessed in two study-level meta-
analyses, and these reported an improved diagnostic performance of the Awaji criteria, with 
higher sensitivity and diagnostic odds ratios (30, 61).  The diagnostic benefits, however, 
82 
  
appeared to be most prominent in ALS patients with bulbar-onset disease.  Interestingly, one 
study reported that 20% of patients classified as “probable laboratory-supported” on the rEEC 
were downgraded to Awaji “possible”(61).  Importantly, both study-level meta-analyses were 
limited by a high heterogeneity of the pooled sensitivity estimates, potentially impacting on 
the outcome.   
 
In order to maximise the statistical power of the analysis, and explore variation at an 
individual patient level, we aimed to perform a systematic review using individual patient 
data. In particular, we aimed to (1) summarise diagnostic accuracy of the rEEC, Awaji, and 
the updated Awaji criteria, (2) explore reasons for heterogeneity in diagnostic accuracy for 
each criteria using patient and study level covariates, (3) compare diagnostic accuracy of the 
rEEC versus the Awaji and updated Awaji criteria, and (4) explore differences in accuracy 
for the diagnostic criteria, when applied to the bulbar and limb-onset subgroups. 
 
Methods 
Selection and eligibility criteria 
All studies assessing the diagnostic accuracy of rEEC and the Awaji criteria in ALS were 
considered eligible for analysis.  The accepted diagnosis of ALS was defined by good clinical 
practice as described in the studies, requiring disease progression deemed to be consistent 
with that evident in ALS.  Clinical progression was used as the reference standard. 
 
Search strategy, study selection and data extraction  
Potentially eligible studies were identified through an electronic search of bibliographic 
databases (MEDLINE through Ovid, PubMed and Web of Science) from 2006, the year of 
the consensus meeting that gave rise to the Awaji recommendations, to March 2015. The 
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following terms were used in the search field tag and combined “awaji.tw OR Escorial.tw 
OR sensitivity.tw OR specificity.tw OR criteria.tw OR accuracy.tw OR electrodiagn$.tw OR 
neurophysiol$.tw OR electromyograp$.tw OR EMG diagnosis.tw”, combined with 
“amyotrophic lateral sclerosis.tw OR motor neuron disease.tw.”  No language restrictions 
were placed on the search strategy.  Reference lists from identified studies were cross-
checked for additional studies.  Senior authors from the identified studies were contacted to 
obtain raw data and unpublished data was solicited from the corresponding authors.  
Selection of studies and data extraction was performed independently by two authors (NG 
and SV) and checked for accuracy.  Disagreement between the independent reviewers was 
resolved by consensus and with a third reviewer (PM). 
 
Quality assessment  
Study quality was assessed by 2 reviewers (NG, SV) using the ‘Quality Assessment of 
Diagnostic Accuracy Studies-2’ (QUADAS-2) checklist (500). The QUADAS-2 is an 11 item 
questionnaire, with each item scored as yes, no, or unclear.  A representative patient 
population included consecutive subjects with suspected ALS/motor neuron disease, who 
were assessed in different centers.  An “adequate reference standard” required evidence of 
clinical disease progression over an adequate follow-up period consistent with ALS.  We 
required that the index tests (rEEC and Awaji criteria) were applied at the same assessment in 
each study. 
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Statistical analysis and data synthesis  
Definition of disease status 
In order to assess the diagnostic performance of the rEEC and Awaji criteria, disease status 
was assigned to subjects as ‘probable’ or ‘definite’ ALS.  For rEEC, “probable ALS-
laboratory supported” was also regarded as positive for ALS.  The ‘possible’ and ‘negative’ 
classifications were regarded as negative for diagnosis of ALS. The Updated Awaji criteria 
extended the Awaji criteria, by including patients with 2 regions of lower motor neuron 
involvement (clinical and/or needle EMG) and one region of UMN involvement in the 
disease group.   
 
Summarising test accuracy for the three sets of diagnostic criteria 
Sensitivity and specificity were calculated for each study, using published and unpublished 
individual patient data. Study specific sensitivity and specificity were displayed in a forest 
plot using Cochrane Revman 5. Since the ALS criteria were designed to be highly specific, 
only four out of the eight studies included a non-disease group and three out of four of these 
studies reported a specificity of 100%. The fourth study reported a specificity of 80% but this 
was only based on 5 individuals (4/5). Consequently, the standard bivariate analysis (501)  
that simultaneously models sensitivity and specificity was not feasible. Hence, all further 
analyses focused on sensitivity only.  Random effects logistic regression, fitting a study as a 
random effect, was used to obtain summary sensitivity and corresponding 95% Confidence 
Interval for each criterion (SAS 9.4, SAS Corp, Cary NC, USA). 
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Exploring reasons for heterogeneity in diagnostic accuracy for each set of criteria using 
patient and study level covariates 
We explored variation in sensitivity by adding each study and individual- level factor in the 
random effects logistic model for each diagnostic criterion. Study-level factors examined 
were: whether study populations had been pre-screened, whether the study was prospective 
and whether assessment of upper motor neuron signs was stipulated. Individual-level factors 
examined were: age, sex, duration of illness, and bulbar vs limb onset. Each model included 
only one variable because of the limited number of studies. 
 
Compare diagnostic accuracy of the rEEC criteria versus the Awaji and Updated Awaji 
criteria 
Comparison of test accuracy within each study was performed using the exact form of 
McNemar’s test, to take account of pairing of test results within patients. Extending the 
random effects logistic regression model to include nested random effects for patients within 
studies to allow for pairing of criteria results, did not converge due to data sparsity. As an 
alternative we used a Generalised Estimating Equation (GEE) model to test for association 
between sensitivity and diagnostic criteria. The model has a binomial error distribution, 
clustering by study, repeated measures (criteria results) for each patient, and patients nested 
within studies.  
 
Explore differences in accuracy for the diagnostic criteria sets, when applied to the bulbar 
and limb-onset subgroups 
Given a priori clinical interest in the difference between bulbar and limb onset subgroups, we 
used random effects logistic regression to estimate summary sensitivity for these subgroups. 
To compare diagnostic accuracy of the rEEC criteria versus the Awaji (and Updated Awaji) 
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criteria for these subgroups, we extended the GEE modelling to include covariates for 
criteria, region of onset, and an interaction (product) term for criteria and region of onset to 
test for effect modification. 
 
Results 
Included Studies 
From the literature review 13 studies were identified that compared the diagnostic accuracy 
between rEEC criteria and the Awaji criteria (52-60, 502-505).  Corresponding authors from 
6 studies provided data on individual patients (53, 55, 59, 60, 502, 504), while patient 
information on individual subjects was extracted from 2 published manuscripts (54, 57) 
(Table 1.1).  Individual patient data from the remaining 5 studies was not available for the 
following reasons: (i) loss of data due to technical reasons (503) (ii) lack of correspondence, 
(52, 56, 505) (iii) inability to provide suitable individual patient data for analysis (58). 
Consequently, individual patient data was available on a total of 1086 patients.  
  
Quality assessment 
On quality assessment of the included studies, all studies included a representative spectrum 
of ALS patients.  The majority of studies recruited or reviewed patient data in a consecutive 
manner. The reference standard utilised to confirm the diagnosis of ALS was sufficient in all 
studies, with most studies utilising clinical and electrophysiological measures, and all studies 
also using “progression” during a follow up period to confirm the diagnosis of ALS.  All 
studies applied the rEEC and Awaji criteria at the same time, hence there was no time lag 
between applying the two sets of diagnostic criteria.  
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Study 
 
Site 
 
Sample 
size 
Study 
design 
Age in 
years, 
Mean, 
(SD), 
[Range] 
Disease 
duration 
in 
months, 
Mean, 
(SD), 
[Range] 
Bulbar 
onset 
(%) 
Neurophysiological 
protocol, (N-
number of muscles) 
Case 
ascertainment 
Boekestein 
et al9 
Netherlands 
213 
(120 
NM) 
Retrospective 58 NA 27 
Yes (B, C, T, and 
LS 
regions), N>6 
Unclear 
Chen et al13 USA 
70 
(16 
NM) 
Retrospective 
62.4 
(12.6) 
[37-89] 
21.6 
(23.7) 
[2-109] 
31 
No (at least 3 of 4 
regions: 
B, C, T, and LS 
regions), 
N=Unclear 
Independent 
(other 
physician) 
De 
Carvalho et 
al8 
Portugal 55 Prospective 
61.8 
(15.2) 
[20-83] 
12.8 
(9.8) [2-
36] 
27 
Yes (B, C, T, and 
LS 
regions) plus 
diaphragm, N>10 
Consensus (2 
investigators) 
Gawel et 
al15 
Poland 160 Retrospective 
55.9 
(11.6) 
[18-81] 
15.3 
(14.9) 
[2-44] 
25 Yes (B, C, T, and 
LS), N>3 
Other 
physician 
Geevasinga 
et al28 
Australia 
146 
(64 
NM) 
Prospective 
56.9 
(9.8) 
[28-86] 
15.6 
(17.1) 
[2-108] 
40 
Yes (B, C, T, and 
LS 
Regions), N=11 
(mean number of 
muscles) 
Consensus (2 
investigators) 
Higashihara 
et al16 
Japan 
129 
(5 NM) 
Retrospective 
64.4 
(10.2) 
[31–87] 
13.2 
(9.1) [2-
52] 
30 Yes (B, C, T, and 
LS), N=3-8 
Independent (2 
investigators) 
Noto et al29 Japan 113 Retrospective 
66.5 
(9.8) 
[34-86] 
13.9 (11) 
[2-59] 
42 
Yes (B, C, T, and 
LS 
regions), N=4-8 
Single 
investigator 
Schrooten  
et al10 
Belgium 
200 
 
Prospective 
61.0 
(12.8) 
12.4 
(13.7) 
[<1-108] 
25 
Yes (C, LS at least 
2 muscles; B, T at 
least 1 muscle), 
N>6 
Independent 
computer 
algorithm 
Table 1.1. Characteristics of the included studies, including demographic and study methodological 
details.  All studies were performed at single centers in the countries listed.  The sample size includes 
patients with ALS as well as NM - neuromuscular controls (who were used to calculate specificity data). 
For neurophysiological protocol, B = Bulbar, C = Cervical, T = Thoracic, LS – Lumbosacral; refer to the 
regions assessed by needle electromyography and N – refers to the number of muscles assessed at the 
time of the neurophysiological assessment. 
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Test accuracy for the three sets of diagnostic criteria  
Meta-analysis was based on a cohort of 881 ALS patients from eight studies that included a 
total pool of 1086 patients, 205 of whom were non-ALS neuromuscular control subjects. The 
summary sensitivity and corresponding 95% confidence interval for the diagnostic criteria 
were derived from separate random effects logistic regression models. The sensitivity 
estimates were higher for the Awaji [0.70 (95% Confidence Interval [CI] 0.51-0.83)] and 
updated Awaji 0.73 (95% CI 0.56-0.85) criteria when compared to rEEC [0.58 (95% CI 0.48-
0.68), Table 1.2].  It should be stressed however, that the Awaji criteria downgraded the 
diagnosis to a “possible” category in 26 (21%) patients classified as “probable laboratory 
supported” by the rEEC. Based on these summary estimates, the Awaji criteria was able to 
identify an additional 12% of ALS patients while the updated Awaji criteria identified an 
additional 15% of patients. 
 
 
 Number of 
patients 
(for calculating 
sensitivity) 
 
rEEC 
 
Awaji 
criteria 
Updated Awaji 
criteria 
Overall 881 
0.58 (0.48-
0.68) 
0.70 (0.51-
0.83) 
0.73 (0.56-0.85) 
Bulbar onset 
subgroup* 
234 
0.55 (0.42-
0.68) 
0.72 (0.51-
0.86) 
0.73 (0.55-0.86) 
Limb onset 
subgroup* 
546 
0.62 (0.42-
0.78) 
0.73 (0.44-
0.91) 
0.76 (0.50-0.91) 
Table 1.2. Summary sensitivity (95% Confidence Intervals) for the three diagnostic criteria. 
rEEC= revised El Escorial Criteria *Not all patients included in the overall analysis had data 
for region of onset.  
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Compare diagnostic accuracy of the rEEC criteria versus the Awaji and Updated Awaji 
criteria 
Sensitivity of the Awaji criteria was significantly higher using the exact form of McNemar’s 
test when compared to rEEC in four studies (53, 55, 502, 504), while in one study the rEEC 
exhibited a higher sensitivity (60) [Table 1.3].  In the remaining three studies, the observed 
sensitivity was higher for Awaji compared with rEEC criteria, but this difference was not 
statistically significant (54, 57, 59).  Only four studies included a non-disease group, with 
three studies (54, 57, 504) reporting a specificity of 100% and one study (60) a specificity of 
80%.   
 
Of further relevance, the observed sensitivity of the updated Awaji criteria, based on the 
McNemar’s analyses for individual studies, was also higher when compared to rEEC criteria 
in all eight studies, and significantly higher in five of these studies (53-55, 502, 504) [Table 
1.3]. GEE modelling provided strong evidence of an association (P<0.0001) between 
sensitivity and criteria, for both Awaji versus rEEC and updated Awaji versus rEEC criteria. 
 
Bulbar-onset disease:  The Awaji criteria exhibited a significantly greater sensitivity using 
the exact form of McNemar’s test when compared to rEEC in three studies (53, 55, 502) 
[Table 1.4].  In contrast, there were no significant differences in the sensitivity between 
Awaji and rEEC criteria in four other studies (57, 59, 60, 504). The updated criteria did not 
lead to a significant improvement in sensitivity over the existing Awaji criteria in bulbar 
onset ALS patients (Table 1.4).   
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Study Number Sensitivity P-Value Sensitivity P-Value 
  rEEC (%) 
Awaji 
criteria 
(%) 
McNemar 
Updated 
Awaji 
criteria (%) 
McNemar 
Boekestein et 
al9 
213 65/93 (70) 66/93 (71) 1.0 72/93 (77) 0.016 
Chen et al13 70 39/54 (72) 40/54 (74) 1.0 40/54 (74) 1.0 
De Carvalho et 
al8 
55 33/55 (60) 52/55 (95) <0.0001 52/55 (95) <0.0001 
Gawel et al15 160 
87/160 
(54) 
86/160 
(54) 
1.0 91/160 (57) 0.22 
Geevasinga et 
al23 
146 29/82 (35) 38/82 (46) 0.023 39/82 (48) 0.0063 
Higashihara et 
al16 
129 
57/124 
(46) 
48/124 
(39) 
0.035 61/124 (49) 0.13 
Noto et al21 113 
69/113 
(61) 
80/113 
(71) 
0.035 86/113 (76) <0.0001 
Schrooten et 
al10 
200 
132/200 
(66) 
170/200 
(85) 
<0.0001 170/200 (85) <0.0001 
Table 1.3. Comparison of the diagnostic utility of revised El Escorial criteria (rEEC), Awaji 
criteria and updated Awaji criteria with a ‘probable laboratory supported’ category (see 
Methods) in the entire ALS cohort irrespective of site of disease onset.  The updated Awaji 
criteria were compared against the rEEC. Total number of patients (N) refers to all patients in 
the included studies (ALS and neuromuscular patients).  The specificity (not shown) of the 
rEEC, Awaji and updated Awaji criteria was available for four studies, being 100% in three 
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Study Number Sensitivity P-Value Sensitivity P-Value 
  rEEC (%) 
Awaji 
criteria 
(%) 
McNemar 
Updated  
Awaji (%) 
McNemar 
Chen et al13 17 11/17 (65) 12/17 (71) 1.0 12/17 (71) 1.0 
De Carvalho et 
al8 
16 5/16 (31) 14/16 (88) 0.0039 14/16 (88) 0.0039 
Gawel et al15 37 27/37 (73) 26/37 (70) 0.317 27/37 (73) NA 
Geevasinga et 
al23 
33 12/33 (36) 13/33 (39) 1.0 14/33 (42) 0.63 
Higashihara et 
al16 
31 15/31 (48) 14/31 (45) 1.0 16/31 (52) 1.0 
Noto et al21 51 30/51 (59) 42/51 (82) 0.0005 42/51 (82) 0.0005 
Schrooten et 
al10 
49 32/49 (65) 45/49 (92) 0.0005 45/49 (92) 0.0005 
Table 1.4. Comparison of the diagnostic utility of revised El Escorial criteria (rEEC), Awaji 
criteria and the updated Awaji criteria in bulbar onset amyotrophic lateral sclerosis (ALS) 
patients.  The updated Awaji criteria were compared against the rEEC.  Total number of patients 
(N) refers to all ALS patients included in the study. The specificity (not shown) of rEEC, Awaji 
and updated Awaji criteria was available in 2 studies and was 100%16,31.  The exact form of 
McNemar’s test was undertaken in each study utilising individual patient data.  P < 0.05 was 
regarded as statistically significant. NA- not applicable - no discordant pairs. 
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Of relevance, the summary sensitivities, based on random effects logistic regression 
modelling, were higher for the Awaji and updated Awaji criteria when compared with rEEC 
criteria (Table 1.2).  Specifically, the sensitivity of the Awaji criteria was 0.72 (95% CI 0.51-
0.86), updated Awaji criteria 0.73 (0.55-0.86), and rEEC 0.55 (95% CI 0.42-0.68). GEE 
modelling provided evidence of effect modification for both the rEEC versus Awaji criteria 
comparison (p=0.009) and the rEEC versus updated Awaji criteria (p=0.033), indicating that 
the improvement in sensitivities was greater in the bulbar-onset subgroup. 
  
Limb-onset disease:  Using the exact form of McNemar’s test, it was evident that the Awaji 
criteria exhibited a significantly higher sensitivity in limb onset disease in three studies when 
compared to rEEC (53, 55, 504). There were no differences in two studies (59, 502), while in 
one study the rEEC criteria appeared to be more sensitive (60) [Table 1.5].  The updated 
Awaji criteria improved the sensitivity in one study (502), while the sensitivity was 
maintained in five studies (53, 55, 57, 59, 504).  Importantly, in the study reporting a higher 
sensitivity of the rEEC (60), the updated Awaji criteria increased the sensitivity such that 
there was no longer a significant difference in sensitivity when compared to rEEC (Table 
1.5).  Although the summary estimates of sensitivity were higher for the Awaji criteria 0.73 
(95% CI 0.44-0.91) when compared to rEEC (0.62, 95% CI 0.42-0.78, Table 1.2), the 
updated Awaji criteria modestly enhanced the sensitivity to 0.76 (95% CI 0.50-0.91) in limb-
onset ALS.   
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Study Number Sensitivity P-Value Sensitivity P-Value 
  rEEC 
(%) 
Awaji 
(%) 
McNemar 
Awaji LS 
(%) 
McNemar 
Chen et al13 30 28/30 (93) 
28/30 
(93) 
NA 28/30 (93) NA 
De Carvalho et 
al8 
39 28/39 (72) 
38/39 
(97) 
0.002 38/39 (97) 0.002 
Gawel et al15 123 
60/123 
(49) 
60/123 
(49) 
1.0 64/123 (52) 0.22 
Geevasinga et 
al23 
49 17/49 (35) 
25/49 
(51) 
0.0078 25/49 (51) 0.0078 
Higashihara et 
al16 
93 42/93 (45) 
34/93 
(37) 0.039 
45/93 (48) 0.25 
Noto et al21 62 39/62 (63) 
38/62 
(61) 
1.0 44/62 (71) 0.0063 
Schrooten et 
al10 
150 
100/150 
(67) 
125/150 
(84) 
<0.0001 
125/150 
(84) 
<0.0001 
 
 
 
 
 
 
Table 1.5. Comparison of the diagnostic utility of revised El Escorial criteria (rEEC), 
Awaji criteria and the updated Awaji criteria in limb onset amyotrophic lateral sclerosis 
(ALS) patients.  The updated Awaji criteria were compared against the rEEC.  Total 
number of patients (N) refers to all ALS patients included in the study. The specificity 
(not shown) of rEEC, Awaji and updated Awaji criteria was available in 2 studies and was 
100%16,31.  The exact form of McNemar’s test was undertaken in each study utilising 
individual patient data. NA- not applicable - no discordant pairs. 
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In order to investigate the factors underlying the heterogeneity of sensitivity of the three 
diagnostic criteria between the studies, the effects of patient and study level covariates were 
assessed. For patient-level covariates, disease duration exerted a significant effect on the 
sensitivity of diagnostic criteria. Specifically, the effects appeared to be non-linear, with the 
highest sensitivity occurring between 6-11 months post-symptom onset (Table 1.6). Although 
the non-linear pattern was evident in all criteria, it was statistically significant in the Awaji 
(χ2=17.8, df 3, P=0.0005) and updated Awaji criteria (χ2=17.8, df 3, P=0.015), but not the 
rEEC (χ2=6, df 3, P=0.11).      
 
Among study-level factors, stipulating the methods by which the upper motor neuron signs 
were assessed was associated with a lower estimate of sensitivity for all criteria including 
rEEC (P=0.032), Awaji criteria (P=0.068) and updated Awaji criteria (P=0.089), although 
this was only statistically significant for the rEEC criteria. There was no association between 
sensitivity and any other study-level or individual-level factors. 
 
  rEEC Awaji criteria Updated Awaji criteria 
Disease 
duration 
(months) 
N Odds 
ratio 
95% 
CI 
Estimated 
sensitivity 
Odds 
ratio 
95%CI Estimated 
sensitivity 
Odds 
ratio 
95% 
CI 
Estimated 
sensitivity 
< 6 140 1 referent 0.49 
 
1 referent 0.63 1 referent 0.67 
6 -11 254 1.63 (0.94, 
2.80) 
0.61 
 
1.83 (0.98, 
3.41) 
0.76 1.80 (0.96, 
3.36) 
0.78 
12-35 312 1.37 (0.81, 
2.31) 
0.51 
 
1.26 (0.70, 
2.26) 
0.69 1.24 (0.69, 
2.24) 
0.72 
≥36 82 1.05 (0.51, 
2.16) 
0.51 0.92 (0.42, 
2.01) 
0.61 0.78 (0.36, 
1.70) 
0.61 
Table 1.6. The effects of disease duration on the sensitivity of the three diagnostic ALS criteria. 
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Discussion 
Utilising individual patient data available from 1086 individuals across 8 published studies, 
the present study established a greater sensitivity of the Awaji criteria when compared to the 
revised El Escorial diagnostic criteria. Specifically, the Awaji criteria exhibited a higher or 
comparable sensitivity in most studies, with the summary sensitivity of Awaji criteria being 
70% compared to 58% for the rEEC, translating to a 12% increase in the diagnostic utility.  
Importantly, this increase in sensitivity was predominantly evident in bulbar-onset ALS 
patients.  Addition of the “probable-laboratory supported” category to Awaji criteria 
increased the sensitivity, particularly in limb-onset disease, translating to an extra 3% of 
patients correctly diagnosed with ALS.   
 
Diagnostic utility of the Awaji criteria 
In the absence of a definitive test, the diagnosis of ALS remains clinically based, relying on 
the identification of a combination of upper and lower motor neuron dysfunction.  This has 
represented a major diagnostic challenge leading to significant delays in diagnosis, 
particularly in younger patients (<45 years) (51, 506).  Consequently, critical delays of 
patient recruitment into clinical trials have ensued, perhaps delaying treatment beyond the 
therapeutic window period.  The consensus Awaji criteria were developed in order to enable 
an earlier clinical diagnosis of ALS by introducing an objective biomarkers of LMN 
dysfunction (6).  Although a number of studies have reported a greater sensitivity of the 
Awaji criteria when compared rEEC (52, 53, 55, 56, 58, 502, 504), some have reported 
equivalent sensitivities (54, 57, 59), while one study documented a lower sensitivity for the 
Awaji criteria (60).  The studies were critiqued for being of varying quality, single center 
design and for specific methodological limitations (507).  A prospective, multicenter study 
conducted in accordance with the Statement for Reporting Studies of Diagnostic Accuracy 
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protocol would represent an ideal approach in comparing the utility of the different ALS 
diagnostic criteria.  
 
A meta-analysis approach could provide unique insights into the utility of the ALS diagnostic 
criteria.  Two study-level meta-analyses reported a higher sensitivity of the Awaji criteria 
(30, 61), with sensitivity being greater for bulbar-onset ALS.  Importantly, there was high 
heterogeneity among studies, perhaps reflecting statistical or methodological diversity (508, 
509).  Individual patient data meta-analysis provides the least biased and most reliable 
information on the effects size of different diagnostic criteria as it allows the pairing of 
criteria results within an individual to be taken into account (508).  Although bivariate IPD 
meta-analysis was not feasible, due to sparsity of specificity data, analysis of sensitivity was 
undertaken confirming a higher sensitivity of the Awaji criteria when compared to rEEC, in 
keeping with study-based meta-analyses (30, 61), with the sensitivity benefit most evident in 
bulbar-onset ALS.   
 
In limb-onset ALS, the Awaji criteria have been reportedly less sensitive (59-61, 502), a 
finding attributed to the omission of the “probable laboratory supported” diagnostic category 
(59, 60, 509).  Importantly, 21% of ALS patients in the current IPD analysis that were 
classified as “probable laboratory-supported ALS” on the rEEC were downgraded to a 
“possible” diagnostic category on the Awaji criteria. Consequently, recruitment into clinical 
trials could be potentially prevented, although it should be acknowledged that some 
therapeutic trials now accept ‘Awaji possible’ patients.  The current IPD analysis suggested 
that the updated Awaji criteria, incorporating a probable laboratory supported category, 
exhibited a higher sensitivity when compared to rEEC, and this increase appeared to be 
evident in bulbar and in limb-onset ALS (Tables 1.2-1.4). 
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Patient and study level covariates were assessed in order to gain further insights into the 
mechanisms underlying the heterogeneity in previous literature-based meta-analyses (30, 61). 
Disease duration appeared to exert a non-linear effect, whereby the sensitivity was highest in 
patients within 6-11 months post-symptom onset. The effect of disease duration on sensitivity 
could be related to atypical phenotypes in patients with a protracted disease duration (≥36 
months), or limited disease burden in patients with a shorter disease duration (<6 months).  
 
Study level factors impacted on the varied sensitivity across studies for the three sets of 
diagnostic criteria. Stipulating whether UMN signs were assessed within a cohort 
significantly influenced the diagnostic sensitivity of the three criteria. This relationship could 
be explained by the well-recognised difficulty in identifying UMN dysfunction in ALS using 
clinical criteria (38), thereby impacting on diagnostic sensitivity.  Objective assessment of 
UMN dysfunction by threshold tracking transcranial magnetic stimulation (TMS) techniques 
has been reported to increase the sensitivity of the Awaji criteria at an early stage in the 
disease process (510). We recommend that future revisions of the Awaji criteria should 
consider incorporating objective biomarkers of UMN dysfunction, such as short interval 
intracortical inhibition (510). 
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Chapter 2 
 
UTILITY OF DIAGNOSTIC CRITERIA 
FOR AMYOTROPHIC LATERAL 
SCLEROSIS:  A MULTICENTER 
PROSPECTIVE STUDY 
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Summary  
While the Awaji criteria in the previous chapter were more sensitive when compared to the El 
Escorial criteria, during the process of the literature review, it was noted that there were no 
prospective multicentre studies evaluating these diagnostic criteria.  Furthermore there was a 
lack of specificity data in most of the studies that had been undertaken.  Subsequently we 
designed the first prospective multicentre study, across three east coast centres in Australia, 
to evaluate the El Escorial and Awaji criteria.  In total we recruited 416 patients (233 ALS 
and 183 non-ALS mimic disorders) between January 1 2012 and August 31 2015, to compare 
the diagnostic accuracy of Awaji and rEEC criteria in a population of suspected ALS.  The 
sensitivity of the Awaji criteria (57%, 50.0-63.3%) was significantly higher when compared 
to the rEEC (45%, 38.7-51.7%, P<0.001), translating to a 12% gain in sensitivity.  The 
specificity of the both criteria were identical 99.5% (95% CI 96-100%), thereby indicating 
the number needed to test in order to diagnose one extra case of ALS was 1.8 (1.5-2) for 
Awaji criteria and 2.4 (2-2.6) for rEEC.  Importantly, the Awaji criteria exhibited a higher 
sensitivity across subgroups, including patients with bulbar (P<0.001) and limb-onset 
(P<0.001) disease. The inclusion of the “possible” diagnostic category as a positive finding 
significantly enhanced the sensitivity of the Awaji criteria and rEEC, particularly in early 
stages of the disease (<12 months form symptom onset), whilst specificity remain unchanged. 
Our study established a higher sensitivity of Awaji criteria when compared to rEEC, with 
diagnostic benefits evident in bulbar and limb-onset disease. Inclusion of “possible” ALS as a 
positive finding significantly enhanced the sensitivity of both criteria, while maintaining 
specificity, and should be considered in clinical practice and future therapeutic trials.  
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder of the human motor 
system, with a median survival of 3-5 years (47, 48).  The diagnosis of ALS remains 
phenotypically based, relying on the identification of upper (UMN) and lower motor neuron 
(LMN) signs within body regions, with the level of diagnostic certainty dependent on the 
extent of upper and lower motor neuron dysfunction (6, 498, 511).   In the absence of a 
pathognomonic test, consensus diagnostic criteria were developed in order to provide a more 
definite diagnosis of ALS and thereby facilitate in patient management and recruitment into 
clinical trials.  
 
The first consensus diagnostic criteria were developed in El Escorial (Spain) at an 
international workshop organized by the World Federation of Neurology in 1990 (511). The 
clinically based El Escorial criteria mandated that the diagnosis of ALS should be based on 
identifying the presence of upper and lower motor neuron signs, with four levels of 
diagnostic certainty. In 1998, the El Escorial criteria were revised (revised El Escorial 
[rEEC], also known as the Airlie House criteria) in order to improve the diagnostic 
sensitivity, whereby an additional “clinically probable-laboratory supported” category was 
added and defined as the presence of upper and lower motor neuron signs in one region or 
isolated upper motor neuron signs in 1 region, with features of lower motor neuron 
dysfunction evident in 2 regions on neurophysiological testing (498).  Although both sets of 
criteria were specific for ALS, the sensitivity remained an issue, particularly in the early 
stages of the disease process resulting in diagnostic delays and recruitment into therapeutic 
trials perhaps, beyond the therapeutic window period (51, 247, 499, 512).  
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In an attempt to reduce the diagnostic delay, a neurophysiologically based Awaji criteria was 
developed in 2006 (6).  These criteria proposed that neurophysiological features of LMN 
dysfunction, including chronic neurogenic and ongoing changes (fibrillation 
potentials/positive sharp waves) were equivalent to clinical features of LMN dysfunction.  In 
addition, fasciculations were deemed equivalent to the presence of fibrillation 
potentials/positive sharp waves.  Upper motor neuron dysfunction, however, remained 
clinically based. 
 
The diagnostic utility of the Awaji criteria was compared to the revised El Escorial criteria by 
a number of single centre retrospective and prospective studies, most of which reported an 
increased sensitivity when compared to rEEC (30, 52-59).  One study (60) reported a lower 
sensitivity of the Awaji criteria and another study suggested that in approximately 20% of 
ALS patients, the diagnostic category was downgraded (61), a finding largely attributed to 
the omission of the “probable-laboratory supported” diagnostic category.  Importantly, the 
diagnostic benefit appeared to be most prominent in bulbar-onset ALS (30, 61).  In addition, 
whilst ALS diagnostic criteria are regarded to be specific, there is a paucity of specificity (30, 
61) data preventing objective conclusions about the reliability of the ALS diagnostic criteria.   
 
Given the uncertainties around the currently available diagnostic ALS criteria, a multicentre 
prospective study could be of importance in further clarifying their utility.  Consequently, the 
aim of the current prospective multicenter study was to compare the sensitivity and 
specificity of the ALS diagnostic criteria (revised El Escorial versus Awaji) and to establish 
their utility in a clinical setting.  
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Methods 
All patients were prospectively and consecutively recruited from four large ALS centers on 
the East Coast of Australia in keeping with the inclusion criteria.  Inclusion criteria were as 
follows:  (i) Suspected diagnosis of ALS by the referring physician; (ii) Pure motor disorder 
with clinical features of upper and lower motor dysfunction in separate body regions, where 
LMN dysfunction developed caudal to UMN dysfunction, with evidence of disease 
progression over 6 months from initial assessment; or (iii) Neuromuscular disorder defined as 
muscle weakness and wasting for at least 6 months in at least one body region, irrespective of 
whether sensory symptoms were present.  At time of assessment, the assessor was blinded to 
the eventual diagnosis, namely whether the diagnosis of ALS or a mimic disorder.   
 
Exclusion criteria included (i) pure UMN syndrome in which laboratory and neuroimaging 
studies suggested a diagnosis other than ALS, such as hereditary spastic paraplegia or 
progressive forms of multiple sclerosis; (ii) diagnosis of a non-neuromuscular neurological 
disorder to explain the patient’s symptoms, such as cerebellar or extrapyramidal syndromes; 
(iii) non-neurological disorders causing the symptoms; (iv) inability or refusal to provide 
informed consent.  All patients provided written informed consent to the procedures approved 
by the Western Sydney Local Health District and South East Sydney Area Health Service 
Human Research Ethics Committees. 
 
Once recruited, all patients underwent a clinical assessment and detailed investigations to 
diagnose mimic disorders.  The investigations were as follows: routine biochemistry, 
hematology, vasculitic screen (ANA, ENA, ANCA), immunoelectrophoeresis, angiotensin 
converting enzyme levels, metabolic screen (vitamin B12, folate, B6, thyroid function tests), 
infective screen (HIV, syphilis serology, HTLV 1 and II), genetic testing (Kennedys disease-
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for male patients, oculopharyngeal muscular dystrophy testing, spinal muscular atrophy), 
anti-ganglioside antibodies (GM1, anti-MAG), voltage-gated K+ channels, acetylcholine 
receptor and muscle specific tyrosine kinase antibodies.  In addition, magnetic resonance 
imaging of brain and spinal cord was undertaken to exclude structural lesion.    
 
Patients were clinically staged using the amyotrophic lateral sclerosis functional rating score 
(ALSFRS-R) (513).  The disease duration (months) from time of symptom onset and site of 
disease onset were recorded.  Muscle strength was assessed by the Medical Research Council 
(MRC) score, with the following muscle groups assessed: shoulder abduction, elbow flexion 
and extension, wrist dorsiflexion, finger abduction and thumb abduction, hip flexion, knee 
extension and ankle dorsiflexion bilaterally, yielding a maximal score of 90.  Upper motor 
neuron function was assessed and graded by a dedicated UMN score (497).   
 
Nerve conduction study and needle electromyography (EMG) was performed according to 
established techniques by experienced neurophysiologists (514).  In all patients, at least three 
body regions were sampled (bulbar, cervical, and lumbosacral), and special attention was 
given to fasciculations.  Two physicians (NG and PM) graded the sensitivity of the revised El 
Escorial (498) and Awaji (6) criteria in all patients. At time of initial assessment the authors 
were blinded to the eventual diagnosis.  Statistical analysis was performed by a separate rater 
(SV).   
 
Statistics 
The primary outcome measure was the diagnostic utility (sensitivity and specificity) of the 
consensus criteria (rEEC versus Awaji) in differentiating ALS from non-ALS mimic 
disorders.  The secondary outcome measures included the diagnostic utility of the criteria in 
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ALS subgroups, defined by site of disease onset (bulbar versus limb), functional disability 
(ALSFRS-R > 38 less severe; <38 more severe disease) and disease duration at time of 
assessment (< 12 months early; >12 months longer disease).  The sensitivity, specificity, and 
number needed to test (NNT) were determined for each criteria (rEEC and Awaji criteria).  
Pearson Chi square test or McNemar test were utilised to assess differences between the 
criteria.  A probability value <0.05 was considered statistically significant.  Results were 
expressed as median (interquartile range).  
 
Results  
Clinical features 
Between January 1 2012 and August 31 2015, we enrolled 416 patients (253 males, 163 
females median age 61 years, [49-69]) with suspected ALS from four neuromuscular clinics 
on the East Coast of Australia who met the inclusion criteria.  After a detailed clinical, 
laboratory, neurophysiological and radiological assessment and follow-up for at least 6 
months, 233 patients were eventually diagnosed with ALS (142 males, 91 females, median 
age 62 years [52-69]), while 212 patients were diagnosed with an ALS mimic disorder (Table 
2.1).   
 
The degree of functional impairment in the ALS patients, as indicated by the ALSFRS-R 
score, was mild (Table 2.1).  Muscle strength, as measured by the MRC score, was 
comparable between the groups, as was the median age at time of assessment (Table 2.1).  In 
contrast, UMN signs were more prominent in ALS patients, while the disease duration was 
significantly shorter in ALS (Table 2.1).  During the course of the study 42 (18%) ALS 
patients died, with median survival from symptom onset being 28 (20-39) months.  At last 
follow-up, the median disease duration in the surviving patients was 35 (26-53.5) months. 
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Comparison of diagnostic criteria 
The sensitivity of the Awaji criteria, as defined by the proportion of patients categorized as 
definite or probable ALS, at time of initial assessment was 57% (95% confidence interval 
[CI] 50.0-63.3%) and was significantly higher when compared to rEEC (45%, 95% CI 38.7-
51.7%; Pearson Chi-Square 124.3, df 2, P < 0.001, Table 2.2).  The specificity for the Awaji 
and revised El Escorial criteria were 99.5% (95% CI 96-100%), with the number needed to 
test in order to diagnose one extra case of ALS, in a population composed of neuromuscular 
diseases, being 1.8 (1.5-2) for the Awaji criteria and 2.4 (2-2.6) for the rEEC.   
 ALS Non-ALS neuromuscular 
mimic disorders 
Median Age 
(years) 
62 
(52-69) 
58 
(44-69) 
Gender 
(Male: Female) 
142:91 111:72 
Disease duration 
(months) 
12 
(6-20.5) 
60 
(33-192) 
ALSFRS-R 
42 
(36.8-44) 
N/A 
MRC total score 
82 
(75.8-88) 
88 
(82-90) 
MRC upper limb score 
56 
(49-60) 
60 
(56-60) 
MRC lower limb score 
29 
(26-30) 
29 
(26-30) 
UMN score 
12 
(8-14) 
0 
(0-0) 
Table 2.1.  Demographic and clinical details of 416 patients with suspected amyotrophic 
lateral sclerosis (ALS).  In total, 233 patients were diagnosed with ALS and 183 diagnosed 
with non-ALS neuromuscular mimic disorders, including chronic inflammatory 
demyelinating neuropathy (63), acquired neuromyotonia (22), myopathy (22), Kennedy’s 
disease (13), myasthenia gravis (13), axonal neuropathy (13), multifocal motor neuropathy 
(10),  spinal muscular atrophy (6), Hirayama’s disease (6), distal hereditary motor 
neuronopathy with pyramidal features (5), FOSMN syndrome (4), cervical radiculopathy (3), 
Lead toxicity (1), post-polio syndrome (1).  All patients were assessed using the amyotrophic 
lateral functional rating score-revised (ALSFRS-R), Medical Research Council (MRC) 
score, N/A – not applicable, and an upper motor neuron (UMN) score.  All data is expressed 
as median (interquartile range). 
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 Awaji criteria 
%  
(95% confidence 
interval) 
Revised El 
Escorial criteria 
%  
(95% confidence 
interval) 
P Value 
Total ALS population 
Sensitivity (def/prob)  
NNT 
Sensitivity (+possible) 
 
57 (50.0-63.3) 
1.8 (1.5-2) 
83.4 (78.0-87.9)* 
 
45 (38.7-51.7) 
2.4 (2-2.6) 
79.6 (73.9-84.5)* 
 
< 0.001 
 
0.28 
    
Bulbar-onset ALS 
Sensitivity (def/prob) 
NNT 
Sensitivity (+possible) 
 
52.2 (39.8-64.4) 
1.9 (1.6-2.5) 
75.8 (63.6-85.5)! 
 
42 (30.2-54.5) 
2.5 (1.9-3.4) 
67.7 (55.2-78.5)x 
 
< 0.001 
    
Limb-onset ALS 
Sensitivity (def/prob) 
NNT 
Sensitivity (+possible) 
 
58.9 (50.9-66.5) 
1.7 (1.5-2) 
87.5 (81.4-92)! 
 
43.1 (31.2-51.4) 
2.3 (2-3.3) 
85 (78.6-90.7)S 
 
< 0.001 
    
ALSFRS-R 
Sensitivity (def/prob)   
 (>38) 
Sensitivity (def/prob)   
(<38) 
 
 49.1 (41.1-57.1) 
 
77.3 (65.3-86.7)# 
 
  36.8 (29.4-44.7) 
 
67.6 (55-78.8)# 
 
< 0.05 
 
0.15 
    
ALSFRS-R 
Sensitivity (+possible)   
 (>38) 
Sensitivity (+possible)   
(<38) 
 
78.9 (71.8-84.9) 
 
90.9 (81.3-96.6) 
 
71.6 (64-78.4) 
 
86.2 (75.3-93.5) 
 
0.13 
 
0.39 
    
Disease duration  
(months) 
Sensitivity (def/prob)   
(<12 months) 
Sensitivity (def/prob)   
(>12 months) 
 
 
62.4 (53.6-70.7) 
 
48.9 (38.1-59.8) 
 
 
47 (38.2-55.9) 
 
  41.4 (30.9-52.4) 
 
 
< 0.05 
 
0.32 
    
Disease duration  
(months) 
Sensitivity (+possible)   
(<12 months) 
Sensitivity (+possible)   
(>12 months) 
 
 
84.2 (76.9-90)$ 
 
  78.9 (68.7-86.6)$ 
 
 
79.7 (71.7-75)$ 
 
75 (64.6-83.6)$ 
 
 
0.34 
 
0.66 
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The identification of early onset disease, ‘possible or suspected ALS’ was more robust in the 
Awaji criteria, upgrading 31 (24%) of patients in the El Escorial criteria to Awaji ‘definite or 
probable’, conversely only 2 (2%) patients classified as ALS possible/suspected on the Awaji 
criteria were upgraded by the rEEC.  In addition, 12 (5.1%) patients were classified as 
“probable-laboratory supported” on the rEEC, resulting in 10 patients classified as 
definite/probable on the Awaji criteria with only 2 patients downgraded to a “possible” 
diagnostic category.   
 
The diagnostic utility of the Awaji and revised El Escorial criteria were further assessed by 
considering the “possible” diagnostic category as a positive finding.  The sensitivity of the 
Awaji [83.4%, 78.0-87.9%, P < 0.001] and revised El Escorial criteria [79.6%, 73.9-84.5%, P 
< 0.001] increased, and interestingly the sensitivity of the Awaji criteria and rEEC were now 
comparable (Table 2.2).  Importantly, the specificity for both the Awaji and revised El 
Escorial criteria remained unchanged [99.5% (95% CI 96-100%)].  As expected the number 
needed to test in order to diagnose an extra ALS case was reduced to 1.2 (1.1-1.3) for the 
Awaji criteria and 1.3 (1.2-1.4) for the rEEC. 
 
Table 2.2. The Awaji criteria exhibited a significantly higher sensitivity when compared to the 
revised El Escorial criteria (rEEC) in the entire cohort of amyotrophic lateral sclerosis (ALS) 
as well as patients with bulbar and limb-onset disease, with a reduced number needed to test 
(NNT).  The specificity of both criteria were identical at 99.5%.  Inclusion of the ALS 
“possible” diagnostic category as a positive finding [sensitivity (+possible)], significantly 
enhanced the sensitivity of both the Awaji and revised El Escorial criteria in ALS and 
subgroups as follows; *P < 0.001 (Awaji [definite/probable] versus Awaji [add possible]); !P 
<0.001 (Bulbar and limb-onset ALS Awaji [definite/probable] versus Awaji [add possible]); 
XP < 0.01 (Bulbar-onset ALS, rEEC [definite/probable] versus rEEC [ add possible]; SP < 
0.001 (Limb-onset ALS, rEEC [definite/probable] versus rEEC [ add possible]; #P< 0.05 
(Awaji and rEEC sensitivity significantly higher in patients with worse functional deficits); $ 
P< 0.001 (Addition of possible category significantly increased sensitivity for Awaji and rEEC 
in patient with shorter and longer disease duration). 
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Comparison of diagnostic utility in ALS subgroups 
Subgroup analysis, based on site of disease onset, disclosed that the sensitivity of the Awaji 
criteria (52.2% [39.8-64.4]) were significantly higher for bulbar onset disease when 
compared to the rEEC (42% [30.2-54.5], Pearson Chi-Square 39.5, df 1, P < 0.001, Table 
2.2).  Importantly, the number of bulbar onset ALS patients needed to be tested in order to 
diagnose one extra case of ALS was 1.9 (1.6-2.5) by the Awaji criteria and 2.5 (1.9-3.4) by 
the rEEC.  In addition, the sensitivity of the Awaji criteria (58.9% [50.9-66.5]) were 
significantly higher in limb-onset patients when compared to rEEC (43.1% [31.2-51.4], 
Pearson Chi-Square 86.4, df 2, P < 0.001, Table 2.2), with the NNT for Awaji criteria being 
1.7 (1.5-2) and for rEEC 2.3 (2-3.3). 
 
The inclusion of the “possible” diagnostic category as a positive finding significantly 
enhanced the sensitivity of both criteria while the specificity remained unchanged.   
Specifically, in bulbar-onset ALS the sensitivity of the Awaji criteria was significantly 
increased to 75.8% (63.6-85.5%, P < 0.001) and rEEC to 67.7% (55.2-78.5%, P < 0.01, Table 
2.2).  In limb-onset ALS a more impressive increase in sensitivity was evident for both the 
Awaji criteria (87.5% [81.4-92%], P < 0.001) and rEEC (85% [78.6-90.7%], P < 0.001).   
 
The degree of functional disability, as indicated by ALSFRS-R score, also influenced the 
sensitivity of both the Awaji and rEEC criteria.  Specifically, the sensitivity of the Awaji 
criteria in patients with greater functional disability (ALSFRS-R < 38) was 77.3% (65.3-
86.7%, Table 2.2), and was significantly higher when compared to patients with less severe 
disease (49.1%, 41.1-57.1%, P < 0.05).  In addition, the rEEC criteria also exhibited a higher 
sensitivity in patients with more severe disease (67.6%, 55-78.8%) compared to patients with 
less functional impairment (36.8%, 29.4-44.7%, P < 0.05).  The Awaji criteria, however, was 
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significantly more sensitive when compared to rEEC in less severe disease (P< 0.05), while 
comparable sensitivities between the criteria were evident in the more severe disease 
subgroup (P=0.15). Taken together, these findings suggest that while both sets of criteria are 
less efficient at diagnosing patients in the earlier stages of the disease process, the Awaji 
criteria may exhibit a greater sensitivity at the early stages.   
 
The inclusion of the “possible” diagnostic category as a positive finding significantly 
enhanced the sensitivity for both criteria.  Specifically, the sensitivity of the Awaji criteria 
was significantly increased to 90.9% (81.3-96.6%, P < 0.05) in patients with more severe 
disease and to 78.9% (71.8-84.9%, P < 0.001) in the less severe group.  Likewise, the 
sensitivity of the rEEC was increased to 86.2% (75.3-93.5%, P < 0.05) in the more severe 
cohort and to 71.6% (64-78.4%, P < 0.001) in the group that was functionally more severe.  
Importantly, the specificity for both criteria was maintained.   
 
The disease duration at time of assessment significantly impacted on the sensitivity of the 
Awaji criteria when compared to rEEC.  Specifically, the sensitivity of the Awaji criteria was 
significantly higher than rEEC in patients with shorter disease duration (< 12 months, Table 
2.2), while the sensitivity was comparable in patients with longer disease duration at time of 
assessment.   Importantly, the sensitivity of both criteria were significantly increased by 
incorporating the “possible” diagnostic category, and this benefit was evident in patients with 
shorter and longer disease duration (Table 2.2, Figure 2.1).   
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Discussion 
An accurate and expeditious diagnosis of ALS is critical for patient management as it enables 
institution of appropriate management strategies, including commencement of riluzole and 
multidisciplinary care, at an earlier stage of the disease process as well as providing 
diagnostic certainty for patients and families that will enable adequate future planning.  In 
addition, an early and accurate diagnosis facilitates recruitment of patients into clinical trials, 
at a stage of the disease process where neuroprotective therapies may be most effective - the 
putative therapeutic window period.  In the absence of a pathognomonic test, the diagnosis of 
ALS has relied on consensus criteria, namely the El Escorial/Airlie House (498, 511) and the 
Awaji (6) criteria, which have exhibited a varied sensitivity (30, 61).  Moreover, specificity 
data were infrequently reported (54, 57, 60, 504), thereby further limiting the interpretation of 
diagnostic utility of the criteria.          
Figure 2.1.  Cumulative probability of reaching a diagnosis of amyotrophic lateral 
sclerosis (ALS) for different diagnostic categories at the time of initial assessment plotted 
as a function of disease duration (months) at first assessment. 
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The current prospective multicenter study, incorporating a total of 435 ALS and non-ALS 
neuromuscular mimic disorder patients, established a higher sensitivity of the Awaji criteria 
when compared to rEEC. Importantly, the increase in sensitivity was evident in both bulbar 
and limb-onset ALS, as well as patients with less severe disease (ALSFRS-R>38) and with 
shorter disease duration (< 12 months).  Of relevance, application of the Awaji criteria 
resulted in a 12% gain in sensitivity, which was lower than previously reported (30, 52-54).  
Given the large sample size (N=233) and a multidisciplinary prospective design, it seems 
plausible to conclude that the present findings reflect more accurately the diagnostic accuracy 
of the criteria in a clinical setting.  This notion is underscored by marked heterogeneity of 
sensitivities in previous studies, with some reporting a higher sensitivity of the Awaji criteria 
(52, 53, 55, 56, 58, 502, 504), others documenting equivalent sensitivities (54, 57, 59), while 
one study established a lower sensitivity for the Awaji criteria (60).   
 
The Awaji criteria has been critiqued for the omission of the “probable laboratory supported” 
diagnostic category, which has been suggested as a likely explanation for the lower 
sensitivity of Awaji criteria in limb-onset disease (59, 60, 509).  Specifically, it has been 
reported that the Awaji criteria downgraded approximately 20% of ALS classified as 
“probable-laboratory supported” on the rEEC.  In the present study, 10 (4.3%) patients were 
classified as probable-laboratory supported, of which 2 were downgraded to the Awaji 
“possible” category.  Importantly, the sensitivity of the Awaji criteria was significantly higher 
when compared to rEEC in limb-onset ALS, thereby arguing against a significant diagnostic 
impact of omitting the “probable laboratory supported” diagnostic category from the Awaji 
criteria.   
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In an attempt to increase the sensitivity of the diagnostic criteria, a number of trials have 
permitted the inclusion of ALS patients classified within the “possible” diagnostic category 
(278, 515).   Of relevance, the latest revision proposed a further liberalization of the El 
Escorial criteria, whereby “possible” ALS was considered a positive finding (63).   While 
such a revision would ultimately increase the sensitivity, the issue of whether specificity is 
maintained remains to be determined.  Importantly the present findings confirm a significant 
increase in sensitivity by incorporating the “possible” diagnostic category for both Awaji and 
Revised El Escorial criteria.  This increase in sensitivity was evident across ALS subgroups, 
as defined by site of disease onset, function deficits and disease duration (Table 2.2).  
Importantly, the specificity remained unchanged, thereby suggesting that liberalisation of the 
criteria could significantly enhance the diagnosis of ALS, which could be of particular 
relevance in the early stages of the disease, ultimately enabling earlier recruitment of patients 
into clinical trials where neuroprotective therapies are likely to be most effective.  
 
The utility of diagnostic criteria may be limited in the restricted or atypical ALS phenotypes.  
Specifically, in clinically pure lower motor neuron phenotypes, such as flail arm syndrome or 
progressive muscular atrophy (63).  Identification of subclinical UMN dysfunction with TMS 
techniques has been shown to facilitate the diagnosis in the flail leg syndrome (240).  In 
addition, a recent revision of the El Escorial criteria suggested that identification of LMN 
dysfunction in isolation could be deemed as consistent with ALS, in the setting of excluding 
mimic disorders (63).  While this modification would potentially diagnose the LMN variants 
of ALS, the specificity needs to be confirmed. Given that the modification was published 
after the commencement of the current study, assessment of specificity in a blinded fashion 
was not possible and future blinded prospective studies should investigate the issue of 
sensitivity.  
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A potential limitation of the diagnostic criteria remains the reliance on clinically identifying 
upper motor neuron dysfunction.  Specifically, the identification of upper motor neuron signs 
in ALS may be difficult for a variety of reasons (38), potentially impacting on the sensitivity 
of criteria.  Objective assessment of UMN function by threshold tracking transcranial 
magnetic stimulation (TMS) techniques has been documented to significantly increase the 
sensitivity of the Awaji and revised El Escorial criteria, reliably differentiating ALS from 
potential mimic disorders and reducing the diagnostic delay by months (237, 510).  
Consequently, incorporation of the threshold tracking TMS technique into future revisions of 
diagnostic criteria could further enhance the diagnosis of ALS.  
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Chapter 3 
 
DIAGNOSTIC UTILITY OF  
CORTICAL DYSFUNCTION IN ALS 
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Summary 
Whilst the previous chapter highlighted that the Awaji criteria could be improved by the 
incorporation of a ‘possible’ criteria, the lack of an objective biomarker of upper motor 
neuron (UMN) dysfunction continued to be problematic.  Given that cortical 
hyperexcitability appears to be an early feature in ALS, with potential as a diagnostic 
biomarker, the present study assessed the diagnostic utility of threshold tracking transcranial 
magnetic stimulation (TMS) technique as an aid to the Awaji criteria in establishing of an 
earlier diagnosis of ALS.  Prospective studies were undertaken on a cohort of 82 patients with 
suspected ALS and results were compared to 34 healthy controls. A measure of cortical 
hyperexcitability, short-interval intracortical inhibition (SICI) was significantly reduced in 
ALS patients (P<0.0001), with a comparable reduction evident in the Awaji groups (SICI 
AWAJI POSSIBLE 1.3±1.3%; SICI AWAJI PROBABLE/DEFINITE 1.4±1.7%).  Central motor conduction 
time was significantly prolonged (P<0.001), while the motor evoked potential amplitude 
(P<0.05) and intracortical facilitation (P<0.05) were increased. The frequency of TMS 
abnormalities was similar across Awaji subgroups, and addition of TMS abnormalities as a 
diagnostic category enabled reclassification of 88% of Awaji possible patients to Awaji 
probable/definite.  Cortical dysfunction, as measured by the threshold tracking TMS, 
potentially facilitates an earlier diagnosis of ALS when combined with the Awaji criteria.  
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Introduction  
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative 
disorder of motor neurons (48). Clinically, ALS is characterized by the presence of a 
combination of upper (UMN) and lower motor (LMN) neuron signs, which form the 
diagnostic basis for ALS (498).  Diagnostic criteria, based on the identification of upper and 
lower motor neuron dysfunction may be insensitive, especially in the early stages of ALS, 
potentially resulting in a diagnostic delay (51) and ultimately institution of neuroprotective 
therapies and recruitment into clinical trials (247).   
 
The Awaji criteria were developed in order to facilitate an earlier diagnosis of ALS (6). These 
consensus criteria proposed that neurophysiological findings of chronic neurogenic changes 
could be equated to clinical features of LMN dysfunction.  In addition, the presence of 
fasciculation potentials was deemed to be a marker of denervation.  The sensitivity of the 
Awaji criteria was reported to be significantly increased, while the specificity appeared to be 
preserved (30, 52-57).  Quantitative dysfunction of UMNs, however, was not captured by the 
Awaji criteria, thereby potentially precluding the diagnosis of ALS prior to development of 
widespread neurogenic changes or when the presenting phenotype is atypical such as such as 
the flail-arm variant (240). 
 
Upper motor neuron function may be assessed by transcranial magnetic stimulation (TMS) 
techniques.  Specifically, resting motor threshold (RMT), motor evoked potential (MEP) 
amplitude, and cortical silent period (CSP) duration are all biomarkers of UMN function, 
elicited by single pulse TMS techniques, and may be abnormal in ALS (39).  Of further 
relevance, short interval intracortical inhibition (SICI) is elicited by paired-pulse TMS 
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techniques, whereby a subthreshold conditioning stimulus suppresses the response produced 
by a subsequent test stimulus when the interstimulus interval is between 1-7 ms (329, 378).   
 
Importantly, cortical dysfunction appears to be an early feature in ALS, distinguishing ALS 
from mimic disorders, and supporting an earlier diagnosis of ALS when compared to the El-
Escorial criteria (237).  The diagnostic utility of TMS when compared to the Awaji criteria in 
identifying ALS, however, remains to be determined.  Consequently, the present study 
assessed the diagnostic potential of the threshold tracking TMS technique in ALS, 
particularly whether the finding of cortical hyperexcitability is more sensitive at establishing 
an earlier diagnosis of ALS than the Awaji criteria.   
 
Methods 
Clinical phenotype 
Studies were undertaken prospectively on a cohort of 82 patients (52 males and 30 females, 
mean age 60) with suspected ALS.  All patients were followed for up to three years, during 
which period the diagnosis of ALS was confirmed.  At the time of initial clinical assessment 
all patients underwent TMS studies. None of the patients with ALS were receiving 
medications, which could potentially interfere with the neurophysiological results. Informed 
consent to the procedures was provided by all patients, with the study approved by the 
Sydney West Area Health Service and Human Research Ethics Committees. 
 
Patients were clinically staged using the Amyotrophic Lateral Sclerosis Functional Rating 
Scale-Revised (ALSFRS-R) (495) and categorised according to site of disease onset as limb 
or bulbar-onset.  In addition, muscle strength was assessed using the Medical Research 
Council (MRC) score (516), with the following muscle groups assessed bilaterally yielding a 
118 
  
total MRC score of 90:  shoulder abduction; elbow flexion; elbow extension; wrist 
dorsiflexion; finger abduction; thumb abduction; hip flexion; knee extension; ankle 
dorsiflexion.  Upper motor neuron (UMN) dysfunction was clinically assessed utilizing the 
UMN score (497).   
 
Neurophysiological studies 
Peripheral studies 
Prior to undertaking cortical excitability studies, all patients were assessed by nerve 
conduction studies and needle electromyography.  The degree of peripheral disease burden 
was assessed in the median nerve, whereby the median nerve was stimulated electrically at 
the wrist using 5-mm Ag-AgCl surface electrodes (ConMed, Utica, USA). The resultant 
compound muscles action potential (CMAP) was recorded from the APB muscle and the 
onset latency and peak-peak amplitude were measured. Subsequently, the neurophysiological 
index (NI) was derived according to a previously reported formula (26). 
 
Needle EMG was performed using a concentric electrode (26G, Alpine Biomed ApS), and at 
least 3 regions were assessed (cranial, cervical and lumbosacral).  The median number of 
muscles studied per patient was 12 (IQR 7-14).  Evidence of ongoing activity (positive sharp 
waves and fibrillation potentials), fasciculations and chronic neurogenic changes were 
recorded.   
 
Cortical excitability 
Cortical excitability was assessed by utilising the threshold tracking TMS technique 
according to a previously reported technique (329).  Briefly, the MEP response was fixed at 
0.2mV (±20%), and changes in test stimulus intensity required to generate the target 
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response, when preceded by a subthreshold conditioning stimuli, were measured.  The 
following TMS parameters were recorded; short interval intracortical inhibition (SICI), 
intracortical facilitation (ICF), resting motor threshold (RMT), central motor conduction time 
(CMCT), MEP amplitude (%CMAP response) and cortical silent period (CSP) duration. 
 
Statistical analysis 
Cortical excitability in ALS patients were compared to control data obtained from 34 healthy 
subjects (17 men; 17 women, mean-age 56 years).  Student’s t-test or a Wilcoxon-Signed 
rank test was used for assessing differences between means. Analysis of variance was used 
for multiple comparisons. A  P value<0.05 was considered statistically significant.  Results 
are expressed as mean ± standard error of the mean (SEM) or median with interquartile range 
(IQR). 
 
Results  
Clinical features 
At the time of TMS testing 61% of patients were classified as Awaji possible while 39% were 
classified as probable/definite (Table 3.1).  During the follow-up period of up to 3 years, 95% 
of patients progressed to be classified as probable or definite ALS.  The median disease 
duration at time of TMS testing from symptom onset was 11 months (IQR 6-18 months).  
Forty percent of patients exhibited bulbar-onset disease while 60% reported limb-onset 
disease. During the follow-up period, 21% of patients died with median survival being 14 
months (3-36).  
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The degree of functional impairment was mild at time of assessment, with the median 
ALSFRS-R score being 42 (IQR 38-45) and similar in the Awaji groups (AwajiPOSSIBLE 43 
[39-45]; AwajiPROBABLE/DEFINITE 41 [37-45], Z= -0.75, P=0.23).  The median MRC sum score 
was 84 (IQR 79-88), while the median MRC score from the APB was 4 (IQR 4-5).  The 
median UMN score was 12 (9-13), indicating the presence of significant clinical UMN 
dysfunction in the ALS cohort. 
 
 
 
 
 
 
 
 
ALS 
(N = 82) 
ALS 
Possible 
(N = 50) 
ALS 
Probable/Definite 
(N = 32) 
Bulbar-
onset 
(N = 33) 
Limb-
onset 
(N = 49) 
Age (years, mean , SEM) 60 (1.5) 61 (2.0) 59 (2.0) 61 (2.5) 59 (1.8) 
Sex 52M, 30F 28M, 22F 24M, 8F 22M, 11F 30M, 19F 
Disease duration (months, IQR) 11 (6-18) 10 (6-24) 11 (6-12) 11 (8-20) 9 (6-18) 
APB (median, IQR) 4 (4-5) 5 (4-5) 4 (4-5) 5 (4-5) 4 (4-5) 
ALSFRS (median, IQR) 42 (38-45) 43 (39-45) 42 (37-45) 42 (38-44) 43 (39-46) 
MRC UL score (median, IQR) 57 (51-60) 58 (55-60) 52 (45-57) 58 (55-60) 56 (50-59) 
MRC LL score (median, IQR) 30 (26-30) 30 (27-30) 29 (23-30) 30 (30-30) 29 (23-30) 
MRC SUM score (median, 
IQR) 
84 (79-88) 86 (82-89) 79 (67-84) 88 (84-90) 81 (76-86) 
UMN Score 12 (0.6) 9.6 (0.8) 10.5 (1.0) 11.5 (0.8) 8.7 (0.8) 
Table 3.1. Clinical features summarized for 82 patients with suspected amyotrophic lateral sclerosis 
(ALS).  All patients were clinically staged by the amyotrophic lateral sclerosis functional rating scale-
revised (ALSFRS-R) and Medical Research Council (MRC) score, in the upper limb (UL), lower limbs 
(LL) and abductor pollicis brevis (APB) muscle. Upper motor neuron (UMN) score was utilised o assess 
the degree of clinical UMN dysfunction.  All data are expressed as mean±standard error of the mean 
(SEM) or median (interquartile range, IQR). 
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Neurophysiological studies 
The CMAP amplitude (ALS 7.2±0.5 mV, controls 9.5±0.5 mV, P<0.0001) and NI (ALS 1.2 
± 0.1; controls 2.3±0.1, P<0.0001) were significantly reduced in ALS patients.  Sub-group 
analysis disclosed a comparable reduction of CMAP amplitude (CMAP POSSIBLE 6.9 ±0.5 mV; 
CMAP PROBABLE/DEFINITE 6.9±0.9 mV) and NI (NI POSSIBLE 1.3±0.2; NI PROBABLE/DEFINITE 
1.1±0.2) in the Awaji subgroups, indicating a comparable degree of peripheral disease 
burden. 
 
Cortical excitability 
Paired-pulse threshold tracking TMS studies disclosed a significant reduction of SICI in ALS 
(Fig. 3.1).  Specifically, averaged SICI was significantly reduced in ALS (ALS1.3±1.1%; 
controls 10.3±1.1%, P<0.0001, Fig. 3.2A), with a similar reduction evident in the Awaji 
groups (SICI POSSIBLE; 1.3±1.3%, SICI PROBABLE/DEFINITE 1.4±1.7%; controls 10.3±1.1%, 
F=14.9, P<0.0001, Fig. 3.2B).  In addition, a comparable reduction of SICI was evident in 
ALS patients with and without out UMN signs (SICI UMN score 0 2.0±1.9; SICI UMN score >0 
1.5±1.3).  Of relevance, peak SICI at interstimulus interval (ISI) 1 and 3 ms were 
significantly reduced in ALS (Fig. 3.1), with a comparable reduction of  peak SICI at 1 ms 
(SICI POSSIBLE 1.0±0.8%; SICI PROBABLE/DEFINITE 1.7±1.7%; SICI CONTROL 6.1±1.3%, F=5.6, 
P<0.01, Fig. 3.2C) and 3 ms (SICI POSSIBLE 2.4±1.9%; SICI PROBABLE/DEFINITE 4.7±2.5%; SICI 
CONTROL 15.4±1.6%, F=13.8, P <0.001, Fig. 3.2D) being evident in the Awaji groups.   
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Intracortical facilitation follows SICI and was significantly increased in ALS (P<0.05, Fig. 
3.1).   Importantly, a comparable increase of ICF was evident in the Awaji groups (ICF 
POSSIBLE -3.6±0.8%; ICF PROBABLE/DEFINITE -4.4±1.6%). 
 
 
 
 
 
Figure 3.1. Short-interval intracortical inhibition (SICI) was significantly reduced 
in amyotrophic lateral sclerosis (ALS) patients compared to controls. 
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Single pulse TMS disclosed a significant increase in MEP amplitude in ALS patients (ALS 
33.3±2.8%; controls 25.5±2.5%, Fig. 3.3A, P<0.05).  Although the increase in MEP 
amplitude was evident in both Awaji subgroups, it was only significant in the Awaji 
possible/definite group (Fig. 3.3B).  In addition, the CSP duration was significantly reduced 
in ALS (ALS 178.1±5.1 ms; controls 214.9±3.6 ms, Fig. 3.3C, P<0.0001), and was 
comparable in the Awaji groups (P=0.13, Fig. 3.3D). 
Figure 3.2. (A) Averaged short-interval intracortical inhibition (SICI), between interstimulus 
interval (ISI) 1-7 ms, was significantly reduced in amyotrophic lateral sclerosis (ALS). (B) The 
reduction of averaged SICI was comparable in Awaji subgroups. Peak SICI at ISI (C) 1 ms and (D) 
3 ms was significantly reduced in Awaji subgroups. ****P<0.0001. 
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The motor cortex was inexcitable in 23% of ALS patients.  In total, 63% of these patients 
were classified as Awaji possible and 37% as probable/definite.  In the remaining 77% of 
patients, the RMT was significantly reduced (ALS cohort 56.7±1.2%; controls 61.0±1.4%, 
P<0.05), with the reduction being similar in both Awaji groups (P=0.13).  The CMCT was 
significantly prolonged in ALS patients (ALS 6.6±0.2 ms; controls 5.3±0.2 ms, Fig. 3.4A, 
P<0.001), and the prolongation was similar in both Awaji groups (CMCTPOSSIBLE 6.7±0.3 ms; 
CMCTPROBABLE/DEFINITE 6.4±0.3 ms, Fig. 3.4B).   
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Figure 3.3. Motor evoked potential (MEP) was significantly increased in (A) amyotrophic lateral 
sclerosis (ALS), although this increase (B) was only evident in the Awaji probable/definite group.  
(C). Cortical silent period (CSP) duration was significantly reduced in ALS.  (D) The reduction in 
CSP duration was evident in both Awaji groups. *P<0.05;**P<0.01;****P<0.0001 
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Clinical correlations 
Combining clinical, neurophysiological and cortical excitability parameters, it was evident 
that RMT significantly correlated with the CMAP amplitude (R= -0.40, P<0.01) and NI (R= -
0.34, P<0.01).  In addition, the MEP amplitude was significantly correlated with the CMAP 
amplitude (R=0.61, P<0.0001).  Taken together, the findings seem to suggest that cortical 
hyperexcitability may be an early feature in ALS, in keeping with previous studies (39).   
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Figure 3.4. (A) Central motor conduction time (CMCT) was significantly prolonged in 
amyotrophic lateral sclerosis (ALS), and (B) was evident in Awaji possible (grey bar) 
and probable/definite (white bar) ALS when compared to controls (black bar). 
**P<0.001; ****P<0.0001. 
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Diagnostic utility of threshold tracking TMS 
In order to assess the diagnostic utility of threshold tracking TMS, a previously established 
cut-off value for averaged SICI < 5.5% (237) along with prolonged CMCT and inexcitability 
of motor cortex, were utilised as biomarkers of cortical dysfunction.  TMS abnormalities 
were evident in 77% of ALS patients, with frequency of abnormalities being similar across 
Awaji groups (Chi square 1.36, P=0.112).  Of relevance, 54% of Awaji possible patients 
exhibited cortical hyperexcitability, while 27% exhibited an inexcitable motor cortex and 
56% prolonged CMCT.  Importantly, the frequency of TMS abnormalities was similar in 
bulbar and limb-onset disease patients (Awaji POSSIBLE BULBAR-ONSET 80%; Awaji POSSIBLE LIMB-
ONSET 78%, P=0.595).  The addition of TMS abnormalities (reduced SICI, prolonged CMCT 
or inexcitable cortex) as a diagnostic category resulted in 88% of Awaji possible patients 
being reclassified as Awaji probable/definite. 
 
Discussion 
The current prospective study has established that the findings of cortical dysfunction, as 
indicated by TMS abnormalities, may be a useful diagnostic biomarker in early symptomatic 
ALS.  Cortical dysfunction was heralded by significant reduction in short-interval 
intracortical inhibition, resting motor threshold and cortical silent period duration, along with 
an increase in the MEP amplitude and intracortical facilitation.  Importantly, cortical 
dysfunction appeared to be an early feature in ALS, with cortical hyperexcitability evident in 
54% and motor cortex inexcitability in 27% of patients classified as Awaji possible ALS.  In 
addition, prolonged CMCT was evident in 56% of Awaji possible patients.  Interestingly 
even in ALS patients who did not exhibit UMN signs, there was evidence of cortical 
dysfunction.  Importantly, 88% of Awaji possible patients could be re-classified as Awaji 
probable/definite if TMS abnormalities, including prolonged CMCT, inexcitable motor 
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cortex or reduced SICI, were used as additional diagnostic parameters.  Taken together, these 
findings suggest that the presence of UMN dysfunction could potentially hasten the diagnosis 
of ALS when compared to the Awaji criteria. 
 
Diagnosis of amyotrophic lateral sclerosis 
In the absence of a pathognomonic test, the diagnosis of ALS has relied on identification of a 
combination of upper and lower motor signs with evidence of disease progression (498).  The 
clinical criteria have proved insensitive in establishing ALS, especially in the early stages of 
disease process, thereby resulting in critical delays in institution of appropriate management 
strategies.  Recently developed Awaji criteria (6) have increased the diagnostic sensitivity for 
ALS without compromising specificity (52-55), although the increase in diagnostic accuracy 
was attributable to patients with bulbar-onset disease (30, 502).  Importantly, UMN 
dysfunction was assessed clinically in the Awaji criteria and as such in patients with 
equivocal or absent UMN signs, the diagnosis of ALS may be delayed.    
 
An objective measure of UMN dysfunction could potentially enable an earlier diagnosis of 
ALS.  TMS techniques have been proposed as an objective tool for establishing UMN 
dysfunction in ALS (39).  A modest prolongation of CMCT has been previously established 
in ALS, and probably reflects degeneration of the fastest conducting corticomotoneuronal 
fibres as well as increased desynchronization of corticomotoneuronal volleys (46, 517).  Of 
relevance, it has been suggested that the sensitivity of prolonged CMCT could be improved 
by recording from cranial muscles in patients with bulbar-onset disease (314).  The findings 
in the present study underscore the diagnostic utility of CMCT in ALS, whereby prolongation 
of CMCT appears to be a sensitive and early biomarker of UMN dysfunction, evident in 
Awaji possible patients irrespective of site of disease-onset.    
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Reduction or absence of SICI is an early and robust biomarker of cortical dysfunction in ALS 
(39).  Degeneration of inhibitory cortical interneurons along with glutamate-mediated 
excitoxicity appears to underlie SICI abnormalities in ALS (224, 406).  Importantly, 
reduction of SICI is specific for ALS among the group of neuromuscular mimic disorders 
(237), while subclinical reduction of SICI is evident in atypical ALS phenotypes (240).  
Absence or reduction of SICI may also lead to an earlier diagnosis of ALS when compared to 
El Escorial criteria (237).  The findings in the present study underscore the potential utility of 
SICI as a diagnostic biomarker in early ALS, being evident in 56% of Awaji possible patients 
and enabling a more definitive diagnosis of ALS when combined with other TMS parameters. 
 
Diagnostic utility of threshold tracking TMS in ALS 
Enrollment of ALS patients into clinical trials remains a major challenge (499), in part related 
to the use of stringent clinical inclusion criteria which rely on identifying UMN and LMN 
signs in multiple body regions (498).  The reliance on such stringent clinical criteria may 
exclude ALS patients in early stages of the disease process from enrollment into clinical 
trials, the very group in which therapeutic agents may be most efficacious.   
 
The Awaji diagnostic criteria were developed in order to enhance the diagnostic accuracy of 
ALS (6). While numerous studies have reported increased sensitivity and preserved 
specificity of the Awaji criteria when compared to El Escorial criteria (30, 52-57), a recent 
study reported a lower sensitivity of the Awaji criteria (60).  The discordance between the 
studies was attributed to the requirement for finding UMN signs in at least 2 regions in order 
that the Awaji probable criteria are attained.  Consequently, utilization of TMS techniques 
may objectively document UMN dysfunction, enabling an earlier diagnosis of ALS, 
commencement of neuroprotective therapies and recruitment into clinical trials. 
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Chapter 4 
 
THE SENSITIVITY AND SPECIFICITY OF 
THRESHOLD-TRACKING 
TRANSCRANIAL MAGNETIC 
STIMULATION FOR THE DIAGNOSIS OF 
AMYOTROPHIC LATERAL SCLEROSIS: 
A PROSPECTIVE STUDY  
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Summary 
 
The earlier study, described in Chapter 3 looked at the diagnostic utility of the threshold 
tracking TMS in ALS.  However, the study design was not undertaken according to the 
‘Standards of reporting of diagnostic accuracy’ (STARD) criteria, which are the ‘gold 
criteria’ for diagnostic clinical studies. Subsequently a prospective multicenter study was 
undertaken on patients referred to three neuromuscular centers in Sydney, Australia between 
January 1 2010 and March 1 2014.  The study was performed in accordance with the STARD 
criteria.  The inclusion criteria included:  (i) Definite, probable, or possible ALS as defined 
by the Awaji criteria; (ii) Pure motor disorder with clinical features of upper and lower motor 
dysfunction in at least one body region progressing over a 6 month follow-up period; (iii) 
Neuromuscular disorder mimicking ALS (non-ALS).  All subjects underwent threshold 
tracking TMS at recruitment, with the reference standard being the Awaji criteria.  The 
primary outcome measure was the sensitivity and specificity of TMS in differentiating ALS 
from non-ALS.  Receiver operator curve analysis, a plot of sensitivity and the false-positive 
rate, was utilized to derive the sensitivity and specificity of TMS.  The investigators who 
performed the index test were blinded to the results of the reference test and all other 
investigations.  In total, 333 patients were studied and 281 patients satisfied the inclusion 
criteria. Eventually, 209 patients were diagnosed with ALS and 68 with NALS.  The 
threshold tracking TMS technique reliably differentiated ALS from NALS with sensitivity of 
73.08% (95% CI: 66.51-78.98%) and specificity of 80.88% (69.53-89.40%) at an early stage 
in the disease process with mean disease duration at time of testing being 16.7±1.1 months. 
The threshold tracking TMS technique reliably distinguishes ALS from non-ALS, and could 
represent a useful diagnostic investigation when combined with the Awaji criteria to prove 
upper motor neuron dysfunction at early stages of ALS.  
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and invariably fatal 
neurodegenerative disorder of the upper and lower motor neurons (48).  The diagnosis of 
ALS relies on the identification of concurrent upper (UMN) and lower motor neuron (LMN) 
dysfunction, with the level of diagnostic certainty dependent on the extent of UMN and LMN 
dysfunction (6, 48, 498).  The clinically based ALS diagnostic criteria were deemed 
insensitive, particularly in early stages of the disease or in the setting of atypical phenotypes, 
potentially  resulting in significant diagnostic delays (51).   Consequently, the institution of 
adequate management strategies, including commencement of neuroprotective therapies such 
as riluzole, and recruitment into therapeutic trials may be delayed, perhaps beyond the 
therapeutic window period (247). 
 
Despite rapidly evolving interest in ALS clinical trial methodology, the process of diagnosis 
remains complex. Attempts to better define a diagnosis of ALS led to the first international 
workshop that aimed to reach consensus agreement, at El Escorial in 1990 (511).  Since then, 
there have been multiple revisions and new approaches (498), including the most recent 
neurophysiologically based Awaji criteria (6).  The Awaji criteria proposed that 
neurophysiological features of LMN dysfunction, as indicated by chronic neurogenic changes 
and fibrillation potentials/positive sharp waves along with fasciculations were equivalent to 
clinical features of LMN dysfunction.  Although the Awaji criteria exhibited a higher 
sensitivity compared to the revised El Escorial criteria (30, 52-56, 58, 60), the diagnostic 
benefit appeared most prominent in patients with bulbar-onset  disease (30).  In addition, the 
clinically probable laboratory-supported diagnostic category was abolished in the Awaji 
criteria thereby necessitating the identification of UMN signs in two regions in order to 
establish a diagnosis of ALS.  Given the difficulties in identifying UMN signs in ALS (38), 
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the sensitivity of the Awaji criteria could be reduced when compared to the revised El 
Escorial criteria (60).  
 
The functional integrity of the upper motor neuronal system in ALS can be objectively 
assessed by transcranial magnetic stimulation (TMS) techniques (39).  Multiple lines of 
evidence, utilising animal and human studies have established a TMS focus on the upper 
motor neuron, with neuronal activation mediated by ion channels and synaptic processes 
acting via multiple neurotransmitter systems (39, 518).  A recently developed threshold 
tracking TMS technique (329), which overcomes the motor evoked potential amplitude 
variability evident with conventional TMS techniques, has established cortical 
hyperexcitability as a specific and early feature of ALS, reliably differentiating ALS from 
mimic neuromuscular disorders (237).  Importantly, it has been postulated that cortical 
hyperexcitability may evolve to normal or hypoexcitability during the course of disease (39).  
While diagnostic threshold tracking TMS values have been reported (237), the study was not 
performed in accordance with the Standards for Reporting of Diagnostic Accuracy (STARD) 
criteria and was limited to a single center.  As such, the generalizability of the results could 
not be definitively evaluated (519).  Consequently, the aim of the present study was to 
determine the diagnostic accuracy of the threshold tracking TMS technique in differentiating 
ALS from mimic neuromuscular disorders.   In order to avoid potential bias and to ensure a 
wider applicability of the findings, patients were recruited across multiple neuromuscular 
clinics in accordance with the STARD criteria.   
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Methods 
Patients 
All patients underwent detailed clinical assessment and grading prior to enrolment, including 
electrodiagnostic investigations.  Recruitment of patients was performed prospectively and 
consecutively in keeping with the inclusion criteria.  The Awaji diagnostic criteria was used 
as the reference standard (6).  The study population comprised patients with suspected ALS, 
although none of the patients were diagnosed with ALS prior to recruitment.  Inclusion 
criteria included:  (i) Definite, probable, or possible ALS as defined by the Awaji criteria (6); 
(ii) Pure motor disorder with clinical features of upper and lower motor dysfunction in 
separate body regions, where LMN dysfunction developed caudal to UMN dysfunction, with 
evidence of disease progression over 6 months follow-up period from initial assessment; (iii) 
Neuromuscular disorders mimicking ALS, defined as muscle weakness and wasting for at 
least 6 months.  At time of assessment, it was not known whether these patients would be 
classified in the “non-ALS” group.   
 
Exclusion criteria included (i) pure UMN syndrome in which laboratory and neuroimaging 
studies suggested a diagnosis other than “possible” ALS; (ii) history of acute migraine 
headaches in the 4 weeks preceding recruitment, since migraine may increase cortical 
excitability; (iii) treatment with medications that could affect TMS parameters; (iv) history of 
head trauma, movement disorder, epilepsy, stroke or transient ischemic attack; (v) presence 
of pacemaker or other cardiac devices, cochlear implants and previous brain surgery such as 
clipping of a cerebral aneurysm; and (vi) unable to tolerate TMS testing or (vi) marked 
wasting of the thenar eminence precluding recording of motor responses.  All patients 
provided written informed consent to the procedures approved by the Western Sydney Local 
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Health District and South East Sydney Area Health Service Human Research Ethics 
Committees.  
 
Once recruited, ALS patients were clinically staged using the amyotrophic lateral sclerosis 
functional rating score (ALSFRS-R) (513).  The disease duration (months) from time of 
symptom onset and site of disease onset were recorded.  Muscle strength was assessed by the 
Medical Research Council (MRC) score, with the following muscle groups assessed: 
shoulder abduction, elbow flexion and extension, wrist dorsiflexion, finger abduction and 
thumb abduction, hip flexion, knee extension and ankle dorsiflexion bilaterally, yielding a 
maximal score of 90.  Upper motor neuron function was assessed and graded by a dedicated 
UMN score(497).   
 
Index test 
Cortical excitability 
Threshold tracking TMS was performed by two examiners (PM, and NG), with neurology 
training and neurophysiological expertise. These examiners were blinded to the results of the 
reference test at time of assessment, as well as the clinical history and all aspects of the 
assessment.  Data analysis was performed by a separate rater (SV) with expertise in analysing 
the results of the index test and reference standard.   
 
The TMS investigation was undertaken in all patients according to a previously reported 
technique (329), using a 90 mm circular coil.  Briefly, the motor evoked potential (MEP) 
amplitude was fixed and changes in the test stimulus intensity required to generate a target 
response of 0.2 mV (±20%), when preceded by a sub-threshold conditioning stimulus, was 
measured (329).  The motor evoked potential (MEP) response was recorded over the right 
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abductor pollicis brevis muscle in all patients.  Resting motor threshold (RMT) was defined 
as the stimulus intensity required to maintain this target MEP response.  Paired-pulse 
threshold tracking was undertaken to determine short interval intracortical inhibition (SICI) 
and intracortical facilitation (ICF), while single pulse TMS was utilized to determine the 
MEP amplitude (mV), cortical silent period (CSP) duration (ms) and central motor 
conduction time (CMCT) according to a previously reported technique (329).  In patients 
with severe wasting of the thenar eminence, as assessed clinically or with nerve conduction 
studies disclosing a median nerve compound muscle section potential of < 1mV, cortical 
excitability testing was not undertaken. 
 
Statistical Analysis 
The primary outcome measure was the diagnostic sensitivity and specificity of TMS in 
differentiating ALS from non-ALS.  The secondary outcome measures included the 
diagnostic utility of TMS in ALS subgroups based on Awaji criteria (definite/probable or 
possible), site of disease onset (bulbar versus limb), phenotype (presence or absence of UMN 
signs), and therapy (riluzole versus non-riluzole).  Receiver operator curve analysis was 
utilized to assess the diagnostic utility of the index test.  The sensitivity, specificity, positive 
likelihood ratio, negative likelihood ratio and diagnostic odds ratio were determined for the 
index test.  In addition, the number needed to test in order to diagnose one extra case of ALS 
with TMS, when applied to a group of patient with neuromuscular disorders, was calculated 
according to the formula reported by Bandolier (http://www.medicine.ox.ac.uk/bandolier/band27/b27-2.html). 
Multiple regression analysis was utilized to assess whether the outcome variables (SICI 
reduction and motor cortex inexcitability) were influenced by independent variables.  A 
probability value <0.05 was considered statistically significant.  Results were expressed as 
mean ± standard error of mean or median (interquartile range). 
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Results 
Clinical features (Table 4.1) 
A prospective study was undertaken between January 1, 2010 and March 1, 2014, with 
subjects recruited from three neuromuscular centers in Sydney, Australia.  The study was 
conducted in accordance with the STARD criteria (Fig 4.1), and the index test and reference 
standard (Awaji criteria) were applied to all subjects at time of recruitment.  No adverse 
events were recorded from performance of the index test. In total, 333 patients (206 males, 
127 females, mean age 57.6±0.8years) satisfied the inclusion criteria.  At recruitment, 209 
patients were suspected of suffering with ALS.  Of these, 52% were classified as Awaji 
definite/probable, 22% as Awaji possible, while 26% of patients did not meet Awaji criteria 
at initial assessment, although most progressed during the follow-up period leading to re-
classification to Awaji definite/probable group (96%). Two patients failed to progress 
appreciably and remained Awaji negative eventually being diagnosed with primary muscular 
atrophy.  A total of 6.3 % (N=21, Fig. 4.1) of patients could not undergo TMS testing due to 
marked hand weakness.  All patients tolerated the study well, and none of the patients 
stopped testing due to intolerance.  Sixty-eight patients were diagnosed as non-ALS (Table 
4.1, Fig. 4.1) and served as pathological controls.  The non-ALS cohort was significantly 
younger than the ALS patients, potentially representing a limitation of the current study.   
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 ALS 
(N=209) 
Non-ALS 
(N=68) 
Mean age at assessment 
(years) 
59.9 
(0.9) 
48.4 
(1.9) 
Male:Female  
 
125:84 45:23 
Mean disease duration 
(months) 
16.7 
(1.1) 
102 
(13.6) 
ALSFRS-R 41 
(38-44) 
 
Median Total MRC score 82  
(79-88) 
86.5 
(84-88) 
Median upper limb MRC 
score 
57  
(51-60) 
57 
(56-60) 
Median lower limb MRC 
score 
30  
(26-30) 
30 
(28-30) 
Upper motor neuron 
score 
12  
(10-13) 
0 
 
Table 4.1.  Demographic features in amyotrophic lateral sclerosis (ALS) and non-ALS 
neuromuscular mimic disorders.  The muscle strength, as measured by the Medical Research 
Council (MRC) score, was comparable between groups.  The amyotrophic lateral sclerosis 
functional rating score (ALSFRS-R) indicated a milder level of dysfunction in the ALS cohort.  
All data are expressed as mean (standard error of mean) or median (interquartile range). 
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Primary outcome measures 
Threshold tracking TMS reliably differentiated ALS from NALS disorders (Fig. 4.2).  
Receiver operating characteristic curve analysis was utilised to assess the diagnostic utility of 
threshold tracking TMS.  Importantly, reduction of averaged SICI [ISI 1-7 ms] appeared to be 
the most robust parameter at differentiating ALS from non-ALS with area under curve of 
0.80 (95% confidence interval [CI], 0.75-0.85, Table 4.2, Fig. 4.3), indicating a “very good” 
Eligible patients n=333
Reference standard 
(Awaji Criteria)
ALS n=153
NALS n=13
Threshold tracking transcranial magnetic stimulation (Index Test)
Hyperexcitable/Inexcitable  motor cortex
(test positive) n=167
Normal Motor Cortical excitability 
(test negative) n=114
Patient exclusions n=52
Pure UMN syndrome n=31, Other exclusions n=21
ALS n=56
NALS n=55
Reference standard 
(Awaji Criteria)
Inconclusive 
n=1
Inconclusive 
n=3
Patients meeting the study inclusion criteria n=281
(i)possible ALS (ii)pure motor disorders (iii)disorders mimicking ALS
 
Figure 4.1.  Flow diagram illustrating the study which was performed in accordance with the   
Standards for Reporting of Diagnostic Accuracy (STARD) criteria. Of the 56 ALS patients exhibiting 
a negative index test, defined as SICI > 5.5% and absence of motor cortex inexcitability, 45% were 
classified as Awaji possible or not meeting criteria, while 55% were classified as Awaji 
definite/probable ALS. The Awaji criterion was part of the inclusion criteria 
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diagnostic utility.  The remainder of the TMS parameters exhibited a lower diagnostic utility, 
as indicated by lower area under curve, and included reduced peak SICI at ISI 3 ms (0.78, 
0.72-0.84), reduced CSP duration (0.73, 0.64-0.79), increased ICF (0.62, 0.54-0.68), 
increased MEP amplitude (0.56, 0.50-0.65), reduced RMT (0.51, 0.50-0.58) and prolonged 
CMCT (0.50, 0.50-0.54).   
 
Consequently, a positive index test was defined as either a reduction of averaged SICI (< 
5.5% as previously reported (237)) or inexcitable motor cortex defined as RMT > 95% of 
maximal stimulator output (504)).  Utilising these diagnostic parameters, the threshold 
tracking TMS technique exhibited a sensitivity of 73.21% (95% CI: 66.66-79.08%), 
specificity of 80.88% (69.53-89.40), positive likelihood ratio of 3.83 (95% CI: 2.33-6.29) and 
negative likelihood ratio of 0. 33 (95%CI: 0.26-0.43).  In addition, the diagnostic odds ratio 
was 11.66 (95% CI: 5.87-22.76), while the number needed to test in order to diagnose one 
extra case of ALS, in a population composed of neuromuscular diseases, was 1.8 (1.5-2.8, 
Table 4.2).   
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Figure 4.2.  Short interval intracortical inhibition (SICI) was significantly reduced in 
amyotrophic lateral sclerosis (ALS) when compared to non-ALS mimic neuromuscular 
disorders (NALS).  (A, B)  Illustrative cases demonstrating differences in SICI between an ALS 
and a non-ALS patient.     (C, D)  Group data confirmed a significant reduction of averaged 
SICI, between interstimulus intervals (ISI) 1-7 ms. ***P < 0.001. 
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Figure 4.3.  Receiver operator characteristic curves for the threshold tracking transcranial 
magnetic stimulation parameters.  The area under the curve (AUC) was highest for averaged 
short interval intracortical inhibition (SICI) between interstimulus intervals (ISI) 1-7 ms.  In 
addition, the AUC was high for peak SICI at ISI 3 ms, followed by cortical silent period (CSP) 
duration.  The diagnostic utility for intracortical facilitation (ICF), motor evoked potential (MEP) 
amplitude and resting motor threshold (RMT) was inadequate.     
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Secondary outcome measures (Table 4.2) 
Subgroup analysis disclosed a comparable area under curve between definite/probable (0.79, 
95% CI 0.72-0.86) and possible/not meeting criteria (0.83, 95% CI 0.76-0.89) patients.  
Given the overlapping 95% CIs, the findings underscore a comparable diagnostic utility of 
the index test in ALS, including in the early stages of the disease process.  In addition, the 
sensitivity (ALSDEFINITE/PROBABLE 71.30% [61.79-89.40]; ALS POSSIBLE/not meeting criteria 73.47% 
[63.59-81.88%], P=0.75) and specificity (ALSDEFINITE/PROBABLE 80.88% [69.53-89.40%]; 
ALS POSSIBLE/ not meeting criteria 80.88% [69.53-89.40%]) of threshold tracking TMS was 
comparable between groups.  The mean time between TMS assessment and progression to an 
ALS diagnosis, as defined by Awaji “definite/probable” category, was 15.8±2.0 months.  An 
extra 34% of ALS patients could be diagnosed at initial assessment when utilising the 
threshold tracking TMS abnormalities compared solely to applying the Awaji criteria.  
Clinical Group Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
+LR 
(95% CI) 
-LR 
(95% CI) 
DOR 
(95%CI) 
NNT 
(95% CI) 
       ALS 
 
73.21 
(66.66- 79.08) 
80.88 
(69.53-89.40) 
3.83 
(2.33- 6.29) 
0.33 
(0.26- 0.43) 
11.66 
(5.87-22.76) 
1.8 
(1.5-2.8) 
 
ALS 
definite 
71.30 
(61.79-89.40) 
80.88 
(69.53-89.40) 
3.73 
(2.25-6.17) 
0.35 
(0.26-0.49) 
10.51 
(5.0-21.9) 
1.9 
(1.3-3.2) 
 
ALS 
Possible/NMC 
73.47 
(63.59-81.88) 
80.88 
(69.53-89.40) 
3.84 
(2.32-6.36) 
0.33 
(0.23-0.47) 
11.72 
(5.52-24.87) 
1.8 
(1.4-3.0) 
 
ALS 
Bulbar-onset 
68.25 
(55.31-79.41) 
80.88 
(69.53-89.40) 
3.57 
(2.13-5.99) 
0.39 
(0.27-0.57) 
9.10 
(4.10-20.33) 
2.0 
(1.5-4.0) 
 
ALS 
Limb-onset 
71.62 
(63.63-78.72) 
80.88 
(69.53-89.40) 
3.75 
(2.27-6.17) 
0.35 
(0.26-0.46) 
10.68 
(5.29-21.55) 
1.90 
(1.5-3.0) 
 
Table 4.2:  The diagnostic utility of threshold tracking transcranial magnetic stimulation (TMS) in 
amyotrophic lateral sclerosis (ALS).  Importantly, the diagnostic utility of threshold tracking TMS, as 
indicated by the sensitivity, specificity, positive likelihood ratios (+LR), negative likelihood ratios (-
LR), diagnostic odds ratios (DOR) and number needed to test in order to diagnose one extra case of 
ALS, was comparable between different subgroups, including patients not meeting the Awaji criteria 
(NMC).  The 95% confidence intervals (CI) are expressed in parenthesis.   
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Further, the sensitivity of the threshold tracking TMS technique was similar between ALS 
patients classified as “not meeting criteria” and the Awaji possible group (ALS not meeting criteria 
72.22% [58.35-83.54%]; ALS POSSIBLE 77.08% [62.68-87.95%], P=0.42).  There was no 
significant difference in sensitivity of threshold tracking TMS technique between patients 
with [UMN score≥3] (74.0%, 66.28-80.56%) and without (65.22%, 42.47-83.58%, P=0.38) 
UMN signs [UMN score<3].   
 
The diagnostic utility of the threshold tracking TMS technique was similar between bulbar 
and limb-onset ALS patients.  Specifically, the sensitivity (ALSBULBAR-ONSET 68.25% [55.31-
79.41%]; ALSLIMB-ONSET 71.62 % [63.63-78.72%], P = 0.76) and diagnostic odds ratio 
(ALSBULBAR-ONSET 9.10, 4.10-20.33; ALSLIMB-ONSET 10.68, 5.29-21.55) were comparable 
between groups.   
 
Riluzole therapy may increase SICI (224) and may limit the diagnostic utility of threshold 
tracking TMS.  In total, 64% of the ALS patients were receiving riluzole therapy at time of 
threshold tracking TMS.  The sensitivity was comparable between patients on riluzole 
(69.03% [59.64-77.39%]) and those yet to be commenced on riluzole (65.08% [52.03-
76.66%], P=0.54).   
 
Multiple regression analysis 
In order to determine whether the outcome variables, namely SICI reduction and motor 
cortex inexcitability, were influenced by independent variables including ALSFRS-R, MRC 
total score, UMN score, disease duration, site of disease onset, gender, and treatment status, a 
multiple regression analysis was utilised.  There was no significant correlation between 
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outcome variables and the independent factors, thereby arguing against any significant effects 
of the independent variables on the outcome parameters.  
 
Discussion 
Findings in the present prospective study, undertaken in accordance with the STARD criteria, 
establish diagnostic utility of the threshold tracking TMS technique in ALS.  Reduction of 
averaged SICI appeared to be the most robust diagnostic biomarker, and when combined with 
motor cortex inexcitability, exhibited high sensitivity and specificity with the number needed 
to test with TMS in order to diagnose one extra case of ALS being only 1.8.  Importantly, the 
diagnostic utility of threshold tracking TMS was comparable between Awaji diagnostic 
categories and was similar in bulbar and limb onset patients, but was not influenced by 
riluzole therapy.  Taken together, the present study underscores the importance of the 
threshold tracking TMS technique as a diagnostic aid in ALS, providing an objective 
biomarker of UMN dysfunction and potentially leading to an earlier diagnosis of ALS, by an 
average of 15.8 months, when combined with clinical and conventional neurophysiological 
measurements.  
 
Diagnosis of ALS 
In the absence of a pathognomonic test, the diagnosis of ALS remains reliant on identifying a 
combination of upper and lower motor neuron dysfunction (47, 498).  Given the diagnostic 
limitations of the clinical criteria, neurophysiologically based Awaji criteria were developed 
in order to increase the diagnostic sensitivity for ALS (6).   Although a number of studies 
have reported increased sensitivity of the Awaji criteria, when compared to the revised El 
Escorial criteria (52, 53, 55, 56, 58), others have failed to detect any significant differences 
(54, 502) and one study reported a decreased sensitivity as UMN signs could not be elicited 
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(60).  These discordant findings may relate to difficulties in detecting UMN signs, which 
remain clinically based in the Awaji criteria.  Identification of UMN signs in ALS may be 
limited by complex physiological factors, including the extent of muscle wasting along with 
dysfunction of descending motor pathways and local spinal circuits that underlie 
development of UMN signs (38).  Separately, secondary adaptive changes within the 
neuromuscular system may further complicate assessment. 
 
Consequently, direct assessment of UMN function by TMS techniques could potentially 
overcome the limitations imparted by the disease process leading to an objective diagnostic 
biomarker of UMN dysfunction.  In the present study, the threshold tracking TMS technique 
reliably differentiated ALS from mimic disorders at an early stage in the disease process.  
Importantly, TMS abnormalities were evident in ~ 70% of ALS patients categorised as Awaji 
possible or “not meeting criteria”.  Reduction of SICI, a biomarker of motor cortical 
inhibitory function first reported by Kujirai and colleagues (378), appeared to be the most 
robust diagnostic parameter supporting previous studies (237, 504).  The present study design 
supports a wider applicability of the current findings and potentially avoids bias, 
underscoring the diagnostic utility of threshold tracking TMS in ALS.   
 
It should be acknowledged that the threshold tracking TMS remains a specialised technique 
requiring specific technology (special hardware and customised software termed QTRACS), 
expertise and training.  Consequently, while the tolerability of the index test remains good, 
the practicability of widespread application of the test are limited, and as such there remains 
uncertainty about the diagnostic reliability of threshold tracking TMS when performed in less 
experienced centers or those using different methodology, such as the constant stimulus TMS 
technique.  Of further relevance, while the intra-rater variability was established (329), inter-
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rater variability remains to be determined.  In addition, it could also be argued that subtle 
differences between cohort characteristics could influence the results.  This seems unlikely 
given that the outcome variables were not influenced by any of the demographic, functional 
and treatment factors in a multiple regression analysis. 
 
The Awaji criteria appears to be less sensitive in patients with limb-onset disease when 
compared to bulbar-onset disease  (30), potentially leading to  diagnostic delays, as recently 
reported (506).  Importantly, the present study provides evidence for diagnostic utility of the 
threshold tracking TMS technique irrespective of site of disease onset.  A potential limitation 
may occur in ALS patients with severe hand wasting, which may preclude TMS testing as 
evident in 6.3% of the current cohort.  Assessment of cortical excitability from lower limb 
muscles, or less affected intrinsic hand muscles, may increase the diagnostic yield of 
threshold tracking TMS.   
 
A major challenge in ALS management remains a delay in definite diagnosis (47).  Riluzole 
has been established as the only effective neuroprotective therapy for ALS, prolonging 
patient survival by 3-6 months (220).  Importantly, riluzole appears to be less effective in 
advanced stages of the disease (520), underscoring the need for an earlier diagnosis.  Reliance 
on inclusion criteria that are based on identifying UMN and LMN dysfunction in multiple 
body regions utilizing clinical and conventional neurophysiological approaches (6, 498) may 
result in low recruitment rates into therapeutic trials, especially in the early stages of the 
disease process where neuroprotective therapies may be most effective (247).  Consequently, 
addition of the threshold tracking TMS technique to the diagnostic algorithm may lead to an 
earlier diagnosis, thereby enhancing recruitment of ALS patients into therapeutic trials when 
combined with clinical and conventional methodologies.  
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Chapter 5 
 
CORTICAL FUNCTION IN 
ASYMPTOMATIC CARRIERS AND 
PATIENTS WITH C9ORF72 ALS 
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Summary 
Having established in Chapters 3 and 4 that cortical hyperexcitability was an early and useful 
biomarker of upper motor neuron (UMN) dysfunction, we aimed to explore the 
pathophysiological processes underlying the most common genetic form of ALS, the c9orf72 
gene expansion.  The pathophysiological mechanism, by which the c9orf72 gene expansion 
leads to neurodegeneration remains to be elucidated.  Cortical hyperexcitability is potentially 
an important pathophysiological process in sporadic and familial ALS (FALS).  To 
investigate whether cortical hyperexcitability formed the pathophysiological basis of c9orf72 
FALS, we utilized the threshold tracking TMS in a prospective single-centre study at a large 
neuromuscular centre. Clinical and functional assessment, along with TMS studies were 
undertaken on 15 c9orf72 FALS patients and 11 asymptomatic c9orf72 expansion carriers 
who were longitudinally followed for up to 3 years.  The results were compared to 73 
sporadic ALS patients and 74 healthy controls.  Cortical excitability variables, including short 
interval intracortical inhibition, were measured in c9orf72 FALS patients and results 
compared to asymptomatic c9orf72 carriers, sporadic ALS patients and healthy controls. 
Short-interval intracortical inhibition (SICI) was significantly reduced in c9orf72 FALS (1.2 
± 1.8%) and sporadic ALS patients (1.6 ± 1.2%) compared to asymptomatic c9orf72 
expansion carriers (10.2 ± 1.8%, F=16.1, P < 0.0001) and healthy controls (11.8 ± 1.0%, 
F=16.1, P < 0.0001).  The reduction of SICI was accompanied by an increase in intracortical 
facilitation (P < 0.01) and motor evoked potential amplitude (P < 0.05) as well as reduction in 
resting motor threshold (P < 0.05) and cortical silent period duration (P < 0.0001). This study 
establishes cortical hyperexcitability as an intrinsic feature of symptomatic C9orf72 
expansion-related ALS, but not in asymptomatic expansion carriers.  
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Introduction  
Identification of increased hexanucleotide repeat expansion (GGGGCC) in the c9orf72 gene 
(97, 98), which appears to underlie over 40% of familial and 8% of “sporadic” ALS cases 
(97, 98, 100) has radically altered the understanding of ALS pathogenesis, broadening the 
clinical heterogeneity of ALS. The c9orf72 hexanucleotide expansion underlies both ALS 
and frontotemporal dementia [FTD] (97, 98), while subtle cognitive abnormalities may be 
evident in up to 50% of ALS patients and FTD may develop in 15% of ALS patients (521).   
 
The precise pathophysiological mechanisms by which c9orf72 gene expansion mediates 
neurodegeneration in ALS has not been established (97, 98), although a number of 
pathogenic mechanisms have been proposed, including haploinsufficiency (97, 98, 112), 
RNA-mediated toxicity (113, 522) and dipeptide repeat protein toxicity related to non-ATG 
(RAN) translation of the expanded c9orf72 gene (111, 115).  Motor neuronal 
hyperexcitability was suggested as a potential pathophysiological mechanism in c9orf72 
ALS, a process mediated by inactivation of K+ channels (523).  Importantly, blockade of 
neuronal hyperexcitability by retigabine, a K+ channel activator, exerted neuroprotective 
benefits, identifying a putative therapeutic target in ALS (523).   
 
In ALS patients, motor neuronal hyperexcitability may be assessed by transcranial magnetic 
stimulation (TMS) techniques (39).  Previous TMS studies in sporadic and familial ALS 
patients, linked to mutations in the superoxide dismuates-1 (SOD-1) gene, have established 
cortical hyperexcitability as an early feature in ALS and linked to the process of 
neurodegeneration, while the level of cortical excitability was normal in asymptomatic SOD-
1 mutation carriers (183, 185, 237, 238).  These studies highlighted the pathogenic 
importance of cortical hyperexcitability in ALS, and suggested that the onset of ALS was 
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potentially triggered by one or more factors acting in concert with genetic mutations.  
Consequently, the present study utilized threshold tracking TMS techniques to assess cortical 
function in asymptomatic c9orf72 expansion carriers, with results compared to c9orf72 FALS 
and sporadic ALS patients, in order to clarify the underlying pathophysiological mechanisms 
in this form of familial ALS. 
 
Methods 
Patients 
Subjects were recruited from the ALS genetic database and from the multidisciplinary ALS 
clinics.  Studies were undertaken on 15 familial ALS patients (7 females and 8 males, mean 
age 60 years, age range 41-78 years), with confirmed c9orf72 hexanucleotide expansion, 
defined as possible or probable/definite ALS according to the Awaji criteria (6).  In addition, 
studies were also undertaken on 11 asymptomatic c9orf72 mutation carriers (10 females and 
1 male, mean age 49 years, age range 26-78 years), that were followed for up to 3 years.  
Seventy-three sporadic ALS patients were also assessed (45 males and 28 females, age range 
28-86, mean age 60). 
 
The ALS patients were clinically reviewed on a regular basis through the multidisciplinary 
ALS clinics.  All patients were clinically staged using the Amyotrophic Lateral Sclerosis 
Functional Rating Scale-Revised (ALSFRS-R) (495) and categorised according to site of 
disease onset as limb or bulbar-onset ALS.  In addition, the disease duration (months) at the 
time of testing was recorded and muscle strength was assessed using the Medical Research 
Council (MRC) rating scale, with the following muscle groups assessed bilaterally yielding a 
total MRC score of 90:  shoulder abduction; elbow flexion; elbow extension; wrist 
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dorsiflexion; finger abduction; thumb abduction; hip flexion; knee extension; ankle 
dorsiflexion.   
  
The degree of upper motor neuron (UMN) dysfunction was assessed by a specific UMN 
score (497).  None of the patients with ALS were receiving medications, which could 
potentially interfere with the neurophysiological results.  Informed consent to the procedures 
was provided by all patients, with the study approved by the Sydney West Area Health 
Service and Human Research Ethics Committees.  
 
Neurophysiological studies 
Cortical excitability was assessed by utilizing a threshold tracking TMS technique according 
to a previously reported method (329).  The MEP response was recorded over the abductor 
pollicis brevis (APB) muscle. The following parameters were recorded in all participants: (i) 
Short interval intracortical inhibition (%), between interstimulus interval (ISI) 1-7 ms; (ii) 
intracortical facilitation (ISI 10-30 ms);  (iii) resting motor threshold (RMT, %); (iv) Motor 
evoked potential (MEP) amplitude (%); (v) cortical silent period (CSP) duration (ms); and 
(vi) central motor conduction time (CMCT, ms). 
 
In the same sitting nerve conduction studies and needle electromyography was undertaken on 
all participants. The compound muscle action potential (CMAP) was recorded from the APB 
muscle and the CMAP onset latency and peak-peak amplitude were measured. Subsequently, 
the neurophysiological index (NI) was derived according to a previously reported formula 
(26). 
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Recordings of the compound muscle action potential (CMAP) and MEP responses were 
amplified and filtered (3 Hz-3 kHz) using a Niolet-Biomedical EA-2 amplifier (Cardinal 
Health Viking Select version 11.1.0, Viasys Healthcare Neurocare Group, Madison, 
Wisconsin, USA) and sampled at 10 kHz using a 16-bit data acquisition card (National 
Instruments PCI-MIO-16E-4).  Data acquisition and stimulation delivery were controlled by 
QTRACS software.  Temperature was monitored with a purpose built thermometer at the 
stimulation site.  
 
Statistical analysis 
Cortical excitability was compared to 74 healthy controls (37 males, 37 females, mean age 
53.1 years, age range 23-83 years).  Data were assessed for normality using the Shapiro-Wilk 
test. Student’s t-test and Wilcoxon-Signed rank test were used to assess differences between 
means. Analysis of variance (ANOVA) with post-Hoc testing using a Bonferroni correction 
(parametric data), or Kruskal-Wallis test (non-parametric data) were used for multiple 
comparisons. A P value < 0.05 was considered statistically significant.  A potential caveat in 
this study relates to the fact that healthy controls were significantly younger than c9orf72 
expansion-related and sporadic ALS patients.  Pearson’s or Spearmen’s correlations were 
used to assess the relationship between parameters. Results are expressed as mean ± standard 
deviation (SD) or median with interquartile range (IQR). 
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Results 
Clinical features 
The clinical phenotype and level of functional impairment was similar between the 15 
clinically affected FALS patients and sporadic ALS patients (Table 5.1).  Specifically, the 
mean ALSFRS-R score in c9orf72 FALS patients was 39.4 ± 10.1, indicating a moderate 
degree of impairment, and was comparable to sporadic ALS patients (41.2 ± 5.4, P = 0.25).   
In addition, the mean MRC total score in the c9orf72 FALS patients was 82.6 ± 7.1, re-
affirming a moderate degree of functional impairment, and was comparable to the MRC total 
score in sporadic ALS patients (80.7± 11.5, P=0.09).  The median UMN score was similar in 
the c9orf72 FALS (14, 10-14, SD 6) and sporadic ALS patients (12, 10-14, SD 5, P =0.32) 
signifying presence of upper motor neuron signs in both cohorts. 
 
At the time of TMS testing, the median disease duration in the FALS patients was 8 months 
(5-12 months, SD 12.6 months) and was comparable to sporadic ALS patients (10.5, 6-18 
months, SD 18.1 months).  Forty percent of the FALS patients exhibited bulbar-onset disease, 
while 60% reported limb-onset disease, which was identical to that evident in the sporadic 
ALS patients. All of the patients were receiving riluzole at time of assessment. 
 
In contrast, the physical examination in all the asymptomatic c9orf72 hexanucleotide 
expansion carriers, including the pre-symptomatic carrier, was normal.  Specifically, there 
were no upper motor neuron features, such as increased muscle tone, hyper-reflexia, extensor 
plantar responses, positive Hoffman sign or the presence of a jaw-jerk in any of the subjects 
at the time of testing.   
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Symptomatic 
c9orf72 
expansion 
carrier 
Age 
(years)/Sex 
ALS 
onset 
Disease 
duration 
(months) 
ALS-FRS UMN 
score 
MRC 
sum 
score 
1 78F Limb 3 44 14 70 
2 41M Bulbar 14 45 15 81 
3 64F Bulbar 10 44 0 90 
4 73F Limb 6 42 12 83 
5 45M Limb 6 48 14 90 
6 66F Limb 38 13 12 83 
7 58M Bulbar 10 36 14 75 
8 70M Limb 12 42 0 87 
9 75M Limb 36 34 14 86 
10 50M Bulbar 4 46 4 90 
11 68M Limb 8 42 12 74 
12 44F Limb 7 39 14 81 
13 56F Limb 4 44 14 83 
14 72F Bulbar 24 30 8 85 
15 44M Limb 7 47 14 88 
Mean  60.3  12.4 39.5 10.7 83.2 
SEM 3.3  2.9 2.2 1.3 1.6 
Sporadic ALS 
Patients  
      
Mean  60.1  15.0 41 10 80 
SEM 1.5  2.4 0.6 0.6 1.4  
Asymptomatic 
c9orf72 
expansion 
carrier  
      
Mean  49.5   48 0 90 
SEM 5.0      
Controls        
Mean  53.1   48 0 90 
SEM 1.3      
 
Table 5.1: Clinical details for the clinically affected c9orf72 FALS cohort with mean data 
for asymptomatic carriers, sporadic ALS cohort and healthy controls. The patients were 
clinically assessed using the amyotrophic lateral sclerosis functional rating scale revised 
(ALSFRS-R), with a maximum score of 48 when there is no disability. Muscle strength was 
clinically assessed using the Medical Research Council (MRC) sum score (upper limbs and 
lower limbs).  Upper motor neuron (UMN) score was utilised to assess the degree of clinical 
UMN dysfunction, with a possible maximum score of 16.  Disease duration refers to the 
period from symptom onset to date of TMS testing.   
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Neurophysiological studies 
Prior to undertaking cortical excitability studies the peripheral disease burden was assessed.  
The CMAP amplitude (FALS 6.3 ± 2.3 mV; SALS 7.0 ± 4.0 mV; controls 9.9 ± 4.3 mV, 
F=6.6, P<0.0001) and neurophysiological index (FALS 1.5 ± 1.2; SALS 1.2 ± 0.9; controls 
2.3 ± 0.9, F=10.3, P<0.0001) were significantly reduced in FALS and sporadic ALS patients 
when compared to controls.  In contrast, there was no significant difference in the CMAP 
amplitude and NI between asymptomatic c9orf72 hexanucleotide expansion carriers and 
controls (CMAP asymptomatic carriers 9.2 ± 3.3 mV; CMAP controls 9.9 ± 4.3 mV, P=0.33; NI 
asymptomatic carriers 1.8 ± 1.3; NI controls 2.3 ±0.9, P=0.20). 
 
Cortical excitability 
Short-interval intracortical inhibition, as reflected by an increase in the conditioned stimulus 
intensity required to track a constant target MEP of 0.2 mV, was significantly reduced in 
FALS and sporadic ALS patients (Fig. 5.1A).  Averaged SICI, between ISIs 1 to 7 ms, was 
significantly reduced in FALS and ALS patients when compared to controls (FALS 1.2 ± 7.0 
%; SALS 1.6 ± 10.3 %; controls 11.8 ± 8.6 %, F=16.1, P<0.0001, Fig. 5.1B), as was SICI at 
ISI 1ms (FALS 0.3 ± 7.0 %; SALS 1.7 ± 6.8 %; controls 6.8 ± 10.3 %, F=4.9, P<0.005, Fig. 
5.2A) and ISI 3 ms (FALS 4.1 ± 9.3 %; SALS 3.5 ± 13.7 %; controls 17.2 ± 12.9 %, F=18.1, 
P<0.0001, Fig. 5.2B).  In contrast, there was no significant difference in the averaged SICI 
(asymptomatic carriers 10.2 ± 6.0 %; controls 11.8 ± 8.6 %, P=0.2, Fig. 5.1B), SICI at ISI 
1ms (asymptomatic carriers 5.6 ± 6.6 %; controls 6.8 ± 10.3 %, P=0.2, Fig. 5.2A), and ISI 
3ms (asymptomatic carriers 15.5 ± 9.6 %; controls 17.2 ± 12.9 %, P=0.1, Fig. 5.2B) between 
asymptomatic c9orf72 carriers and controls.   
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Following SICI, a period of intracortical facilitation (ICF) develops between ISI of 10-30 ms.  
Intracortical facilitation was increased in FALS and sporadic ALS patients (FALS -3.2 ± 4.3 
%; SALS -4.1 ± 6.0 %, F=3.3, P < 0.05) when compared to controls (-1.4 ± 6.9 %).  In 
contrast, ICF was comparable between the asymptomatic expansion carriers (-1.2 ± 2.0 %, 
P=0.40) and controls.  
 
Single pulse TMS disclosed a significant increase in the MEP amplitude, expressed as a 
percentage of CMAP response, in both the FALS and sporadic ALS patients when compared 
to controls (FALS 45.2 ± 25.5 %; SALS 32.2 ± 23.1 %; controls 23.4 ± 13.8 %, Fig. 5.3A, 
F=3.5, P < 0.01). In contrast, the MEP amplitude in asymptomatic expansion carriers was 
similar to controls (asymptomatic expansion carriers 24.4 ± 12.9 %, controls 23.4 ± 13.8 %, 
P=0.42).  In addition, the CSP duration was significantly reduced in FALS and sporadic ALS 
patients (FALS 186.1 ± 40.7 ms; SALS 173.8 ± 41.9 ms; controls 214.1 ± 33.6 ms, F=10.8, 
P<0.0001, Fig. 5.3B), but not in the asymptomatic expansion carriers (211.4 ± 44.1 ms, 
P=0.40).   
 
Of further relevance, the RMT was significantly reduced in the c9orf72 FALS patients (52.2 
± 8.1%) when compared to sporadic ALS, asymptomatic carriers and control cohorts (SALS 
57.2 ± 11.1%; asymptomatic carriers 58.5 ± 16.6 %; controls 60.3 ± 12.0%, F=3.4, P<0.05).  
In addition, the CMCT was significantly increased in FALS and sporadic ALS patients 
(FALS 5.9 ± 1.9 ms; SALS 6.6 ± 1.7 ms; controls 5.5 ± 2.6 ms, F=4.4, P<0.01, Fig. 5.3D). In 
contrast, the CMCT was not significantly increased in asymptomatic carriers (asymptomatic 
carriers 5.2 ± 2.0 ms; controls 5.5 ± 2.6 ms, P=0.3). 
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Figure 5.1.  Averaged SICI is reduced in c9orf72 FALS 
(A) Short-interval intracortical inhibition (SICI) was significantly reduced in c9orf72 familial 
amyotrophic lateral sclerosis (FALS) patients when compared to asymptomatic c9orf72 expansion 
carriers and controls. The reduction of SICI was comparable to that evident in in sporadic ALS 
patients (SALS) patients. (B) Averaged SICI, between interstimulus intervals (ISI) 1-7ms, was 
significantly reduced in FALS and SALS patients. ****P<0.0001. 
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Figure 5.2. The peak components of SICI are reduced in c9orf72 FALS 
(A) Peak short interval intracortical inhibition (SICI) at interstimulus interval (ISI) 1 ms and (B) 
3 ms was significantly reduced in the familial amyotrophic lateral sclerosis (FALS) and sporadic 
ALS (SALS) patients compared to asymptomatic c9orf72 expansion carriers and controls. 
***P<0.001, ****P<0.0001. 
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Correlation studies 
Combining, clinical, peripheral neurophysiological and cortical excitability findings, it was 
evident that in the c9orf72 familial ALS cohort the averaged SICI (ISI 1-7 ms) significantly 
correlated with the CMAP amplitude (R= -0.55, P < 0.05), MRC upper limb score (Rho=-
0.80, P < 0.01) and the MRC APB score (Rho = -0.46, P < 0.05).  In addition, intracortical 
facilitation significantly correlated with the CMAP amplitude (R = -0.67, P < 0.05) as did the 
Figure 5.3. Cortical hyperexcitability is a feature of c9orf72 FALS  
(A)  Intracortical facilitation (ICF) follows was significantly increased in familial amyotrophic lateral 
sclerosis (FALS) and sporadic ALS (SALS) patients.  (B) Motor evoked potential (MEP) was 
significantly increased in FALS and SALS patients when compared to asymptomatic c9orf72 
expansion carriers and controls. (C)  The cortical silent period (CSP) duration was significantly 
reduced in FALS and SALS patients when compared to asymptomatic c9orf72 expansion carriers and 
controls. (D) Central motor conduction time (CMCT) was significantly increased in FALS and SALS 
patients.*P< 0.05, **P<0.01, ***P< 0.001, ****P<0.0001. All P-values were corrected for multiple 
comparisons using post-Hoc Bonferroni testing. 
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cortical silent period duration (R= -0.59, P < 0.05) and the resting motor threshold (R=0.53, P 
< 0.05).  Taken together, these findings suggest the features of cortical hyperexcitability was 
most prominent when muscle strength and motor amplitudes were relatively preserved.      
 
Discussion 
The findings in the present study have confirmed cortical hyperexcitability as an intrinsic 
feature of c9orf72 expansion related ALS as well as apparently sporadic FALS.  Cortical 
hyperexcitability was associated by a marked reduction of short-interval intracortical 
inhibition and cortical silent period duration, combined with an increase in MEP amplitude 
and intracortical facilitation.  In contrast, cortical excitability was normal in the asymptomatic 
c9orf72 expansion carriers, and was significantly different when compared to familial and 
sporadic ALS cohorts.   The potential mechanisms underlying these findings and their 
pathophysiological implications for ALS are further discussed.   
 
Cortical hyperexcitability and ALS pathogenesis 
The pathophysiological mechanisms underlying the development of motor neuron 
degeneration in ALS appears to be multifactorial, with a complex interaction between genetic 
factors and dysfunction of vital molecular pathways (47).  Identification of the dominantly 
inherited c9orf72 gene as an important genetic aetiology of ALS (97, 98), has altered the 
understanding of ALS pathogenesis, building on the concept of ALS as a multisystem 
neurodegenerative disorder (524) and emphasising the importance of cortical mechanisms in 
ALS pathophysiology.  This notion was further underscored by neuropathological studies 
demonstrating cortical intraneuronal inclusions that were evident in both c9orf72 associated 
ALS and frontotemporal dementia [FTD] (101).   
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Cortical hyperexcitability was a feature of c9orf72 FALS in the present study, being 
comparable to findings in the sporadic ALS cohort and evidenced by marked reduction of 
short interval intracortical inhibition.  Short interval intracortical inhibition is mediated by 
activation of cortical inhibitory circuits, acting via GABAA receptors, as well as 
glutaminergic neurotransmission (39, 224, 379). Consequently, the reduction of SICI could 
have been mediated by degeneration and dysfunction of inhibitory cortical interneurons (406, 
525), as well as glutamate mediated excitoxicity.  A significant reduction in the CSP duration 
and resting motor thresholds, along with an increase in the MEP amplitude, further support 
the presence of cortical hyperexcitability in the c9orf72 ALS patients.   
  
The findings of cortical hyperexcitability in the present c9orf72 FALS cohort was similar to 
previous studies in familial ALS patients attributed to different genetic mutations (185, 405).  
As such, cortical hyperexcitability appears to represent a uniform pathophysiological process 
in ALS, irrespective of the underlying genetic status.  Of relevance, recent mathematical 
modeling has inferred a six-step process in ALS (154), with a prolonged prodromal period, 
perhaps extending to the perinatal period (155).  Cortical hyperexcitability could represent 
one of the final steps in ALS pathogenesis, perhaps developing just prior to, or at onset of 
neuronal degeneration, a notion supported by findings of significant correlations between 
features of cortical hyperexcitability and motor amplitude and muscle strength.  Recent 
animal studies lend credence to this assumption, identifying neuronal hyperexcitability at a 
pre-clinical stage, upstream of the spinal motor neuron (158, 526). 
 
Further supporting a multistep process in ALS, is the finding of normal cortical excitability in 
the asymptomatic c9orf72 expansion carriers, similar to findings in SOD-1 mutation carriers 
(185).  Consequently, the development of neuronal hyperexcitability in familial ALS appears 
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to be dependent on additional factors other than the inheritance of genetic mutations.  
Identifying and modulating these “triggering” factors could be therapeutically significant for 
ALS.  In addition, the findings of normal cortical excitability in the asymptomatic familial 
ALS cohorts would argue against therapeutic benefits of prophylactic riluzole.  
 
It could be argued that cortical hyperexcitability was an adaptive process in response to 
peripheral neurodegeneration, and could serve as a neuroprotective strategy.  Underscoring 
this notion are recent animal studies suggesting that an increase in neuronal excitability may 
be neuroprotective (223).  While this notion could not be absolutely discounted in ALS 
patients, it seems unlikely given that riluzole, an anti-glutaminergic agent that prolongs 
survival (217, 220), reduces cortical hyperexcitability (224).  Of further relevance, reduction 
of neuronal hyperexcitability by pharmacological agents such as retigabine appear to be 
neuroprotective (523), while normalizing astrocyte function by “knocking-down” the 
expression of mutated genes, and thereby normalizing glutamate homeostasis, appear 
neuroprotective (304).  In addition, features of cortical hyperexcitability were not evident in 
non-ALS neuromuscular cohorts despite a comparable degree of peripheral 
neurodegeneration (237, 238, 357), further arguing against the notion that cortical 
hyperexcitability represents a simple compensatory mechanism. Rather, cortical 
hyperexcitability may serve as a final common pathway in ALS, mediating neuronal 
degeneration via a trans-synaptic glutamate process, and the identification and modulation of 
factors that trigger cortical hyperexcitability may prove therapeutically useful.   
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Chapter 6 
 
AXONAL ION CHANNEL DYSFUNCTION 
IN C9ORF72 FAMILIAL AMYOTROPHIC 
LATERAL SCLEROSIS   
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Summary 
Having established that cortical hyperexcitability played a pivotal role in familial ALS 
(FALS) in the previous chapter, the next study evaluated the role of the peripheral nervous 
system in FALS.  Specifically, in sporadic amyotrophic lateral sclerosis (SALS) phenotypes 
there has been documentation of peripheral nerve axonal excitability abnormalities, 
characterised by upregulation of persistent Na+ conductances and reduced K+ current, linked 
to the development of clinical features such as fasciculations as well as neurodegeneration.  
We wanted to investigate whether abnormalities of axonal ion channel function, particularly 
upregulation of persistent Na+ conductances and reduced K+ currents, form the 
pathophysiological basis of c9orf72 FALS.  Subsequently a prospective single-centre study at 
a large neuromuscular centre was undertaken.  Clinical and functional assessment, along with 
motor nerve excitability studies were undertaken in 10 clinically affected c9orf72 FALS 
patients, 9 asymptomatic c9orf72 mutation carriers and 21 sporadic ALS (SALS) patients.   
Axonal excitability variables were measured in c9orf72 ALS patients and results compared to 
matched SALS patients and healthy controls.  Strength-duration time constant (τSD) was 
significantly increased in the c9orf72 FALS and SALS patients (c9orf72 0.50±0.02 ms; 
SALS 0.52±0.02 ms, P < 0.01) when compared to controls (0.44 ± 0.01).  In contrast, there 
were no significant changes of τSD in asymptomatic c9orf72 mutation carriers (P=0.42).  An 
accompanying increase in depolarising threshold electrotonus at 90-100 ms (TEd90-100 ms) 
was also evident in the c9orf72 FALS (P<0.05) and SALS cohorts (P < 0.01).   Mathematical 
modelling suggested that an increase in persistent Na+ conductances along with reduced K+ 
currents, best explained the changes in axonal excitability. Importantly, these abnormalities in 
axonal excitability correlated with the motor amplitude (τSD, R= -0.38, P<0.05; TEd 90-100 
ms, R = -0.44, P<0.01), muscle weakness (TEd 90-100 ms, R = -0.32, P < 0.05) and the ALS 
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functional rating scale (TEd 90-100 ms, R= -0.34, P<0.05).   Findings from the present study 
establish that upregulation of persistent Na+ conductances and reduced K+ currents were 
evident in both c9orf72 FALS and SALS cohorts, and these changes in axonal excitability 
were associated with motor neuron degeneration.  
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and universally fatal 
neurodegenerative disorder of the motor neurons (48).  A genetic etiology has been identified 
in up to 60% of familial and 20% of apparently sporadic ALS cohorts, with at least 21 genes 
and genetic loci implicated in ALS pathogenesis (90).  Recently, an increased hexanucleotide 
repeat expansion (GGGGCC) in the first intron of the c9orf72 gene on chromosome 9p21 
was reported to be the most common of the genetic mutations in ALS, underling 
approximately 40% of familial and 20% of sporadic ALS cases (97, 98), although subsequent 
studies have established a c9orf72 mutation frequency of 4-8% (100).   
 
The c9orf72 phenotype may be characterised by ALS and frontotemporal dementia with 
psychiatric features, although the penetrance and expression of the genotype may vary within 
and between cohorts (97, 98, 105, 527).  The c9orf72 associated ALS phenotype is clinically 
characterised by co-existence of upper (UMN) and lower motor neuron (LMN) signs 
encompassing multiple body regions, with an earlier age of onset and shorter survival (103).   
Importantly, LMN signs are characterized by fasciculations, muscle wasting and weakness, 
clinically indistinguishable from the LMN features in sporadic ALS cohorts.   
 
The pathophysiological mechanisms by which c9orf72 gene hexanucleotide expansion leads 
to development of neurodegeneration and thereby the clinical features of ALS, particularly 
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fasciculations, remains to be established (97, 98).  Widespread axonal ion channel 
dysfunction, including upregulation of persistent Na+ conductances and reduction of slow and 
fast K+ channel conductances, has been extensively documented in sporadic ALS, resulting in 
motor axonal hyperexcitability (33-35, 413, 528-533).  Importantly, such changes in motor 
axonal excitability were postulated to underlie motor neuron degeneration and the 
development of clinical features of ALS, particularly fasciculations (33-35, 413, 438, 528-
531).  In addition, motor axonal hyperexcitability, as reflected by upregulation of persistent 
Na+ conductances, was also reported in familial ALS cohorts secondary to mutations in the 
superoxide dismuate-1 (SOD-1) gene and linked to the process of neurodegeneration.   
 
Threshold tracking techniques may provide unique insights into nodal and internodal axonal 
membrane properties by sequentially assessing multiple excitability parameters (444, 446, 
456).  The strength-duration time constant (τSD), a measure of the rate at which the threshold 
current for a target potential declines as stimulus duration increases (34, 419, 423, 534-536), 
appears to be a biomarker of persistent Na+ conductances (409).  This notion is underscored 
by computer modelling studies of the human motor axon establishing that the τSD reflects the 
behaviour of persistent Na+ conductances (423).  In addition, depolarising and 
hyperpolarising threshold electrotonus, along with superexcitability and late subexcitability, 
appear to be robust biomarkers of fast and slow K+ conductances respectively (409).  
Consequently, the present study utilised axonal excitability techniques in an attempt to 
determine whether upregulation of persistent Na+ conductances and reduction of K+ currents 
was a feature of c9orf72 FALS, and whether such changes in axonal excitability were linked 
to the processes of neurodegeneration, potentially informing the pathophysiological basis of 
c9orf72 FALS.  In addition, the present study also aimed to determine whether axonal ion 
channel dysfunction was evident in asymptomatic c9orf72 mutation carriers.  
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Methods 
Studies were undertaken on 10 clinically affected familial c9orf72 ALS patients as defined by 
the Awaji criteria (6 males, 4 females, mean age 63 years age range 41-78 years) and 9 
asymptomatic c9orf72 mutation carriers (1 male, 8 females, mean age 45 years, age range 24-
60 years).  For comparison, 21 sporadic ALS patients were studied (16 males, 5 females, 
mean age 55 years age range 32-73).  All ALS patients (sporadic and familial) were clinically 
staged using the ALS-functional Rating Scale-Revised (ALSFRS-R) (537).  In addition, 
muscle strength was assessed by utilising the Medical Research Council (MRC) score with 
the following muscle groups assessed bilaterally yielding a total MRC score of 90:  shoulder 
abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger abduction; thumb 
abduction; hip flexion; knee extension; ankle dorsiflexion (532, 538) .  The degree of upper 
motor neuron (UMN) dysfunction was assessed by a specific UMN score incorporating the 
following parameters: brisk jaw jerks (1 point), brisk facial reflex (1 point), pathologically 
brisk biceps, triceps, supinator, finger, knee and ankle reflexes (1 point for each, assessed 
bilaterally) and extensor plantar responses (1 point each and assessed bilaterally).  The UMN 
score ranged from 0 [no UMN dysfunction] to 16 [severe UMN dysfunction] (497). 
Cognitive screening was undertaken only in the c9orf72 FALS patients and asymptomatic 
mutation carriers utilising the Addenbrooke's Cognitive Examination - Revised (ACE-R) 
(539). Patients and carriers suffering with diabetes mellitus or chronic renal failure were 
excluded from the study.  None of the subjects were taking medications that could affect the 
results.  All subjects gave informed consent to the procedures, which were approved by the 
South East Sydney Area Health Service Human Research Ethics Committee.   
 
Following clinical staging and phenotyping, the median nerve was stimulated at the wrist and 
the resultant CMAP recorded from the abductor pollicis brevis (APB) using surface 
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electrodes. The active recording electrode was placed over the motor point of APB and the 
reference was placed 4 cm distally, at the base of the thumb.  Skin temperature was 
monitored close to the site of stimulation for the duration of each study.  Prior to excitability 
studies, CMAP amplitude and onset latency, F-wave latency and frequency were all 
measured.  The neurophysiological index (NI), a marker of peripheral disease burden in ALS, 
was derived according to a previously reported formula (540):   
         
Axonal excitability 
All ALS patients underwent axonal excitability studies on the median motor nerve according 
to a previously described protocol (444).  The median nerve was stimulated at the wrist using 
5 mm non-polarizable Ag-AgCl electrodes (ConMed, Utica, USA) with the cathode 
positioned over the skin crease and anode ~ 10 cm proximally over the lateral forearm.  
Stimulation was computer controlled and converted to current using an isolated linear bipolar 
constant current simulator (maximal output ± 50 mA; DS5, Digitimer, Welwyn Garden City, 
UK).  The CMAP responses were recorded from the APB muscle with the active (G1) 
electrode positioned over the motor point and the reference (G2) electrode placed at the 
proximal phalanx 4 cm away.   
 
Test current pulses were applied at 0.5s intervals and combined with either sub-threshold 
polarizing currents or suprathreshold conditioning stimuli according to previously described 
protocols (444).  The CMAP amplitude was measured from baseline to negative peak, with 
the target set to 40% of maximum for all tracking studies.  Proportional tracking was utilized 
NI = CMAP amplitude (mV)* F-wave frequency/Distal motor latency (ms), 
 where F-wave frequency was expressed as the proportion of F responses recorded in 20. 
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to determine the changes in threshold current required to produce and maintain a target 
response (408).  
 
Electrical stimuli were increased in incremental steps to generate the motor stimulus-response 
(SR) curve.  Subsequently, the strength-duration time constant (τSD), a biomarker of persistent 
Na+ conductance, and rheobase, defined as the threshold current for a stimulus of infinitely 
long duration, were measured according to Weiss’ formula (34, 408, 422, 534).   
 
Following the determination of the stimulus strength-duration relationship, threshold 
electrotonus (TE) was determined using sub-threshold polarizing currents of 100 ms duration, 
set to +/- 40% of controlled threshold current (408, 409, 444).  Test stimuli of 1 ms duration 
were used to produce and maintain a target response of 40% of maximum CMAP amplitude.  
Three stimulus combinations were tested sequentially: test stimulus alone (measured control 
threshold current); test stimulus + depolarizing current; test stimulus + hyperpolarizing 
current.  Threshold was tested at 26 time points before, during, and after the 100 ms 
polarizing pulse.  The stimulus combinations were repeated until three valid estimates were 
recorded within 15% of target response (444).  The following TE changes were recorded with 
sub-threshold depolarizing currents: TEd (10-20 ms); TEd (40-60 ms); and TEd (90-100 ms).  
In addition, changes in membrane threshold to hyperpolarizing currents at 10-20 ms, TEh 
(10-20 ms) and at 90-100 ms, TEh (90-100 ms) were also measured.               
 
The current-threshold relationship (I/V), a biomarker of inward and outward rectifying 
membrane currents (409), was assessed by tracking threshold changes following sub-
threshold polarizing currents of 200-ms duration which were altered in ramp fashion from 
+50%  (depolarizing) to  -100% (hyperpolarizing) of controlled threshold in 10% steps. 
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Conditioning stimuli were alternated with test stimuli until three valid threshold estimates 
were recorded.  The following parameters were recorded: (i) resting I/V slope, calculated 
from polarizing currents between +10% to -10%; and (ii) hyperpolarizing I/V slope, 
calculated from polarizing current between -80% to -100%. 
 
Lastly, the recovery cycle of axonal excitability was recorded according to a well-established 
protocol (444, 445).  The following parameters were measured; (i) relative refractory period 
(RRP, ms), defined as the first intercept at which the recovery curve crosses the x-axis and a 
biomarker of transient Na+ channel function (409); (ii) superexcitability (%), defined as the 
minimum mean threshold change of three adjacent points and a biomarker of paranodal fast 
K+ channel conduction (409); (iii) late subexcitability (%), defined as the largest increase in 
threshold following the superexcitability period and a biomarker of nodal K+ channel 
conduction (409).  
 
Recordings of CMAP responses were amplified and filtered (3 Hz-3 kHz) using a Nicolet-
Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys Healthcare 
Neurocare Group, Madison, Wisconsin, USA) and sampled at 10 kHz using a 16-bit data 
acquisition card (National Instruments PCI-MIO-16E-4).  Data acquisition and stimulation 
delivery were controlled by QTRACS software (TROND-F, version 16/02/2009, © Professor 
Hugh Bostock, Institute of Neurology, Queen Square, London, UK).   
 
Mathematical modelling of axonal excitability changes 
To model the axonal excitability changes evident in c9orf72 FALS and sporadic ALS 
patients, mathematical simulations were undertaken using an established model of the human 
motor axon (541-545).  Nodal transient and persistent Na+ currents were modelled using data 
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from voltage-clamp and latent addition studies in human axons (546, 547).  This model 
incorporates: slow and fast K+ currents at both the node and internode; the hyperpolarization-
activated current Ih at the internode; and leak and pump currents at both the node and 
internode (Howells et al., 2012).  The discrepancy between the model and the group data was 
calculated as the weighted sum of the squares of the error terms: (xm - x̄) 2, where xm is the 
model threshold and x̄ is the mean threshold for the group data.  The weights were 0.5 for the 
strength-duration time constant and 1 for each of the other threshold measurement types (i.e. 
threshold electrotonus, current-threshold relationship and the recovery cycle).  The model 
was first adjusted to fit the normal control data using an interactive least squares procedure 
which minimized the discrepancy between model and data (548). 
 
Statistical analysis 
Axonal excitability studies were compared to 34 age-matched controls (13 males; 21 females, 
mean age 51.1±2.2 years), with the Student t-test utilised for assessing differences between 
means in patients, carriers and controls.  All of the axonal excitability data was normally 
distributed as assessed by the Shapiro-Wilk test.  Pearson's correlation coefficients were used 
to examine the relationship between parameters.  Since measures of excitability may vary 
with age and temperature, parameters were compensated for age, temperature and sex if 
required before statistical analysis, using the relations established previously in control 
subjects (549).   The ACE-R score was non-parametrically distributed and a Mann-Whitney 
test was utilised to compare differences between c9orf72 FALS and asymptomatic mutation 
carriers.  A probability (P) value of <0.05 was considered statistically significant, and the 
probability values were corrected for multiple comparisons.  Results were expressed as mean 
± standard error of the mean or median [interquartile range]. 
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Results 
Clinical phenotype 
The clinical features for the 10 clinically affected FALS patients, 9 asymptomatic c9orf72 
mutation carriers and 21 sporadic ALS patients are summarized in Table 6.1.  At the time of 
assessment, the c9orf72 FALS and sporadic ALS patients presented with the classical “ALS” 
phenotype.  Bulbar-onset disease was evident in 40% of c9orf72FALS and 29% of sporadic 
ALS patients, while limb-onset disease was reported in 60% of c9orf72 FALS and 71% of 
sporadic ALS patients.  At the time of assessment, the mean age of onset was unexpectedly 
higher in the c9orf72 FALS cohort (FALS c9orf72 63 ± 3.8 years; sporadic ALS 55 ± 2.5 years, 
P = 0.08), while the disease duration from symptom onset was comparable between the 
FALS and sporadic ALS patients (FALS c9orf72 14.3 ± 3.9 months; sporadic ALS 12.5 ± 2 
months, P = 0.35). 
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Clinical features c9orf72 FALS SALS AMC 
Mean age at assessment 
[years] 
63 
(3.8) 
55 
(2.5) 
45 
(5.4) 
Sex 
(M:F) 
6:4 16:5 1:8 
Mean disease duration 
(months) 
14.3 
(3.9) 
12.5 
(2.0) 
 
- 
Site of disease onset 
Bulbar:40% 
Limb :60% 
Bulbar:29% 
Limb:71% 
 
ALSFRS-R 
39 
(3.2) 
41.6 
(1.4) 
48 
Mean  
MRC upper limb score 
54 
(2.2) 
53.8 
(1.8) 
 
60 
Mean  
MRC lower limb score 
28 
(0.7) 
28 
(0.8) 
 
30 
Mean  
MRC total 
82 
(2.3) 
82 
(1.5) 
90 
 
Table 6.1.  Clinical details for the 10 s9orf72 familial amyotrophic lateral sclerosis     
(FALS) patients, 21 sporadic ALS patients (SALS) and 9 asymptomatic c9orf72 
mutation carriers (AMC).  Disease duration refers to the period from symptom 
onset to date of testing.  The patients were clinically graded using the amyotrophic 
lateral sclerosis functional rating scale revised (ALSFRS-R), with a maximum 
score of 48 when there is no disability.  Muscle strength was clinically assessed 
using the Medical Research Council (MRC), with an upper limb, lower limb and 
total score being generated (see Methods). 
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The mean ALSFRS-R score in the c9orf72 FALS was 39±3.2, and was comparable to the 
sporadic ALS patients (41.6 ± 1.4, P = 0.22), indicating a similar degree of functional 
impairment.  In addition, the degree of muscle weakness was similar between the groups as 
reflected by the upper limb (FALS c9orf72 54 ± 2.2; sporadic ALS 53.8 ± 1.8, P = 0.25, 
maximal score of 60 when normal strength), lower limb FALS c9orf72 28 ± 0.7; sporadic ALS 
28 ± 0.8, P = 0.20, maximal score 30 when muscle strength normal) and total MRC scores 
(FALS c9orf72 82 ± 2.3; sporadic ALS 82 ± 1.5, P = 0.48, maximal score 90 when muscle 
strength normal).  In addition, there was a comparable degree of upper motor neuron 
dysfunction in both the c9orf72 FALS and sporadic ALS patients (FALS c9orf72 UMN score 10.7 
± 1.8; sporadic ALS UMN score 10 ± 0.6).  While frontotemporal dementia was not evident in 
the current c9orf72 ALS cohort, there was a mild reduction of the ACE-R score suggesting 
the presence of subtle cognitive dysfunction in c9orf72 FALS patients (ACE-RACE-R c9orf72 86 
[76-92]; ACE-R asymptomatic mutation carriers 97 [95-98], P <0.05).  
 
Neurological examination was normal in all the asymptomatic c9orf72 mutation carriers.  
Specifically, there was no clinical evidence of upper or lower motor neuron dysfunction at 
time of assessment.  To date, all of the asymptomatic mutation carriers have remained well.     
 
Neurophysiology 
The mean CMAP amplitudes were significantly reduced in the c9orf72 FALS and sporadic 
ALS patients when compared to normal controls (FALS c9orf72 3.4 ± 0.3 mV; sporadic ALS 
5.6 ± 0.8 mV; controls 8.8 ± 0.4 mV, F = 17.9, P < 0.01).  Importantly, there were no 
significant differences in CMAP amplitudes between the c9orf72 FALS and sporadic ALS 
cohorts (P = 0.112).  In addition, the neurophysiological index was also significantly reduced 
in the c9orf72 FALS and sporadic ALS patients when compared to controls (FALS c9orf72 1.1 
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± 0.2; sporadic ALS 1.2 ± 0.2; controls 2.5 ± 0.1, P < 0.01).  While these findings indicate a 
significant degree of LMN dysfunction in the C9orf72 FALS and SALS cohorts, there was a 
trend for the CMAP amplitude to be lower in the c9orf72 FALS patients, despite a 
comparable clinical disease burden.  This discordant finding could be potentially explained 
by a greater sensitivity of neurophysiological techniques in detecting LMN dysfunction 
(550).    Of further relevance, clinical and electrical evidence of fasciculations were evident 
in all the C9orf72 FALS and SALS patients.   
 
In contrast, there was no significant differences in the CMAP amplitude (c9orf72 mutation 
carriers 7.0 ± 0.6 mV; controls 8.8 ± 0.4 mV) and neurophysiological index (asymptomatic 
c9orf72 mutation carriers, 2.5 ± 0.3; controls 2.5 ± 0.1) between the c9orf72 mutation carriers 
and normal controls, re-affirming the structural integrity of the peripheral nerves at time of 
assessment in asymptomatic controls.   
 
Strength duration time-constant and rheobase 
Strength-duration time constant is a biomarker of persistent Na+ conductances at the node of 
Ranvier (34, 421, 423, 534-536).  The mean τSD was significantly increased in the c9orf72 
FALS (0.5 ± 0.02 ms, P < 0.05, Fig. 6.1A, B) and sporadic ALS patients (0.52 ± 0.02 ms, P < 
0.01, Fig. 6.1A, B) when compared to controls.  In contrast, there were no significant 
differences in τSD between asymptomatic c9orf72 mutation carriers and controls 
(asymptomatic c9orf72 mutation carriers, 0.45 ± 0.04; controls 0.44 ± 0.01, P = 0.42, Fig. 6. 
1A, B).  Of further relevance, rheobase was significantly reduced in both c9orf72 FALS (1.61 
± 0.5 mA, P < 0.001, Fig 6.1A, C) and sporadic ALS patients (1.35 ± 0.10 mA; controls 2.27 
± 0.23 mA, P < 0.001, Fig 6.1A, C).  In contrast, rheobase was slightly increased in the 
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asymptomatic c9orf72 mutation carriers (2.64 ± 0.72 mA, Fig 1A, C), but again this increase 
was not significant. 
 
 
 
 
 
Figure 6.1.  Strength-duration time constant in amyotrophic lateral sclerosis.   
The strength-duration time constant (SD) reflects nodal persistent Na+ channel 
conductances.  (A)  The SD was significantly increased in c9orf72 familial amyotrophic 
lateral sclerosis patients [FALS] (clear triangles) and sporadic amyotrophic lateral 
sclerosis (SALS, clear circles) when compared to asymptomatic c9orf72 mutation 
carriers (AMC, clear diamonds) and controls (clear squares).  (B)  Mean SDTC was 
significantly increased in FALS and SALS patients.  (C) Rheobase was significantly 
reduced in FALS and SALS patients. *P < 0.05; **P< 0.01; ***P< 0.001. 
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Threshold electrotonus 
Threshold electrotonus (TE) provides insight into nodal and internodal membrane 
conductances.  Previously, two types of abnormalities of TE have been described in SALS, 
namely the type I abnormality, in which there is a greater change in response to a sub-
threshold depolarizing pulse, and the type II abnormality, in which there is a sudden decrease 
in membrane excitability marked by an abrupt increase in threshold (530).  In the present 
study, the type I abnormality was evident in 40% of the c9orf72 FALS patients and 29% of 
sporadic ALS patients, while the type II abnormality was not evident.  Further, neither the 
type I nor type II abnormalities were evident in the asymptomatic c9orf72 mutation carriers.   
 
Group data analysis disclosed the presence of significant difference in TE between FALS and 
sporadic ALS patients, asymptomatic c9orf72 mutation carriers and controls (Fig. 6.2A).  
Specifically, TEd (90-100 ms) was significantly increased in both the c9orf72 FALS (51.0 ± 
1.9%, P < 0.05, Fig 6.2B) and sporadic ALS (50.3 ± 1.4%, P < 0.01, Fig. 6.2B) patients when 
compared to controls (45.6 ± 0.6%).  Although there was a greater threshold change to 
hyperpolarizing sub-threshold conditioning pulses in the c9orf72 FALS and sporadic ALS 
patients (FALS c9orf72 -128.7 ± 8.7%; sporadic ALS -122.5 ± 0.6%; controls -117.5 ± 3.2%, P 
= 0.13, Fig. 6.2), this difference was not significant.   
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Current/threshold (I/V) relationship 
The I/V relationship estimates the inward and outward rectifying properties of nodal and 
internodal axonal segments, with the hyperpolarising I/V gradient reflecting conductances via 
inward rectifying currents (408, 551).  The hyperpolarizing I/V gradient was significantly 
increased in c9orf72 FALS (0.42 ± 0.02, P < 0.05) and sporadic ALS patients (sporadic ALS, 
0.41 ± 0.02, P < 0.05) when compared to asymptomatic mutation carriers (0.34 ±0.03) and 
controls (0.36 ± 0.01).   
 
 
Figure 6.2.  Threshold electrotonus measures in amyotrophic lateral sclerosis. Threshold 
electrotonus reflects changes in membrane excitability in response to long duration polarizing 
currents.  Threshold reduction with depolarization is represented in an upward direction and 
hyperpolarization in a downward direction.  (A) Depolarising threshold electrotonus was 
significantly increased in c9orf72 familial amyotrophic lateral sclerosis patients (FALS) (clear 
triangles) and sporadic ALS (SALS, clear circles) when compared to asymptomatic c9orf72 
mutation carriers (AMC, filled diamonds) and controls (clear squares).  In contrast, 
hyperpolarising threshold electrotonus was not significant (NS) between groups.  (B) Mean 
TED90-100 ms was significantly increased in c9orf72 FALS and SALS. *P < 0.05; **P < 0.01.  
 
A B 
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Recovery cycle of excitability   
The RRP duration was not significantly different when compared to controls (FALSc9orf72, 3.7 
± 0.2 ms, P = 0.06; sporadic ALS, 3.8 ± 0.3 ms, P = 0.08; asymptomatic c9orf72 mutation 
carriers, 3.2 ± 0.1 ms, P = 0.36; controls, 3.3 ± 0.1 ms).  In addition, there were no significant 
differences in superexcitability and late subexcitability between groups. 
 
Correlation with clinical parameters and disease duration   
Combining measures of axonal excitability, clinical assessment and disease severity, it was 
evident that τSD (R = -0.38, P < 0.05, Fig. 6.3A) and TEd [90-100 ms] (R = -0.44, P < 0.01, 
Fig. 6.3B) in c9orf72 FALS and sporadic ALS patients correlated with the CMAP amplitude, 
thereby suggesting that the increase in τSD and TEd [90-100 ms] were potentially linked to 
axonal degeneration.  In addition, the TEd [90-100 ms] was significantly correlated with the 
ALSFRS-R (R =-0.34, P < 0.05) and MRC upper limb score (R = -0.32, P < 0.05).  Taken 
together, these findings suggest that abnormalities of axonal excitability, particularly 
increased τSD and TEd [90-100 ms], are late features of c9orf72 FALS, and linked to the 
process of neurodegeneration.   
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Mathematical modelling of abnormal excitability properties  
To assist in interpreting the changes observed in axonal excitability, a mathematical model of 
the human motor axon was adjusted to provide a close match to the control group (Figs. 6.4 
and 6.5).  The model was then used to explore which membrane parameter changes could 
reproduce the changes seen in the combined FALS and sporadic ALS patient recordings.  The 
axonal excitability data in c9orf72 FALS and sporadic ALS was best modeled by a 30% 
reduction in the nodal slow K+ conductance along with an increase in persistent Na+ 
conductances and increase in Ih current, reducing the overall discrepancy by 81.7%.  The 
modelled changes resulted in a net depolarization of resting membrane potential (RMP) of 
0.8 mV. 
 
Figure 6.3.  Correlation of axonal excitability parameters with motor amplitudes.  
(A) The strength-duration time constant (SDTC) and (B) depolarising threshold 
electrotonus at 90-100 ms (TEd 90-100 ms) significantly correlated with the compound 
muscle action potential (CMAP) amplitude, thereby suggesting that SDTC and TEd 90-
100 ms were linked with the process of axonal degeneration.  
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Figure 6.4.  Mathematical modelling of axonal excitability parameters in ALS. 
Comparison of group data (controls, open circles; combined c9orf72 and sporadic 
ALS, filled circles) and mathematical model (open triangles, normal model; c9orf72 
and sporadic ALS model, filled triangles).  A. Threshold electrotonus group data.  
B. Modelled threshold electrotonus.  C. Current-threshold relationship.  D. 
Modelled current-threshold relationship. 
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Figure 6.5.  Mathematical modelling of strength-duration time constant in ALS. 
Comparisons of recorded and modelled strength-duration time constant (τSD) data.  
The τSD was significantly increased in c9orf72 familial amyotrophic lateral sclerosis 
(FALS) and sporadic ALS (SALS) patients.  Modelled strength-duration time 
constant for normal and combined SALS and FALS datasets. 
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Discussion 
The present study has established a pattern of axonal excitability abnormalities in c9orf72 
FALS that resembled changes observed in sporadic ALS patients.  Specifically, the strength-
duration time constant was significantly longer and depolarising threshold electrotonus at 90-
100 ms significantly greater in the c9orf72 FALS and sporadic ALS cohorts.  Mathematical 
modelling suggested that the changes in axonal excitability were best explained by a 
reduction of slow nodal K+ currents along with an increase in persistent Na+ conductances, 
inward rectification and Na+ pump activity.  Importantly, the abnormalities of axonal 
excitability correlated with functional (ALSFRS-R and MRC upper limb score) and 
neurophysiological (CMAP amplitude) biomarkers of peripheral disease burden.  In contrast, 
axonal excitability was normal in asymptomatic c9orf72 mutation carriers.  Taken together, 
the findings from the present series have identified a potential role for a reduction of slow 
nodal K+ currents and an upregulation of persistent Na+ conductances in the pathophysiology 
of c9orf72 associated FALS. 
 
Axonal ion channel dysfunction in c9orf72 FALS 
Strength-duration time constant, or chronaxie, is a measure of the rate at which the threshold 
current declines as stimulus duration increases (423).  The τSD is a biomarker of persistent 
Na+ conductances (34, 35, 408, 409, 419, 421, 529, 534-536, 552), a notion supported by 
computer modelling of the human motor axon (423).  Prolongation of τSD has previously been 
established as a feature of sporadic ALS, attributed to upregulation of persistent Na+ 
conductances (34, 35, 413, 529).  Importantly, upregulation of persistent Na+ conductances 
has been linked to the development of axonal degeneration in ALS (35, 413, 438), including 
the split-hand pattern of degeneration (533), as well as motor axonal hyperexcitability and 
generation of fasciculations (34, 35, 413, 529, 532, 533).  In addition, prolongation of  τSD 
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was also reported in SOD-1 FALS and correlated with biomarkers of peripheral disease 
burden (184), thereby suggesting that upregulation of persistent Na+ conductances 
contributed to development of clinical features and neurodegeneration in SOD-1 FALS, a 
finding in keeping with transgenic SOD-1 mouse model studies (523). 
 
The present study establishes that prolongation of τSD, and thereby upregulation of persistent 
Na+ conductances, was a pathophysiological feature of c9orf72 FALS, a notion supported by 
mathematical modelling of axonal excitability.  The correlation between prolongation of τSD 
and biomarkers of peripheral disease burden (including the CMAP amplitude) suggests that 
persistent Na+ conductances may contribute to motor neuron degeneration in c9orf72 FALS.  
Importantly, findings from the present study imply the existence of a common pathogenic 
pathway in ALS, irrespective of the underlying genotype. 
 
In addition to prolongation of τSD, there were significant changes in depolarising threshold 
electrotonus.  Specifically, the type I abnormality of threshold electrotonus, in which there 
was a greater change in response to a sub-threshold depolarizing pulse, was evident in the 
c9of72 FALS cohort, but not asymptomatic mutation carriers.  In addition, the mean TEd 
[90-100ms] was significantly increased in c9orf72 FALS and sporadic ALS, correlating with 
peripheral biomarkers of peripheral disease burden, and thereby suggesting that reduction of 
slow K+ currents contributed to development of axonal hyperexcitability and clinical features 
in c9orf72 FALS.  Importantly, mathematical modelling indicated that reduction of slow K+ 
currents in a large part accounted for the changes observed in axonal excitability, suggesting 
an important role for slow K+ channels in c9orf72 pathophysiology.  This notion is further 
underscored  by recent patch-clamp studies reporting that retigabine, a K+ channel activator, 
reduces axonal hyperexcitability and improves motor neuron survival in pluripotent stem 
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cells derived from c9orf72 FALS patients, thereby implying a therapeutic potential for 
retigabine (523).  Of further relevance, a similar degree of reduction in slow K+ currents in 
the c9orf72FALS and sporadic ALS patients underscores the existence of common 
pathogenic pathways. 
 
It could also be argued that the observed reduction in slow K+ conductances contributed to 
the increase in τSD through depolarisation of the RMP.  Such a hypothesis cannot be 
discounted given that modelling studies suggested that reduction in slow K+ plays a bigger 
role in reducing the discrepancy in the measure of τSD than the increase in fraction of 
persistent Na+ channels.   Given that axonal excitability parameters, such as superexcitability 
and threshold electrotonus which are reduced with RMP depolarisation (456), remained 
unchanged argues against the notion that membrane depolarization solely accounted for the 
increase in τSD.   
 
In contrast to previous studies in sporadic ALS patients (35, 413), paranodal fast K+ channel 
function appears to be preserved in c9orf72 FALS patients and the current SALS cohort.  
Specifically, superexcitability and TEd [10-20ms], both biomarkers of paranodal fast K+ 
channels (409), were not significantly altered in the c9orf72 FALS and sporadic ALS cohorts.   
Importantly, paranodal fast K+ channel dysfunction appears to evolve with disease 
progression and seems most pronounced immediately prior to motor axonal loss (553).   
Consequently, the discordant findings between the current and previous ALS cohorts may 
relate to differences in the extent and stage of motor axonal loss, reflecting the membrane 
properties of surviving motor axons at the time of assessment.    
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An increase in the hyperpolarising I/V gradient was also evident in the c9orf72 FALS and 
sporadic ALS cohorts and is best explained by an increase in inward rectifying currents (Ih).  
The increase in Ih most likely represents an adaptive response to the increased demands on 
surviving motor axons, perhaps secondary to axonal hyperexcitability due to reduction in 
slow K+ currents and upregulation of persistent Na+ conductances.   
 
In contrast to abnormalities of axonal excitability evident in the c9orf72 FALS and SALS 
patients, there were no significant changes in asymptomatic c9orf72 mutation carriers.  This 
finding is in keeping with previous studies in SOD-1 asymptomatic mutation carriers (184), 
implying that factors other than inheritance of the genetic mutation may be required to trigger 
the disease process.  
 
Clinical implications 
The mechanisms by which axonal ion channel dysfunction leads to neurodegeneration and 
adverse survival in ALS (554) remains to be elucidated, although it has been postulated that 
an influx of Na+ ions results in reverse operation of the Na+/Ca2+-exchanger, intra-axonal 
accumulation of Ca2+ and ultimately activation of Ca2+-dependent enzyme pathways leading 
to motor neuron degeneration  (210, 555-558) .  In addition, reduction of slow K+ currents 
and upregulation of persistent Na+ conductances would increase the depolarizing drive, 
thereby leading to axonal hyperexcitability and development of cramps and fasciculations, 
both prominent symptoms in ALS (15, 36, 48, 559-562). 
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Chapter 7 
 
CORTICAL EXCITABILITY CHANGES 
DISTINGUISH THE MOTOR NEURON 
DISEASE PHENOTYPES FROM 
HEREDITARY SPASTIC PARAPLEGIA 
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Summary 
Having established that cortical hyperexcitability is an important pathogenic mechanism in 
ALS, we wanted to explore whether cortical hyperexcitability is a common process across the 
ALS/MND phenotypes, including amyotrophic lateral sclerosis (ALS) and primary lateral 
sclerosis (PLS).  Separately, the clinical distinction between PLS and “mimic disorders” such 
as hereditary spastic paraparesis (HSP) may be difficult, potentially delaying diagnosis.  
Consequently, the aim of the present study was to determine the nature and spectrum of 
cortical excitability changes across the ALS/MND phenotypes, and to determine whether the 
presence of cortical dysfunction distinguishes PLS from HSP.  Cortical excitability studies 
were undertaken on a cohort of 14 PLS, 82 ALS and 13 HSP patients with mutations in the 
spastin gene.  Cortical hyperexcitability, as heralded by reduction of short interval 
intracortical inhibition (PLS 0.26%, -3.8 to 1.4%; ALS -0.15%, -3.6 to 7.0%, P<0.01) and 
cortical silent period duration (CSP PLS 172.2±5.4 ms; CSP ALS 178.1±5.1ms, P<0.001) along 
with an increase in intracortical facilitation, were evident in ALS and PLS phenotypes, 
appearing more frequently in the former.  Inexcitability of the motor cortex was more 
frequent in PLS (PLS 71%, ALS 24%, P<0.0001).  Cortical excitability was preserved in 
HSP.  Cortical dysfunction appears to be an intrinsic process across the MND phenotypes, 
with cortical inexcitability predominating in PLS and cortical hyperexcitability 
predominating in ALS. Importantly, cortical excitability was preserved in HSP, thereby 
suggesting that the presence of cortical dysfunction could help differentiate PLS from HSP in 
a clinical setting.  
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Introduction 
Motor neuron disease (MND) encompasses a group of neurodegenerative disorders exhibiting 
a heterogeneous clinical phenotype (48).  The commonest phenotype is amyotrophic lateral 
sclerosis (ALS), a rapidly progressive neurodegenerative disorder affecting both the upper 
and lower motor neurons (48, 563).  In contrast, the upper motor neuron (UMN) phenotype, 
termed primary lateral sclerosis (PLS), is characterized by a slowly progressive UMN 
syndrome with absence of LMN features (66, 70, 564, 565).  Given the phenotypic 
variability, the issue as to whether common pathophysiological processes underlie the varied 
MND phenotypes remains to be elucidated. 
 
Corticomotoneuronal hyperexcitability and disinhibition has been implicated in ALS 
pathogenesis, with neuronal degeneration mediated by an anterograde glutamate-mediated 
excitotoxic process (24).  Transcranial magnetic stimulation (TMS) techniques have 
established cortical hyperexcitability as an early and specific feature of ALS, linked to the 
process of motor neuron degeneration (39, 183, 185, 237).  In contrast, TMS studies in PLS 
have been limited (70, 76, 78), disclosing cortical inexcitability and prolongation of central 
motor conduction time (70, 76, 78).  Whether corticomotoneuronal hyperexcitability and 
disinhibition are features of PLS remains unknown, and resolution of this issue may shed 
light on whether PLS forms a pathophysiological continuum with ALS.  Consequently, the 
present study utilized threshold tracking TMS techniques (329) in order to dissect out the 
underlying pathophysiological processes in the varied MND phenotypes, with a particular 
aim of delineating the nature and spectrum of cortical dysfunction between ALS, PLS and the 
mimic disorder pure hereditary spastic paraplegia (HSP), and to determine whether the 
presence of cortical dysfunction could differentiate PLS from HSP.   
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Methods  
Clinical assessment: 
Studies were undertaken on 14  primary lateral sclerosis patients (8 males and 6 females, 
mean age 62, range 48-75 years) that were diagnosed according to previously established 
criteria (66, 70).  Specifically, the PLS diagnostic criteria utilized in the present cohort 
included: (i) presence of UMN signs with absence of focal muscle atrophy, fasciculations and 
EMG evidence of denervation for at least 3, but preferably 4 years after symptom onset; (ii) 
age of onset > 40 years; and (iii) exclusion of mimic disorders by laboratory and 
neuroimaging investigations (66, 70).  Clinical and cortical excitability findings were 
compared to a cohort of 13 genetically confirmed hereditary spastic paraplegia (HSP) patients 
(6 males and 7 females, mean age 56, range 24-72 years) secondary to mutations in the 
spastin gene (SPG42p21-22), 82 ALS patients (48 males, 34 females, mean age 60 years, 
range 40-85 years, Table 7.1) diagnosed according to the Awaji criteria (6) and in part 
previously reported (504), as well as 37 healthy controls (18 males and 19 females, mean age 
58, range 46-73 years).  Informed consent to the procedures was provided by all patients, 
with the study approved by the Sydney West Area Health Service and Human Research 
Ethics Committees. 
 
Patients were clinically staged using the Amyotrophic Lateral Sclerosis Functional Rating 
Scale-Revised [ALSFRS-R] (495) or the Spastic Paraplegia Rating Scale [SPRS](566).   
Muscle strength was assessed by the Medical Research Council (MRC) score (496) , with the 
following muscle groups assessed bilaterally yielding a total MRC score of 90:  shoulder 
abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger abduction; thumb 
abduction; hip flexion; knee extension; ankle dorsiflexion.  The degree of upper motor neuron 
(UMN) dysfunction was assessed by an UMN score incorporating the following parameters: 
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jaw jerk, facial reflex, upper and lower limb deep tendon reflexes and plantar responses with 
the score ranging from 0 [no UMN dysfunction] to 16 [severe UMN dysfunction] (497).  In 
all patients, the site of disease onset was recorded as either limb or bulbar.    
 
All patients were initially assessed by nerve conduction studies and needle electromyography.  
The degree of peripheral disease burden was assessed by stimulating the median nerve 
electrically at the wrist using 5-mm Ag-AgCl surface electrodes (ConMed, Utica, USA). The 
resultant compound muscles action potential (CMAP) was recorded from the abductor 
pollicis brevis (APB), as was the neurophysiological index (NI) according to a previously 
reported formula (26). 
 
Brain and spinal cord magnetic resonance imaging (MRI) studies excluded mimic disorders 
such as structural, metabolic or demyelinating lesions in the current PLS cohort.  High T2 
signal intensity in the corticospinal tract (internal capsule) was evident in one PLS patient.  
Nerve conduction study and needle electromyography excluded lower motor neuron 
dysfunction.  Basic biochemistry, full blood count, vasculitic screen (ANA, ENA, ANCA), 
immunoelectrophoeresis, angiotensin converting enzyme levels, vitamin B12, folate, and B6 
levels, thyroid function studies, coeliac disease serology, very-long-chain fatty acids, 
infective serology (human immunodeficiency virus, human T-lymphotrophic virus I and II, 
syphilis) and paraneoplastic screen were normal or negative.   In addition, cerebrospinal fluid 
analysis was unremarkable in all PLS patients as was genetic testing for the spastin gene 
mutation.     
 
Cortical excitability was assessed by utilizing a threshold tracking TMS technique according 
to a previously reported method (329).  Specifically, TMS studies were undertaken by 
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applying a 90 mm circular coil connected to two high-power magnetic stimulators connected 
via a BiStim device (Magstim Co., Whitland, South West Wales, UK).  The coil position was 
adjusted such that an optimal stimulating site was determined as indicated by a point on the 
vertex, at which a maximal motor evoked potential (MEP) amplitude was evoked by the 
smallest TMS current.  The MEP response was recorded over the abductor pollicis brevis 
(APB) muscle. 
 
Short interval intracortical inhibition and intracortical facilitation were assessed by the 
paired-pulse threshold tracking TMS technique as previously reported (329).  Briefly, the 
MEP amplitude was fixed and changes in the test stimulus intensity required to generate a 
target response of 0.2 mV (± 20%), when preceded by sub-threshold conditioning stimuli, 
were measured.  Resting motor threshold (RMT) was defined as the stimulus intensity 
required to maintain the target MEP response of 0.2 mV (±20%).   
 
Short-interval intracortical inhibition was determined over the following interstimulus 
intervals (ISIs): 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms, while ICF was measured at ISIs of 10, 
15, 20, 25 and 30 ms. Stimuli were delivered sequentially as a series of three channels: 
channel 1: stimulus intensity, or threshold (% maximal stimulator output) required to 
produce the unconditioned test response (i.e., RMT); channel 2: sub-threshold conditioning 
stimulus (70% RMT); and channel 3 tracks the stimulus (% maximal stimulator output)  
required to produce the target MEP when conditioned by a sub-threshold stimulus equal in 
intensity to 70% of RMT.   
 
Single pulse TMS technique was utilized to determine the MEP amplitude (mV), MEP onset 
latency (ms) and central motor conduction time.  The MEP amplitude was recorded with the 
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magnetic stimulus intensity set to 150% of the RMT, and four responses were recorded and 
averaged at this stimulus intensity. The resultant MEP amplitude was normalized by being 
expressed as a percentage of the compound muscle action potential (CMAP) response.  The 
cortical silent period (CSP) was recorded while performing a weak voluntary contraction, 
approximately 30% of maximum voluntary contraction, and calculated from commencement 
of the MEP response to return of electromyography activity (329, 366).  The central motor 
conduction time (CMCT) was derived by utilizing the F-wave method according to the 
previously following formula (567).   
 
Recordings of the CMAP and MEP responses were amplified and filtered (3 Hz-3 kHz) using 
a Nicolet-Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys 
Healthcare Neurocare Group, Madison, Wisconsin, USA) and sampled at 10 kHz using a 16-
bit data acquisition card (National Instruments PCI-MIO-16E-4).  Data acquisition and 
stimulation delivery were controlled by QTRACS software.  Temperature was monitored 
with a purpose built thermometer at the stimulation site.  
 
Statistical analysis 
All data was assessed for normality using the Shapiro-Wilk test.  Student’s t-test and Mann-
Whitney U test were utilized to assess differences between groups, while Chi square testing 
(χ²) was used for assessing differences between categorical variables.  Analysis of variance 
(ANOVA), with a Bonferroni correction or Kruskal-Wallis test, was used for multiple 
comparisons. No statistical analysis was performed for cortical excitability changes in the 4 
PLS patients, but rather the values are expressed as a function of the 95% confidence interval 
as calculated from normative data (see above). A P value < 0.05 was considered statistically 
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significant.  All data are expresses as mean ± standard error of the mean (SEM) or median 
[interquartile range (IQR)]. 
Results 
Clinical phenotypes 
The PLS phenotype was characterized by a progressive spastic paraparesis with generalized 
hyper-reflexia affecting the bulbar, cervical and lumbosacral regions as indicated by a median 
UMN score of 14 (14-15).  Importantly, UMN bulbar dysfunction, as characterized by a 
spastic dysarthria, slow tongue movement and absence of tongue atrophy and fasciculations, 
was evident in 64% of the PLS cohort.  The mean age of symptom onset was 58±3.3 years, 
with the mean disease duration being 85.5 ± 14 months.  The median ALSFRS-R score was 
41 (35-43), while the total median MRC score was 88 (84-90), indicating mild-moderate 
level functional impairment in the PLS cohort (Table 7.1).  Bladder dysfunction was evident 
in 29% of PLS patients, while none of the PLS patients exhibited sensory dysfunction (Table 
7.1). 
 
 
 
 
 
 
 
 
 
 PLS HSP ALS 
Mean age of disease 
onset 
(SEM, years) 
58  
(3.3) 
39  
(3.0) 
57  
(1.1) 
Mean disease duration 
(SEM, months) 
85.5  
(14) 
244.4  
(32.7) 
15.6  
(1.9) 
Clinical features (%) 
-Bulbar dysfunction 
   -Urinary urgency 
-Sensory symptoms 
 
 
64 
29 
0 
 
 
0 
69 
92 
 
 
37 
0 
0 
Median MRC sum 
score 
(IQR) 
88 
(84-90) 
90 
(90-90) 
84 
(79-88) 
 
UMN score 
(IQR) 
14 
(14-15) 
14 
(14-15) 
12 
(9-13) 
Table 7.1.  Clinical features for the 14 primary lateral sclerosis (PLS), 82 amyotrophic 
lateral sclerosis (ALS) and 13 hereditary spastic paraparesis (HSP) patients.  The mean age 
of disease onset was significantly greater for PLS patients.  The Medical Research Council 
(MRC) sum score (see Methods) was comparable between PLS and HSP patients, as was the 
upper motor neuron (UMN) score, indicating a comparable degree of functional impairment 
and clinical upper motor neuron dysfunction.   All data are expressed as mean ± standard 
error of the mean (SEM) or median (interquartile range, IQR). 
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The hereditary spastic paraparesis cohort was clinically characterized by a slowly evolving 
progressive spastic paraparesis with a similar degree of UMN dysfunction (median UMN 
score 14, 14-15) when compared to the PLS cohort.  There was a moderate degree of 
functional impairment as indicated by a median SPRS score of 17 (IQR 11-24), while the 
muscle strength appeared to be preserved (Table 7.1).  In contrast to PLS, HSP patients 
exhibited a significantly younger age of symptom onset (39 ± 3.0 years, Table 7.1, P < 
0.0001), with the mean disease duration being significantly longer (244.4 ± 32.7 months, P < 
0.001).  In addition, bladder dysfunction (69%) and sensory abnormalities (92%) were more 
frequent in the HSP cohort, while bulbar dysfunction was not evident in HSP.   
 
Prior to undertaking cortical excitability studies, the degree of peripheral disease burden was 
assessed.  The CMAP amplitude (PLS 9.0 ± 0.8 mV; HSP 11.0 ± 1.0mV; ALS 6.9±0.5mV; 
controls 9.9 ± 0.5 mV, F = 8.5, P < 0.001) and NI (PLS 2.2 ± 0.3; HSP 2.2 ± 0.3; ALS 1.2 ± 
0.2; controls 2.3 ± 0.1, F = 13.4, P < 0.001) were similar in the PLS and HSP cohorts and 
comparable to normal controls, but were significantly greater when compared to the ALS 
cohort.   Taken together, these findings confirmed preserved lower motor neuron function in 
the PLS and HSP cohorts.  
 
Cortical excitability 
Transcranial magnetic stimulation studies disclosed a significant increase in the frequency of 
motor cortex inexcitability, defined as a resting or active motor threshold > 95% of maximal 
stimulator output, in PLS patients.  Specifically, the motor cortex was inexcitable in 71% of 
PLS and 24% of ALS patients, while a “normal” level of motor cortex excitability was 
evident in the HSP patients (x2=37, P<0.0001, Figure 7.1A).  In the remaining four PLS 
patients, threshold tracking TMS studies disclosed a significantly increased RMT (PLS 74.5 
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± 6.4%, 95% confidence interval [CI] 55.3-60.9%, Figure 7.1B).  There was no significant 
difference in RMT between HSP and ALS patients and controls (RMT HSP 52.0 ± 2.2%; RMT 
CONTROLS 58.1±1.4%, P<0.05, RMT ALS 56.8±1.1%, Figure 7.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
Paired pulse TMS was utilized to assess short interval intracortical inhibition and 
intracortical facilitation, both biomarkers of motor cortical function (39).  Short interval 
intracortical inhibition was reduced in PLS (0.26%, -3.8 to 1.4%, 95% CI 9.7-13.9%, Figure 
7.2A) and ALS phenotypes (-0.15%, -3.6 to 7.0%, P < 0.01, Figure 7.2A) when compared to 
HSP 7.0% (6.8 to 10.1%) and controls 12.0% (7.3 to 15.4%).   
 
 
Figure 7.1.  (A)  The frequency of motor cortex inexcitability was more frequent in 
primary lateral sclerosis (PLS) patients when compared to amyotrophic lateral sclerosis 
(ALS) and hereditary spastic paraparesis (HSP) patients.   (B)  The resting motor 
threshold was significantly increased in PLS patients. ****P < 0.0001. 
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Following SICI, a period of intracortical facilitation develops between ISI of 10-30 ms (568).  
Intracortical facilitation was increased in PLS (-5.6%, -8.5 to -5.3%, 95% CI -2.5 to -0.7%, 
Figure 7.2B) and ALS (-3.2%, -6.6 to -0.5%, P < 0.01, Figure 7.2B) phenotypes when 
compared to HSP (-0.17%, -0.80 to 1.0%, P < 0.01, Figure 7.2B) and healthy controls  
(-0.70%, -3.1 to 2.7%, P < 0.01, Figure 7.2B).  Importantly, ICF was comparable between 
PLS and ALS cohorts (Figure 7.2B). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.  (A)  Averaged short interval intracortical inhibition (SICI) between 
interstimulus interval (ISI) 1-7 ms was significantly reduced in primary lateral sclerosis 
(PLS) and amyotrophic lateral sclerosis (ALS) patients when compared to hereditary 
spastic paraparesis (HSP) patients and controls.   (B)  Intracortical facilitation (ICF), 
between ISI of 10-30 ms, was significantly increased in PLS and ALS patients. **P < 0.01.  
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Single-pulse TMS studies the CSP duration was reduced in PLS (CSP PLS 172.2 ± 5.4 ms, 
95% CI 206.4-222 ms, Figure 7.3) and ALS patients when compared to the HSP cohort and 
healthy controls (CSP ALS 178.1±5.1ms CSP HSP 202.1±7.9ms; CSP CONTROLS 214.2±3.9ms, F 
= 13.5, P < 0.001, Figure 7.3). In contrast, while there was a trend for the MEP amplitude to 
be increased in the PLS (30.0 ± 7.8%, 95% CI 19-28.6%) and ALS phenotypes when 
compared to HSP and controls, this difference was not significant (MEP ALS 31.0±2.1%; MEP 
HSP 22.5±2.8%; MEP CONTROLS 23.8±2.4%, F = 1.6, P = 0.18).  Surprisingly, central motor 
conduction time was comparable between groups (CMT PLS 6.9±0.6 ms; CMT ALS 6.0±0.1ms; 
CMT HSP 6.2±0.3ms; CMT CONTROLS 5.5±0.3ms).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3.  The cortical silent period (CSP) duration was significantly reduced 
in primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) 
patients when compared to hereditary spastic paraparesis (HSP) patients and 
controls.***P< 0.001 
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Discussion 
The findings in the present establish that cortical dysfunction was an intrinsic feature across 
the ALS and PLS, with motor cortex inexcitability predominant in the PLS phenotype.  In 
contrast, cortical hyperexcitability was the predominant feature in the ALS phenotype, 
heralded by a marked reduction in short interval intracortical inhibition and CSP duration 
along with an increase in intracortical facilitation.  By comparison, cortical excitability was 
preserved in hereditary spastic paraplegia, despite a comparable degree of clinical upper 
motor neuron dysfunction.  These findings suggest that cortical dysfunction appears to be an 
important pathophysiological process across the MND phenotypes, with the PLS and ALS 
phenotypes forming a pathophysiological continuum.  In addition, the findings in the present 
study underscore the potential utility of the threshold tracking TMS technique in 
differentiating PLS from the potential mimic disorder HSP. 
 
Pathophysiological processes underlying the MND phenotypes 
Neuropathological studies in PLS have reported marked neuronal degeneration in the primary 
motor cortex, prefrontal cortex and corticospinal tracts (70, 565).  Ubiquitin-positive and 
hyaline inclusions have also been observed in the frontal cortex and anterior horn cells, 
although the motor neuron population in the spinal cord and hypoglossal nucleus appear 
relatively preserved.  Similar neuropathological abnormalities have been documented in ALS, 
characterized by degeneration of inhibitory cortical neurons (188), although the extent of 
neuronal degeneration, particularly Betz cell loss, seems less prominent (70, 565).  
Separately, neuroimaging studies have established cortical abnormalities in both ALS and 
PLS phenotypes, characterized by cortical atrophy along with reduction in the N-
acetylaspartate/creatinine ratio, fluorodeoxyglucose and [(11) C]-flumazenil binding and 
cerebral blood flow underscoring the neuropathological findings (70, 569, 570).  
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The TMS abnormalities evident in the PLS and ALS phenotypes most likely relate to the 
underlying pathology of the corticomotoneuronal system, although the extent and nature of 
the dysfunction seems to be different between the phenotypes.  Importantly, the frequency of 
motor cortex inexcitability was significantly greater in the PLS phenotype.  Given that resting 
motor threshold may reflect the density of corticomotoneuronal projections onto spinal motor 
neurons as well as excitability of large motor cortical neurons (Betz cells) (39), the findings 
in the present study may reflect a greater degree of neurodegeneration within the motor 
cortex (Betz cells) and corticospinal tracts in the PLS phenotype.   
 
In contrast, cortical hyperexcitability was the predominant TMS feature in the ALS 
phenotype and was characterized by marked reduction of SICI and CSP duration along with 
an increase in ICF.  While features of cortical hyperexcitability were also evident in PLS, 
their frequency was less when compared to the ALS cohort, being evident in 28% of PLS 
subjects.  Given that the TMS parameters are modulated by GABAergic inhibitory cortical 
circuits located within the motor cortex and glutamatergic activity (39, 396), the findings in 
the present study suggests that glutamate excitoxicity and cortical disinhibition form the 
pathophysiological basis in the ALS phenotype.   A similar pathophysiological process was 
also evident in a proportion of PLS patients, thereby suggesting that the ALS and PLS 
phenotypes represent a pathophysiological continuum.  While the finding of increased resting 
motor threshold in the PLS phenotype could potentially argue against the notion of a 
pathophysiological continuum, this finding could be accounted for by a greater degree of 
corticomotoneuronal degeneration in the PLS phenotype, a notion supported by previous 
TMS studies [28-30]. 
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Importantly, the TMS differences between ALS and PLS, may in part account for the 
discordant rate of neurodegeneration of spinal and bulbar motor neurons.  Motor neuronal 
degeneration in ALS was postulated to be mediated via an anterograde glutamate mediated 
excitotoxic process (24).  Given that cortical hyperexcitability was not a prominent feature in 
the current PLS cohort, the relative sparing of spinal and bulbar motor neurons in PLS may 
argue against the existence of significant glutamate excitotoxicity.   Alternatively, it could 
also be argued that motor neurons in PLS patients may be less susceptible to the toxic effects 
of glutamate.  Specifically, a number of molecular features may render motor neurons more 
vulnerable to glutamate toxicity, including expression of glutamate receptors that are more 
permeable to influx of Ca2+ ions (197, 198, 200, 201), a reduced capacity to buffer 
intracellular Ca2+ (203), and an inability to regulate intracellular calcium (204).  As such, the 
motor neurons in PLS patients may lack these harmful factors or alternatively may have 
evolved specific defence processes against the deleterious effects of glutamate excitoxicity, 
although this notion remains speculative and needs to be further verified in future studies.   
 
In contrast to findings in the PLS and ALS phenotypes, cortical function remained preserved 
in HSP despite a comparable degree of clinical UMN dysfunction.  These discordant findings 
likely reflect differences in the underlying neuropathology, whereby a length dependent 
dying-back axonopathy of the corticospinal tracts seems to predominate in HSP (571).  While 
more extensive neuropathological abnormalities have been reported in complicated forms of 
HSP, including thinning of the corpus callosum, degeneration within the thalamus, cerebral 
white matter, substantia nigra, motor cortex and the cerebellum (572, 573), the neuroanatomy 
of the motor cortex and corticomotoneuronal system seems to be preserved in the pure UMN 
phenotype of spastin related HSP (574).  Importantly, findings from the present study suggest 
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that HSP is a unique disease entity that involves the upper motor neurons, with a spinal 
predominant pathophysiological process.   
 
Diagnostic utility of threshold tracing TMS in differentiating the clinical phenotype 
In addition to providing pathophysiological insights, the present study has established 
potential utility of the threshold tracking TMS technique in differentiating PLS from HSP.   
Specific clinical features, including age of onset, mild sensory symptoms, urinary urgency 
and bulbar dysfunction have been proposed as diagnostic aids in differentiating PLS and HSP 
(66, 70, 575).  A substantial clinical overlap, however, has been reported between the PLS 
and HSP phenotypes, limiting the diagnostic utility of these clinical features (78, 576).  In 
addition, a family history of HSP has also been proposed as a potential diagnostic aid, 
although apparently sporadic forms of HSP have been reported (577).   The present study has 
established marked differences in cortical excitability between PLS and HSP, with absence of 
overlap in TMS abnormalities, thereby underscoring the utility of the threshold tracking TMS 
technique as a diagnostic aid in differentiating PLS from HSP in a clinical setting.   
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Chapter 8 
 
CORTICAL CONTRIBUTIONS TO THE 
FLAIL LEG SYNDROME: 
PATHOPHYSIOLOGICAL INSIGHTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
204 
  
Summary 
 
Having established that cortical hyperexcitability reliably underscores upper motor neuron 
dysfunction across the MND/ALS phenotypes, we wanted to explore whether cortical 
hyperexcitability formed the pathophysiological basis for the flail leg syndrome (FL), an 
atypical ALS variant, with predominant lower motor neuron findings.  Cortical excitability 
studies were undertaken on 18 FL patents, using the threshold tracking transcranial magnetic 
stimulation (TMS) technique, and results were compared to healthy controls, upper and lower 
limb-onset ALS as well as bulbar-onset and the flail arm variant ALS.  Cortical 
hyperexcitability was a feature of FL and was heralded by a significant reduction of short 
interval intracortical inhibition (FL 7.2±1.8%; controls 13.2±0.8%, P<0.01) and cortical silent 
period (CSP) duration (FL 181.7±10.8ms; controls 209.8±3.4ms; P<0.05) along with an 
increase in motor evoked potential amplitude (FL 29.2±5.1%; controls 18.9±1.2%, P < 0.05). 
The degree of cortical hyperexcitability was comparable between FL and other ALS 
phenotypes, defined by site of disease onset.  In addition, the CSP duration correlated with 
biomarkers of peripheral neurodegeneration in FL.  Cortical hyperexcitability is a feature of 
the flail leg syndrome, being comparable to other ALS phenotypes.  Importantly, cortical 
hyperexcitability correlates with neurodegeneration, and as such may contribute to the 
underlying pathophysiology in FL.  
 
 
 
 
205 
  
Introduction 
 
The flail leg (FL) syndrome, also referred to as leg amyotrophic diplegia (84) or 
pseudopolyneuritic variant of amyotrophic lateral sclerosis (ALS), is considered to be an atypical 
variant of ALS, first described in the early 20th century .  Clinically, the FL syndrome is 
characterised by a predominant lower motor neuron phenotype with absent or subtle upper motor 
neuron (UMN) signs, with disease remaining confirmed to the lower limbs for a prolonged 
period (84, 87, 88).  The median survival for the FL phenotype has been reported to be 90 
months (84, 88), suggesting a more favourable prognosis when compared to the typical ALS 
phenotype. Importantly, there appears to be a heterogeneity of the FL phenotype, with some 
studies reporting a greater degree of UMN dysfunction and shorter survival, approximating the 
disease course to more classical ALS (89).  While it has been suggested that the clinical 
heterogeneity is best explained by differences in definition of the FL phenotype, with inadvertent 
inclusion of classical ALS phenotypes (84), the underlying pathophysiological mechanisms 
remain to be clarified. 
 
The pathophysiological processes underlying the various ALS phenotypes appear to be 
multifactorial, with a complex interaction of molecular and genetic mechanisms (47, 48).  
Cortical hyperexcitability has been established as an intrinsic process in sporadic and familial 
forms of ALS, occurring at the early stages of the disease and linked to peripheral 
neurodegeneration (183, 185, 510).  In addition, cortical hyperexcitability has been identified 
even in atypical ALS phenotypes, including the flail arm variant ALS (FA), where there is a 
general paucity of upper motor neuronal features on clinical examination (240, 578).  
Specifically, despite the absence of UMN signs, cortical hyperexcitability appeared to be a 
206 
  
uniform finding in FA and was comparable to the classical ALS phenotype.  Given the 
similarities in the natural history between FL and FA, and that LMN dysfunction predominates 
in both phenotypes (88, 240, 579), it would seem plausible that cortical dysfunction may also 
contribute to development of the flail leg syndrome, perhaps forming the pathophysiological 
basis of the clinical heterogeneity evident in FL.   
 
Cortical excitability can be assessed non-invasively by utilising threshold tracking transcranial 
magnetic stimulation (TMS) techniques (329).  Single pulse TMS studies have reported  
prolongation of central motor conduction time in FL (580), which was commensurate with 
findings in classical ALS phenotypes, thereby suggesting the presence of subclinical UMN 
dysfunction, a finding underscored by pathological studies documenting degeneration of the 
corticospinal tracts (581, 582).   The issue, however, of whether cortical hyperexcitability was 
evident in FL syndrome, and whether it was a uniform finding across the FL phenotype remains 
to be elucidated.  Consequently, the present study has attempted to better define the phenotype of 
flail limb presentations. In addition, cortical excitability has been assessed in the FL phenotype, 
in order to determine whether differences in cortical hyperexcitability were evident in the FL 
syndrome.   
 
Methods 
This prospective study recruited patients with the FL phenotype, which was defined according to 
the following criteria: (i) lower motor neuron disorder of the lower limbs that is characterised by 
progressive distal onset wasting and weakness; (ii) confined to lower limbs for at least 12 
months; (iii) brisk tendon reflexes or pathological reflexes, such as the extensor plantar response 
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or Hoffman sign, could be present in patients with the flail leg pattern of muscle wasting and 
weakness as outlined in point 1; (iv) absence of hypertonia or clonus (88).  The clinical and 
neurophysiological findings in the flail leg syndrome ALS patients were compared with other 
ALS subgroups, including 23 lower limb-onset and 43 upper limb-onset ALS patients, as well as 
8 the flail arm variant ALS (240), and 48 bulbar-onset ALS patients. The Awaji diagnostic 
criteria was applied in the flail leg syndrome and typical ALS patients (6). Specifically, needle 
EMG testing was undertaken in all ALS patients in at least three regions (upper limb, lower limb, 
bulbar or thoracic) and lower motor neuron dysfunction was defined according to the Awaji 
criteria (6), including the presence of chronic neurogenic changes together with fibrillation 
potentials/positive sharp waves or fasciculations.  EMG abnormalities had to be evident in at 
least 2 muscles innervated by different nerves and nerve roots in the spinal region, or one muscle 
in the bulbar/thoracic region. The assessment of upper motor neuron dysfunction remained 
clinically based.  All patients provided written informed consent to the procedures approved by 
the Western Sydney Local Health District and South East Sydney Area Health Service Human 
Research Ethics Committees.  
 
At assessment, all patients underwent conventional neurophysiological testing to exclude mimic 
disorders according to established techniques (514). Demographic data was collected from all 
patients and included age, gender, handedness, disease duration (months), region of onset, use of 
Riluzole. Patients were also clinically staged using the revised amyotrophic lateral sclerosis 
functional rating scale (ALSFRS-R) (495) and the Medical Research Council (MRC) score for 
assessing muscle strength from the following muscle groups bilaterally: shoulder abduction, 
elbow flexion and extension, wrist dorsiflexion, finger abduction and thumb abduction, hip 
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flexion, knee extension and ankle dorsiflexion, yielding a total score of 90.  Upper motor neuron 
(UMN) function was assessed by a dedicated UMN score(497), which ranged from 0 (no UMN 
signs) to 16 (widespread UMN signs).  
 
Cortical function was assessed by applying a 90 mm circular coil (Magstim, UK) to the vertex of 
the cranium, with the ensuing  motor evoked potential (MEP) responses recorded over the right 
abductor pollicis brevis (APB) muscle, according to a previously reported technique (329).  A 
threshold tracking paradigm was utilised, whereby a target MEP response of 0.2 mV (±20%) was 
tracked (329).  Resting motor threshold (RMT) was defined as the stimulus intensity required to 
generate and maintain the target MEP response.  A paired-pulse threshold tracking paradigm, 
with subthreshold condition stimulus set to 70% RMT, was utilised to determine the short 
interval intracortical inhibition (SICI) and intracortical facilitation (ICF) as previously described 
(329).  Single pulse TMS was utilized to determine the maximal MEP amplitude (mV), cortical 
silent period (CSP) duration (ms) and central motor conduction time (CMCT), with details of the 
technique described previously (329). 
 
Formal assessment of the lower motor neuronal system was also undertaken in the same sitting. 
compound muscle action potential (CMAP) was recorded over the APB, first dorsal interosseous 
and the abductor digit minimi muscles according to previously established techniques (13).  The 
resultant baseline-peak CMAP amplitude (mV), onset latency (ms), minimum F-wave latency 
and F-wave frequency were measured.   
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Recordings of the CMAP and MEP responses were amplified and filtered (3Hz-3 kHz) using a 
Nicolet-Biomedical EA-2 amplifier (Viking Select version 11.1.0, Natus, Madison, USA) and 
sampled at 10 kHz using a 16-bit data acquisition card (National Instruments PCI-MIO-16E-4).  
Data acquisition and stimulation delivery were controlled by QTRACS software (version 
16/02/2009, © Professor Hugh Bostock, Institute of Neurology, Queen Square, London, UK).   
 
Statistical analysis  
Cortical excitability results were compared to 60 healthy controls (mean age 50.8±1.3 years, 33 
males, 27 females, range 28-73 years). All data were tested for normality using the Shapiro-Wilk 
test prior to analysis. Analysis of variance (ANOVA) with Bonferroni post hoc analysis was used 
for multiple comparisons between normally distributed variables while the Kruskal-Wallis test 
was used for variables without normal distribution. Student t-test or Mann-Whitney U test was 
used for comparisons between groups. A probability (P) value of <0.05 was considered 
statistically significant. Results were expressed as mean ± standard error of the mean (SEM) or 
median (interquartile range). 
 
Results  
Clinical features 
From a cohort of 140 consecutive ALS patients, studied over a four year period until June 2015, 
18 FL syndrome patients were identified comprising 12.9% of the total ALS cohort (Table 8.1).  
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 FL ALSLL ALSUL FA Bulbar 
      
NUMBER 
(%TOTAL) 
18(12.4) 27(18.6) 44(30.3) 8(5.5) 48(33.1) 
      
AGE(YEARS) 
SEM 
64 
1.9 
57.5 
2.2 
56.1 
2.1 
60.1 
3.1 
62.6 
1.7 
      
GENDER(M:F) 8:10 17:10 27:20 5:3 27:21 
      
Disease Duration 
at TMS testing 
[months(IQR)] 
17.5 
(10.5-24) 
 
11 
(6-20) 
 
9 
(6-15) 
 
12.5 
(8.8-33) 
 
12 
(8-19) 
 
      
Disease Duration 
at census date 
[months (IQR)] 
38 
(24-53) 
29 
(19-41) 
26 
(18-32.8) 
52 
(23-69) 
31 
(19-42) 
 
     
ALSFRS-R 
(maximum 48) 
41.5
 
(4.-44) 
40 
(35.3-42.8) 
43 
(39-46) 
44.5 
(42-46.3) 
42 
(37.3-44) 
      
MRC LL 
(maximum 30) 
P value 
22.5 
(17-25.5) 
(<0.001) 
25 
(20.3-27.8) 
30 
(28-30) 
30 
(30-30) 
30 
(30-30) 
      
MRC UL 
(maximum 60) 
P value 
60 
(58-60) 
(<0.001) 
53.5 
(47.3-60) 
52 
(47-56) 
42 
(31.3-49.3) 
58 
(56-60) 
      
MRC APB 
(maximum 5) 
P value 
5 
(5-5) 
(<0.05) 
4 
(4-5) 
4 
(4-5) 
4.5 
(3.8-5) 
5 
(4-5) 
 
      
MRC SUM 
(maximum 90) 
80.5 
(76.8-83.8) 
79 
(70.3-82.8) 
81 
(75-85.3) 
72 
(61.3-79.3) 
89 
(84-90) 
      
UMN SCORE 
(maximum 16) 
P Value 
9 
(1.3-12) 
(<0.01) 
11 
(8.8-12) 
12 
(10-12) 
5.5 
(0-10.5) 
12 
(8.3-14) 
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The flail limb phenotype was characterised by progressive distal onset weakness and wasting of 
the lower limbs in all patients, which was confined to the lower limbs for at least 12 months 
(Table 8.1).  UMN signs became evident in 78% while absent UMN signs were noted in 22% of 
flail leg syndrome patients. Importantly, the median UMN score was significantly lower in flail 
leg syndrome patients when compared to bulbar and upper limb onset ALS (χ2 = 19.2, df 4, P < 
0.01, Table 8.1), and none of the flail leg syndrome patients exhibited pathological reflexes, 
spasticity or clonus.  At the time of assessment, 9 (50%) flail leg syndrome patients were 
classified as Awaji “possible”, and 3 (17%) as Awaji probable. Six (33%) patients did not exhibit 
upper motor neuron signs and were best categorised as a progressive muscular atrophy 
phenotype.   
    
Evidence of disease spread to other regions was documented in 56% (N=10) of flail leg 
syndrome patients at a median time of 29.5 (25.3-38.3) months after symptom onset. The next 
Table 8.1.  Demographic characteristics of 18 patients with flail leg (FL) syndrome is 
summarised and compared with four other amyotrophic lateral sclerosis (ALS) phenotypes 
including lower limb onset ALS (ALSLL), upper limb onset ALS(ALSLL), flail arm variant 
ALS (FA) and bulbar onset classic ALS (Bulbar). Significant differences in characteristics 
between ALSFL and other phenotypes are explained below. The degree of functional 
disability, as indicated by the amyotrophic lateral sclerosis functional rating scale-revised 
(ALSFRS-R) was comparable between different ALS phenotypes.  Lower limb muscle 
strength, as measured by the Medical Research Council (MRC) score was significantly lower 
in FL patients when compared to upper limb onset, bulbar onset and flail arm variant ALS 
phenotypes (P < 0.001), but comparable to lower limb onset ALS. Upper limb strength, as 
measured by the MRC score (MRC UL) was significantly higher in FL when compared to 
flail arm variant, upper and lower limb onset ALS phenotypes but not bulbar onset ALS (P < 
0.001). The abductor pollicis brevis (APB) strength was significantly higher in FL and bulbar 
onset ALS phenotypes when compared to the other three ALS phenotypes (P < 0.05).The 
upper motor neuron (UMN) score significantly lower in FL patients when compared to 
bulbar and upper limb onset ALS (P< 0.01), but comparable to lower limb onset ALS and 
flail arm variant ALS.  
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region of spread included bilateral upper limbs in 4 patients, right upper limb in 3, left upper 
limb in 2 and respiratory system in one patient. Importantly, UMN signs were significantly less 
prominent in flail leg syndrome patients that remained localised to the lower limbs (UMN Localised 
1.5 [0-10]; UMN Spread 11 [8.3-13], P < 0.05).  The median survival during the follow-up period 
(June 30 2015) was significantly longer in the flail leg syndrome cohort when compared to the 
other ALS phenotypes (χ2 = 24.9, P < 0.001, Table 8.1).  Importantly, 5 (28%) flail leg syndrome 
patients died during the study period, with median survival being 39 (22-44) months. 
Importantly, UMN signs were significantly more prevalent in the flail leg syndrome patients that 
died (UMNDEAD 12 [10-12.5]; UMNALIVE 2 [0-10.5], Z=-2.1, P < 0.05).   
 
The degree of functional disability, as assessed by the ALSFRS-R score, was similar between 
flail leg syndrome patients and other ALS phenotypes (χ2 = 8.4, df 4, P =0.08, Table 8.1). As 
expected, the degree of lower limb muscle strength was significantly lower in flail leg syndrome 
patients when compared to upper limb onset, bulbar onset and flail arm variant ALS phenotypes, 
but comparable to lower limb onset ALS (χ2 = 67.7, df 4, P < 0.001, Table 8.1).  In contrast, 
upper limb strength was relatively preserved in flail leg syndrome patients, with the MRC upper 
limb scores being significantly higher in flail leg syndrome when compared to flail arm variant, 
upper and lower limb onset ALS phenotypes (χ2 = 41.7, df 4, P < 0.001, Table 8.1), but was 
comparable to bulbar onset ALS (Table 8.1).  In keeping with higher upper limb MRC scores, 
the APB strength was significantly higher in flail leg syndrome and bulbar onset ALS 
phenotypes when compared to the other three ALS phenotypes (χ2 = 11.8, df 4, P < 0.05, Table 
8.1).  
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Diagnostic studies:  Magnetic resonance imaging studies of the brain and spinal cord were 
normal in all patients as were the following laboratory investigations: basic biochemistry, 
haematology, vasculitic screen (anti-nuclear antibody, extractable nuclear antibody, anti-
neutrophil cytoplasmic antibody and angiotensin converting enzyme), immunoelectrophoeresis, 
anti-ganglioside antibodies (GM1, GQ1b), Kennedys disease genetic testing (male patients only), 
thyroid function studies, paraneoplastic screen, infective (human immunodeficiency virus, 
hepatitis-B, hepatitis C and syphilis) and coeliac disease serology.  Cerebrospinal fluid (CSF) 
analysis was undertaken in 5 flail leg syndrome patients and did not reveal any abnormality.  
Nerve conduction studies (NCS) excluded conduction block and other features of nerve 
demyelination in all patients.  The tibial and common peroneal nerve motor CMAP responses 
were reduced in all patients, while median and ulnar nerve motor NCS were normal. Sensory 
responses were normal throughout.   
 
The CMAP amplitude from the target APB muscle in flail leg syndrome patients was 8.0±0.8mV 
and was comparable to healthy controls (10.4±0.4mV, P=0.13).  In contrast, the CMAP 
amplitude from APB muscles, was significantly reduced in other ALS phenotypes when 
compared to healthy controls (Table 8.2). 
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 FL ALSLL ALSUL FA Bulbar Control 
Mean CMAP* 
(SEM) 
P value 
8.0 
0.8 
7.0  
1.1 
(<0.01) 
6.6  
0.5 
(<0.01) 
5.0  
0.8 
(<0.01) 
6.8  
0.5 
(<0.01) 
10.4 
0.4 
 
Mean SICI (%) 
(SEM) 
P value 
7.2 
1.8 
(<0.01) 
3.6 
1.3 
2.4 
1.4 
1.6 
3.1 
1.9 
1.3 
13.2 
0.8 
CSP duration 
(ms) (SEM) 
P Value 
181.7 
10.8 
(<0.05) 
189.0 
8.8 
186.5 
7.5 
182.5 
9.8 
180.5 
6.8 
209.8 
3.4 
MEP Amplitude 
 (SEM) 
P Value 
29.2 
5.1 
(<0.05) 
36.8 
3.2 
29.8 
3.5 
34.4 
5.4 
36.1 
3.7 
18.9 
1.2 
CMCT (ms) 
(SEM) 
P value 
6.7 
0.5 
(<0.001) 
6.5 
0.4 
6.6 
0.3 
6.4 
0.4 
6.7 
0.3 
5.6 
0.2 
RMT (%) 
(SEM) 
59.3 
2.0 
54.8 
2.2 
56.0 
1.3 
60.1 
3.1 
57.7 
1.5 
58.9 
1.0 
Table 8.2.  The neurophysiological findings in the flail leg (FL) syndrome and other amyotrophic 
lateral sclerosis (ALS) phenotypes.  The mean compound muscle action potential amplitude 
(CMAP*, mV) was significantly reduced in other ALS phenotypes, including lower limb onset 
(ALSLL), upper limb onset (ALSUL) and flail arm variant ALS (FA), but not the FL syndrome 
when compared to healthy controls.  Mean short interval intracortical inhibition (SICI) and 
cortical silent period (CSP) duration were significantly reduced in FL when compared to controls, 
but were comparable to other ALS phenotypes.   The motor evoked potential (MEP) amplitude, 
expressed as percentage of the corresponding CMAP amplitude, was significantly increased in FL 
when compared to healthy controls but comparable to other ALS phenotypes.  Central motor 
conduction time (CMCT) was prolonged in FL when compared to healthy controls, but 
comparable to other ALS phenotypes. Resting motor threshold (RMT) was similar across all 
groups.  Data is expressed as mean ± standard error of mean (SEM).  
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Cortical Function 
At the time of cortical excitability testing, the median disease duration in flail leg syndrome 
patients was 17.5 (10.5-24) months and was longer when compared to other ALS phenotypes, 
although this was not significantly different (P =0.18, Table 8.1). The motor cortex was 
inexcitable in one flail leg syndrome patient (6%) and consequently, cortical excitability studies 
were undertaken in 17 flail leg syndrome patients.  
 
Short interval intracortical inhibition was significantly reduced in flail leg syndrome patients 
when compared to healthy controls (FL 7.2±1.8%; controls 13.2 ± 0.8%, P<0.01, Figure 8.1A).  
Importantly, although SICI was higher in flail leg syndrome when compared to other ALS 
phenotypes, this difference was not significant (P=0.30, Figure 8.1B, Table 8.2). Subgroup 
analysis disclosed a significant reduction of SICI in flail leg syndrome patients with evident 
UMN signs compared to those without UMN signs (SICIUMN>1 6.0±2.0%; SICIUMN=0 10.9±0.8%, 
P<0.05, Figure 8.2A).  In addition, SICI was lower in flail leg syndrome patients that died during 
the follow up period (SICIDIED 3.3±3.2%; SICIALIVE 8.5±2.2%, P<0.05 Figure 8.2B).  There was 
no significant difference in ICF between flail leg syndrome patients and healthy controls (F=1.4, 
df 5, P=0.21, Figure 8.1A, Table 8.2).  
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Figure 8.1. (A) Short interval intracortical inhibition (SICI) was significantly reduced in 
the flail leg (FL) syndrome when compared to controls.  There was no significant 
difference in intracortical facilitation (ICF) between groups.  (B)  Mean short interval 
intracortical inhibition (SICI), between interstimulus interval 1-7 ms, was significantly 
reduced in flail leg (FL) syndrome when compared to healthy controls, but was 
comparable to other amyotrophic lateral sclerosis (ALS) phenotypes including lower limb 
onset (ALLL), upper limb onset (ALUL), flail arm variant ALS (FA) and bulbar onset ALS.   
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Figure 8.2. Short interval intracortical inhibition (SICI), between interstimulus interval (ISI) 1-7 
ms was significantly reduced in flail leg syndrome (FL) patients with (A) prominent upper motor 
neuron (UMN) signs and (B) in patients that had died during the follow up period. *P < 0.05. 
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Single pulse TMS disclosed a significant reduction of the cortical silent period (CSP) duration in 
flail leg syndrome patients when compared to healthy controls (FL 181.7±10.8ms; controls 
209.8±3.4ms; P<0.05, Figure 8.3A).  Importantly, the reduction in CSP duration was only 
evident in flail leg patients with UMN signs (FLUMN=0 206.5 ±13.9 ms; FLUMN>1 161 ±10.0 ms, F 
=13.6, P < 0.001, Fig 8.3B).  In contrast, there was no significant difference in CSP duration 
between flail leg syndrome patients and other ALS phenotypes (F=0.11, df 4, P=0.98, Figure 
8.3A, Table 8.2). The CSP duration was significantly correlated with the CMAP amplitude 
(R=0.42, P < 0.05), suggesting that a reduction in CSP duration, and thereby cortical 
hyperexcitability, was linked with the process of neurodegeneration.   
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Figure 8.3.  (A)  The cortical silent period (CSP) duration was significantly reduced in in flail leg (FL) 
syndrome when compared to healthy controls, but was comparable to other amyotrophic lateral 
sclerosis (ALS) phenotypes including lower limb onset (ALLL), upper limb onset (ALUL), flail arm 
variant ALS (FA) and bulbar onset ALS.  (B) The CSP duration was significantly reduced in FL 
patients with upper motor neuron (UMN) signs. *P<0.05. 
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Of further relevance, the MEP amplitude was significantly increased in flail leg syndrome 
patients when compared to healthy controls (FL 29.2 ± 5.1%; controls 18.9 ± 1.2%, P < 0.05, 
Figure 8.4A), but similar to other ALS phenotypes (F=1.3, df 4, P=0.26, Figure 8.4B, Table 8.2).  
Interestingly, the MEP amplitude significantly correlated with the UMN score (Rho = 0.47, P < 
0.05, Fig 8.3B).  As previously reported (583), the central motor conduction time was 
significantly longer in flail leg syndrome patients when compared to healthy controls (FL 
6.7±0.5 ms; controls 5.6 ± 0.2 ms, P<0.05), but comparable to other ALS phenotypes (P=0.98, 
Table 8.2).  The CMCT was comparable in flail leg syndrome patients with and without UMN 
sign (P=0.24). In contrast, there was no significant differences in the resting motor threshold 
between FL patients and other ALS phenotypes or healthy controls (P=0.44, Table 8.2). 
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Figure 8.4. (A)  The motor evoked potential amplitude (MEP) was significantly increased in FL 
syndrome when compared to healthy controls, but was comparable to other ALS phenotypes including 
ALLL, ALUL, FA and bulbar onset ALS.  (B)  The MEP amplitude was significantly correlated with the 
upper motor neuron (UMN) score. *P < 0.05. 
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Discussion 
The findings in the present study suggest that the flail leg syndrome is a heterogeneous 
phenotype, characterised by the core clinical features of regional restriction of muscle wasting 
and weakness, and relatively prolonged survival. Importantly, the degree of upper motor 
neuronal abnormalities varied within the flail leg syndrome phenotype, whereby prominent 
UMN signs were evident in 78% of cases, and the absence of UMN signs was associated with a 
more favourable prognosis. In addition, cortical hyperexcitability, as heralded by a significant 
reduction of short interval intracortical inhibition, was only evident in the flail leg syndrome 
patients exhibiting UMN signs, with the degree of cortical hyperexcitability comparable to other 
ALS phenotypes.  In contrast, cortical excitability appeared to be preserved in flail leg syndrome 
patients with absent UMN signs, despite a prolonged central motor conduction time in the entire 
cohort.  Taken together, the present findings imply heterogeneity of the clinical phenotype and 
underlying pathophysiological processes, with cortical dysfunction evident in flail leg syndrome 
patients exhibiting UMN signs, resembling that seen in the classical ALS phenotypes. 
 
Flail leg phenotype 
The definition of the FL syndrome has varied between different studies leading to uncertainties 
in diagnosis and prognosis (88, 89, 579, 584).  Specifically, while some studies have mandated 
the restriction of disease to the lower limbs for at least 12 months and allowed pathological 
reflexes to evolve during this period, others have defined the flail leg syndrome as a pure LMN 
disorder confined to the lower limbs for at least 24 months (84).  Consequently, differences in 
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prognosis have varied between studies, with some reporting prolonged survival (84, 88, 579), 
while others have documented a shorter survival that was commensurate with typical forms of 
ALS (89).  The differences in survival were attributed to inadvertent recruitment of lower limb 
onset ALS patients (84).  In contrast, others have failed to establish a significant association 
between the presence of UMN signs and survival in the FL syndrome (88).   
 
In the present study, UMN signs were evident in most flail leg syndrome patients, despite the 
characteristic phenotype of distal muscle weakness and wasting confined to the lower limbs for 
at least 12 months.  Importantly, the degree of clinical UMN dysfunction appeared to be 
associated with increased mortality, supporting the importance of UMN dysfunction in FL 
pathogenesis, and in keeping with previous studies reporting a higher mortality in progressive 
muscular atrophy phenotypes developing UMN signs (585). 
 
FL syndrome and pathophysiology 
Cortical hyperexcitability is an intrinsic process in ALS, including atypical phenotypes such as 
the flail arm variant (183, 185, 240, 510), and is linked to lower motor neuron degeneration (184, 
185, 187).   In the present study, cortical hyperexcitability, as heralded by a significant reduction 
of SICI, was a feature in the flail leg syndrome patients exhibiting UMN signs, and was 
comparable to other ALS phenotypes.  In contrast, the degree of cortical excitability was 
preserved in flail leg patients exhibiting the clinically pure LMN phenotype. Importantly, the 
mortality rate in the flail leg cohort exhibiting features of cortical hyperexcitability was 
significantly higher (Fig. 8.3B), suggesting a heterogeneity of the underlying pathophysiological 
processes.  At a pathophysiological level, TMS features of cortical hyperexcitability appear to be 
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mediated by degeneration of parvalbumin positive inhibitory cortical interneurons acting via 
GABAA receptors (188), as well as glutamate excitoxicity (224, 379), which therefore could  
form the pathophysiological basis in the flail leg cohort exhibiting UMN signs. 
 
In addition to reduction of SICI, there was a significant reduction in CSP duration along with an 
increase in the MEP amplitude, which was more prominent in flail leg patients with UMN signs.  
Given that the CSP duration is mediated  by cortical inhibitory circuits distinct to those 
mediating SICI (369), and the MEP amplitude reflects cortical output (39),  the findings provide 
further support for a pathophysiological importance of cortical hyperexcitability in flail leg 
patients with UMN signs and underscore the presence of heterogeneity in the flail leg syndrome.   
 
A potential limitation of the present study relates to measurement of cortical excitability from the 
APB muscle rather than the more affected lower limb muscles.  The main reason for assessing 
cortical excitability form the APB muscle was a technical one, with resting motor thresholds 
being significantly higher in lower limb muscles and therefore limiting a reliable recording of 
SICI (39).  Future application of threshold tracking TMS to lower limb muscles may be of 
importance by potentially disclosing that cortical hyperexcitability is a focal finding related to 
the region of onset. 
 
Separately, spinal cord abnormalities, as heralded by prolonged central motor conduction time, 
were a uniform finding in the flail leg syndrome, and were in keeping with previous TMS studies 
documenting prolonged CMCT despite an absence of pyramidal signs (583).  Given that CMCT 
reflects conduction along the corticospinal tracts (39), the present findings would imply a 
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dysfunction of the pyramidal tracts, perhaps reflecting the pathological findings of extensive 
degeneration of myelinated fibers in the lateral corticospinal tracts (586).   Consequently, the 
combination of cortical hyperexcitability along with prolonged CMCT could reflect a more 
extensive pathophysiological process in the flail leg syndrome phenotypes exhibiting UMN 
signs. Identifying factors that govern the differences in the pathophysiological processes across 
the flail leg phenotype could be of therapeutic significance, with strategies aimed at modulating 
these putative factors resulting in restricted disease and prolonged survival.  
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This thesis encompasses work undertaken to improve on the current diagnostic criteria in 
amyotrophic lateral sclerosis (ALS), whilst also utilising a novel transcranial magnetic 
stimulation (TMS) technique to gain insights into cortical dysfunction, and thereby understand 
pathophysiological mechanism underlying ALS.  In chapter 1 an individual patient data (IPD) 
analysis was undertaken on the currently published diagnostic studies in ALS, looking at the 
Awaji and revised El Escorial criteria (EEC).  The IPD analysis revealed the Awaji criteria to be 
more sensitive than the EEC.  We proposed a new ‘laboratory supported Awaji criteria’, which 
was more sensitive than the existing Awaji criteria.  In our analysis of the published studies to 
date, all the studies were single center by design, with some retrospective in nature.  Furthermore 
in the published studies there was a lack of specificity data, confounding the interpretation of the 
findings from the primary studies.   
 
Therefore in chapter 2 we designed the first prospective multicenter study to further evaluate the 
two diagnostic criteria.  Our study revealed that both diagnostic criteria were highly specific 
(99.5%), with the Awaji criteria being more sensitive across the bulbar and limb subgroups of 
ALS.  By loosening the current Awaji criteria to ‘possible’, there was an improvement in the 
sensitivity of the criteria, without a significant loss of specificity.  One of the limitation of both 
diagnostic criteria, was the lack of an objective biomarker of upper motor neuron (UMN) 
dysfunction.   
 
We then utilised a novel threshold tracking TMS technique, in chapter 3, where we identified 
cortical dysfunction heralded as cortical hyperexcitability, being evident early in the ALS disease 
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process.  Cortical hyperexcitability was a useful biomarker of UMN dysfunction, and when used 
in combination with the Awaji criteria, there was an improvement in the diagnostic accuracy, 
with 88% of Awaji possible patients having evidence of cortical dysfunction. 
 
While this study revealed cortical hyperexcitability to be a useful biomarker of cortical 
dysfunction, the study was not performed according the ‘Standards for reporting of diagnostic 
accuracy’ (STARD) criteria, the ‘gold standard’ for diagnostic tests. Subsequently a multicenter 
prospective study was undertaken in chapter 4.  In this study utilising threshold tracking TMS 
testing, the averaged short interval intracortical inhibition (SICI) was the most robust diagnostic 
biomarker when plotted on receiver operating characteristic curves.  Furthermore by using 
biomarkers of cortical dysfunction, it was possible to reliably differentiate ALS from similar 
mimic disorders. 
 
Having established that cortical hyperexcitability was an early and specific biomarker in ALS, 
we explored whether the same process of cortical hyperexcitability was evident in the most 
common familial form of ALS, the c9orf72 gene expansion. In chapter 5, our study revealed that 
cortical hyperexcitability was uniform across both sporadic and familial ALS.  Thereby 
suggesting that irrespective of the underlying aetiology in ALS, cortical hyperexcitability 
appears to be a universal finding.  Furthermore, whilst affected individuals with familial ALS 
had evidence of cortical hyperexcitability, asymptomatic carriers had normal cortical 
functioning, thereby suggesting that the c9orf72 gene expansion may be risk factor in developing 
ALS, but other triggers may exist that result in the expression of the gene. 
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Given that cortical dysfunction is similar in familial and sporadic ALS, we then used axonal 
excitability testing in chapter 6, to explore peripheral nervous system abnormalities.  Using 
mathematical modelling we identified an increase in persistent Na+ conductances along with 
reduced K+ currents to best explain the changes in axonal excitability in familial ALS secondary 
to the c9orf72 gene expansion.  Furthermore, similar to finding normal cortical functioning in 
asymptomatic carriers in chapter 5, we found that asymptomatic carriers had normal findings on 
axonal excitability testing. 
 
In chapter 7 and 8 we aimed to evaluate whether cortical hyperexcitability was a universal 
findings across the ALS phenotypes. In chapter 7, we investigated an UMN predominant form of 
ALS, primary lateral sclerosis (PLS) and a similar condition which can often mimic PLS, 
hereditary spastic paraparesis (HSP).  We established that PLS patients more often had an 
inexcitable motor cortex on TMS testing, while patients with ALS had features of cortical 
hyperexcitability.  Conversely in HSP, cortical function was “normal”, arguing for the presence 
of disparate pathophysiological processes and suggesting that TMS can be utilised as a 
diagnostic biomarker in differentiating PLS from HSP.   
 
In chapter 8 we explored whether cortical hyperexcitability was a feature in the clinically lower 
motor neuron phenotype of ALS, the flail-leg syndrome.  Importantly, cortical hyperexcitability 
was evident in a subgroup of flail leg syndrome patients, being comparable to sporadic and 
familial ALS cohorts.  Interestingly, cortical excitability was preserved in the flail leg syndrome 
patients with a pure LMN phenotype.  Taken together, these findings suggest heterogeneity of 
the disease process in ALS, particularly the atypical ALS variants such as the flail leg syndrome.  
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Understanding the factors that govern these discordant pathophysiological findings could be of 
therapeutic significance in ALS.    
 
Future Directions 
Cortical hyperexcitability appears to be an early and specific biomarker, preceding the 
development of LMN dysfunction in ALS.  Future studies will utilise threshold tracking TMS 
technique to explore whether the development of cortical hyperexcitability occurs prior to onset 
of disease in specific body regions, such as cranial and lumbosacral regions.  These studies will 
assist in identifying the pattern of disease spread in ALS, thereby probing whether 
corticomotoneurons act as a conduit for ALS progression in a non-contiguous manner.  The 
studies will be undertaken on a cohort of sporadic ALS patients in a longitudinal manner, with 
ongoing review of patients every 6 months.  In addition to utilising TMS derived cortical 
excitability markers, we will also be utilising ‘Motor Unit Number Estimation’ techniques, to 
quantitatively evaluate lower motor neuron loss over time. 
 
In addition, further longitudinal studies will be undertaken on c9orf72 gene expansion 
asymptomatic carriers from chapter 4 and 5, to identify if cortical and peripheral markers of 
dysfunction can be seen prior to disease conversion in the asymptomatic carrier cohort.  Our 
research group has already identified similar findings in longitudinal studies of SOD-1 mutation 
carriers, whereby cortical hyperexcitability was an early phenomenon preceding the onset of 
clinically evident disease.  
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Of further relevance, the role of corticomotoneurons in ALS pathogenesis will be further 
investigated by combing threshold tracking TMS techniques with sophisticated MRI 
neuroimaging.   Specifically, cross-sectional and longitudinal studies will be undertaken on 
sporadic ALS patients and c9orf72 expansion carriers.  The corticomotoneuronal function will be 
assessed by utilising cortical thickness analysis, resting state networks, ‘connectomics’ and 
sodium coil imaging in concert with TMS studies, in order to establish the timing and site of 
disease onset, along with patterns of disease spread.  Ultimately, such an approach will shed 
further light on ALS pathogenesis, with the hope of uncovering novel therapeutic targets. 
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GLOSSARY OF ABBREVIATIONS 
 
ALS                      amyotrophic lateral sclerosis 
ALSFRS-R           amyotrophic lateral sclerosis functional rating scale-revised 
AMPA                  α amino 3 hydroxy 5 methyl 4 isoxazole proprionic acid 
ANOVA               analysis of variance 
APB                      abductor pollicis brevis 
ATP                      adenosine tri phosphate 
CMAP                  compound muscle action potential 
CMCT                  central motor conduction time 
CSP                      cortical silent period  
DAP                     depolarizing after depolarization            
DNA                     deoxyribonucleic acid 
EMG                    electromyography 
FTD                     frontotemporal dementia 
FUS                     fused in sarcoma 
GABA                 gamma amino butyric acid 
ICF                      intracortical facilitation 
ITPR                    inositol 1,4,5-triphosphate receptor 
I/V                      current threshold relationship 
KD                     Kennedy’s Disease 
LA                      latent addition 
LICI                    long interval intracortical inhibition 
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LMN                   lower motor neuron 
MEP                   motor evoked potential 
MMNCB           multifocal motor neuropathy with conduction block 
MND                 motor neuron disease 
MRC                 Medical Research Council 
MT                    motor threshold 
MUNE              motor unit number estimation 
MUP                 motor unit potential 
NCS                 nerve conduction study 
NI                    neurophysiological index 
NMDA            N-methyl, D-aspartate receptor 
PBP                 progressive bulbar palsy 
PLS                 primary lateral sclerosis 
PMA               progressive muscular atrophy 
PSW               positive sharp waves 
RMT              resting motor threshold 
RNA               ribonucleic acid 
ROC               receiver operating characteristic  
RRP               relative refractory period 
SDTC            strength duration time constant 
SICI               short-interval intracortical inhibition 
SMA              spinal muscular atrophy 
SOD               superoxide dismutase 
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SR                  stimulus response curve 
STARD          standards for reporting of diagnostic accuracy 
TARDBP       transactive region deoxyribonucleic acid binding protein 
TEd                threshold electrotonus depolarising 
TEh                threshold electrotonus hyperpolarising 
TMS               transcranial magnetic stimulation 
UMN              upper motor neuron 
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